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Discovery of anticancer drugs with high efficacy coupled with action at novel target 
sites is necessary to combat cancer. As part of a multidisciplinary project to identify 
anticancer leads from diverse natural product resources, our group has been studying 
fungi from different ecological habitats, including filamentous Ascomycota from 
terrestrial, freshwater, and symbiotic fungi (fungal endophytes), as a source of novel 
scaffolds for drug design and development. During the course of my research work, 56 
bioactive compounds have been isolated and identified, with 30 of the isolated leads 
representing new chemical entities. Our lab relies on bioactivity-directed fractionation 
methodology for the isolation and purification of cytotoxic lead compounds from fungi, 
in which the bioassay results guide the purification processes. However, one of the 
inefficient outputs of utilizing this methodology is the re-isolation of previously known 
compounds, particularly mycotoxins. It is hypothesized that discovery of cytotoxic 
bioactive compounds with novel structures will be expedited by development and 
application of a dereplication methodology that has the capability to identify known 
compounds at the level of the crude extract. A dereplication methodology has been 
developed and implemented successfully for the identification of fungal secondary 
metabolites in crude culture extracts using a UPLC-PDA-HRMS-MS/MS method. 
Finally, the chemical diversity of the isolated compounds was analyzed through principal 
component analysis. 
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CHAPTER I 
 
INTRODUCTION 
 
Cancer is defined as a class of diseases characterized by uncontrolled growth of 
abnormal cells that have the capability to metastasize to other tissues.1 More than 100 
types of cancer are known so far.1 The global impact of cancer is enormous; it is the 
leading cause of death in developed countries and the second leading cause of death in 
developing countries, exceeded only by cardiovascular diseases.2 Global cancer statistics 
revealed that of the 12.7 million cancer cases that have been diagnosed in 2011, breast 
cancer ranked number one with 23%, followed by lung cancer with 17%. Of the 
diagnosed cases, 7.6 million deaths were reported, or the death of about 21,000 people 
per day. Globally of these, lung cancer was the leading cause of death, followed by breast 
cancer, with 23% and 14% of the mortality, respectively.3 In the US, the estimated 
number of new cases of cancer for 2013 was 1,660,290 (excluding non-invasive cancer), 
while the estimated number of deaths was 580,350.2 While these are staggering statistics, 
the number of deaths can be reduced by early diagnosis and treatment, and most 
importantly, by implementing preventive measures, for certain types of cancer, including 
changing the style of life. Cancer treatment depends primarily on the type and stage of 
cancer. Four standard methods of treatment are available: surgery, radiation therapy, 
chemotherapy, and biological therapy. For chemotherapeutic agents, there is no single 
cure for all types of cancer. A combination of several drugs for varying lengths of time is
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usually used. A critical problem in cancer chemotherapy is the development of drug 
resistance.4 Consequently, there is always a necessity for discovering new anticancer 
agents with novel mechanisms of action. 
Historically, natural products have been a key player in drug discovery programs, 
particularly in the field of cancer, by providing novel drugs and drug leads for synthetic 
modifications. For example, of the 175 small molecules that were introduced as 
anticancer drugs over the time period between the 1940s and 2010, 74.8% were other 
than synthetic, and 48.6% were either natural products or directly derived therefrom.5 
Moreover, one-third of the global annual $9-billion market for chemotherapeutic agents 
as calculated in 2003, could be attributed to camptothecin, taxol and their structural 
analogues, first-in-class natural chemotherapeutic agents.6 Of the thirteen natural 
product–derived drugs that were approved in the US between 2005 and 2007, five were 
the first members of new classes.7 
Nature’s supply of secondary metabolites comes through the six kingdoms of life: 
Plantae, Eubacteria, Fungi, Archaea, Animalia, and Protoctista, with the first three being 
the most prominent.8 The impact of fungi on the drug discovery process is immense and 
cannot be overlooked. It has been the source of many life-saving drugs. Penicillin G, the 
first natural antibiotic, was isolated from Penicillium chrysogenum.9 Moreover, the top 
selling cholesterol-lowering class of drugs, statins, represented by lovastatin, was 
discovered from fungi.10 In the area of cancer, there are a number of promising fungal-
derived compounds that are currently under development in different phases of clinical 
trials. Interestingly, two compounds, polysaccharide K (PKS) and lentinan were approved 
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in Japan for the adjuvant treatment of cancer patients. On the other hand, one of the most 
promising compounds in the field of cancer chemotherapy is the fungus-derived 
compound, irofulven, which showed potent anticancer properties, and currently is in 
phase III clinical development against several types of solid tumors.11 Although several 
breakthrough drugs were discovered from fungi, it is still considered a highly 
underexplored source of bioactive secondary metabolites. 
Fungi are one of the most extremely diverse groups of organisms that live on earth. 
They exist everywhere and have the ability to grow in a wide range of habitats.12 This 
dissertation presents part of the findings of my research, which studied the chemical 
mycology of fungi from different ecological habitats, including filamentous Ascomycota 
from terrestrial, freshwater, and symbiotic fungi (fungal endophytes), as a source of novel 
scaffolds for drug design and development, particularly in the field of cancer. 
The dissertation includes chapters devoted to the isolation and characterization of 
fungal secondary metabolites from terrestrial filamentous fungi using bioactivity-guided 
fractionation methodology, as part of a multi-disciplinary project to identify anticancer 
agents from diverse natural sources. So far, more than 100 compounds representing 
diverse chemical classes of bioactive cytotoxic fungal agents were isolated and 
elucidated. Chapters 2-5 present selected examples of such studies. Two benzoquinones, 
of which one was new, and a terphenyl compound were isolated and identified as 
phosphodiesterase-4B inhibitors from a fungus of the order Chaetothyriales (MSX47445) 
(Chapter 2). Two known and one new polyketide-derived γ-lactones were identified from 
a Volutella species (MSX58801) (Chapter 3). Eight sorbicillinoid analogues, of which 
4 
four were new, with cytotoxic and selective anti-Aspergillus activities along with two 
phthalides and one naphthalenone were isolated and identified from an organic extract of 
the fungus Scytalidium album (MSX51631) (Chapter 4). Sixteen polyketides, six of 
which were new, belonging to diverse structural classes, including monomeric/dimeric 
tetrahydroxanthones and resorcylic acid lactones, were isolated from an organic extract of 
the fungus (MSX45109) (Chapter 5). These are followed by chapters focused on the 
chemical mycology of freshwater fungi (Chapters 6 and 7), in which new compounds 
belonging to diverse structural classes are presented along with their antimicrobial 
evaluation. Six isochromenones, of which two were new, one isobenzofuranone, and two 
tetrahydronaphthalene derivatives, with one being new, were identified from a culture of 
the fungus Paraphoma radicina (G104), which was isolated from submerged wood 
sampled in October of 2011 from a freshwater lake in Greensboro, North Carolina, USA 
(Chapter 6). Thirteen new resorcylic acid lactones, along with the known 
cryptosporiopsin A, were isolated from an organic extract of a culture of the freshwater 
aquatic fungus Zalerion varium Anastasiou (G87) (Chapter 7).  Z. varium Anastasiou 
(G87) was isolated from a sample of submerged wood collected in October of 2011 from 
a freshwater stream on the campus of the University of North Carolina at Greensboro. 
Chapter 8 presents details of an interesting finding during the course of my work in 
endophytic fungi, in which three of the seven flavonolignans that constitute silymarin, an 
extract of the fruits of milk thistle (Silybum marianum), were detected for the first time 
from a fungal endophyte, Aspergillus iizukae, isolated from the surface-sterilized leaves 
of S. marianum.  
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A major challenge of working with fungi as a source of bioactive lead compounds is 
re-isolation of previously known compounds, particularly mycotoxins, which can be 
observed across different fungal species. Examples of these include aflatoxins, 
ochratoxins, trichothecenes, citreoviridin, fumonisins, and various indole-derived 
tremorgenics.13 Such re-isolations waste time and resources, distracting chemists from 
focusing on more promising leads. To address this problem, a dereplication methodology 
was developed and implemented successfully in our lab for the identification of fungal 
secondary metabolites in crude culture extracts using a UPLC-PDA-HRMS-MS/MS 
method. Chapter 9 is devoted to description of the details of this dereplication 
methodology, with examples presented to show the applicability of the method. So far, 
more than 350 fungal extracts have been dereplicated, with approximately more than 
30% of these eliminated from further study after the confident identification of known 
compounds. Moreover, knowing that certain fungi make known compounds of interest is 
helpful for the reisolation of compounds that are undergoing further development.   
A multidisciplinary project has been undertaken to identify anticancer leads from 
diverse natural product sources, including filamentous fungi, cyanobacteria, and tropical 
plants. The structural variety of the resulting leads was broad, ranging from peptides to 
polyketides to terpenoids and myriad combinations thereof. Through principal component 
analysis, the chemical space covered by compounds isolated and characterized from these 
three sources was compared to each other and to the chemical space of selected FDA-
approved anticancer drugs. Chapter 10 is devoted to this chemical diversity study, 
including visual representations of the data through plots of the principal components.    
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CHAPTER II 
 
BENZOQUINONES AND TERPHENYL COMPOUNDS AS 
PHOSPHODIESTERASE-4B INHIBITORS FROM A FUNGUS OF THE ORDER 
CHAETOTHYRIALES (MSX47445) 
 
Tamam El-Elimat, Mario Figueroa, Huzefa A. Raja, Tyler N. Graf, Audrey F. 
Adcock, David J. Kroll, Cynthia S. Day, Mansukh C. Wani, Cedric J. Pearce, and 
Nicholas H. Oberlies. Journal of Natural Products 2013, 76, 382-387. 
 
Three bioactive compounds were isolated from an organic extract of an ascomycete 
fungus of the order Chaetothyriales (MSX47445) using bioactivity-directed fractionation 
as part of a search for anticancer leads from filamentous fungi. Of these, two were 
benzoquinones [betulinan A (1) and betulinan C (3)] and the third was a terphenyl 
compound BTH-II0204-207:A (2). The structures were elucidated using a set of 
spectroscopic and spectrometric techniques; the structure of the new compound (3) was 
confirmed via single crystal X-ray diffraction. Compounds (1-3) were evaluated for 
cytotoxicity against a human cancer cell panel, for antimicrobial activity against 
Staphylococcus aureus and Candida albicans, and for phosphodiesterase (PDE4B2) 
inhibitory activities. The putative binding mode of 1-3 with PDE4B2 was examined using 
a validated docking protocol, and the binding and enzyme inhibitory activities correlated. 
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Historically, natural products have played an important role in drug discovery. Of 
the 1355 newly approved drugs worldwide during the time period of 1981–2010, ~50% 
can be traced to, or were inspired by, natural products.5 Moreover, of the thirteen natural 
product–derived drugs that were approved in the US between 2005 and 2007, five were 
the first members of new classes,7 and in 2010, fingolimod, an analogue of the fungal 
metabolite myriocin, was approved as the first oral drug to reduce multiple sclerosis 
relapses.14 In July of 2012, carfilzomib, an analogue of the natural product epoxomicin, 
which was isolated originally from an Actinomycete,15 was approved to treat patients 
with multiple myeloma.16 In short, natural products remain an invaluable source for novel 
bioactive leads. 
As part of a multidisciplinary project to identify structurally diverse anticancer 
leads,11,17 the Mycosynthetix library, representing over 55,000 accessions of filamentous 
fungi, is being examined systematically.18-22 Fungi represent an under explored source for 
bioactive secondary metabolites. In 1991, the number of fungi was estimated as 1.5 
million species,23 while current estimates suggest more than 5.1 million species.8 
Regardless, less than 100,000 species have been characterized taxonomically,8 with likely 
a smaller percentage studied for bioactive secondary metabolites, and only a portion of 
these have been evaluated for anticancer activity. 
An organic fraction of the filamentous fungus MSX474459, which was isolated from 
highly decomposed woody debris from a tropical forest in 1990, displayed modest but 
equipotent cytotoxic activity against a panel of three cancer cell lines: MCF-7, H460, and 
SF268 (~75% inhibition of cell growth when tested at 20 µg/mL). Hence, this fungus was 
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selected for further study, and three compounds, two benzoquinones (1 and 3) and one 
terphenyl compound (2), were isolated and characterized. All three compounds were 
evaluated for cytotoxicity against a human cancer cell panel, for antimicrobial activity 
against Staphylococcus aureus and Candida albicans, and for their phosphodiesterase 
(PDE4B2) inhibitory activities; the results with the latter were the most encouraging and 
led to docking studies. 
Results and Discussion 
A solid-phase culture of MSX47445 was extracted with 1:1 CHCl3-MeOH and 
partitioned with organic solvents to yield an orange-red extract, which was purified using 
flash chromatography to yield seven fractions. Of these, fraction 2 was the most cytotoxic 
against three cancer cell lines, and it was subjected to further purifications using 
preparative and semipreparative HPLC to yield three compounds (1-3) with > 97% purity 
as measured by UPLC (Supporting Information Figure 4). 
Compound 1 (30.2 mg) was obtained as an orange powder. The molecular formula 
was determined as C20H16O4 by HRESIMS. The NMR data, in conjunction with HRMS 
data and UV maxima of 194, 238, and 320 nm, identified 1 as the known compound 
betulinan A, first described by Lee et al.24 in 1996 from the fungus Lenzites betulina. 
Compound 2 (12.1 mg) was obtained as a pale yellow powder. HRESIMS data 
suggested a molecular formula of C19H16O3. The compound showed distinctive UV 
maxima at 202, 259, and 315 nm. The NMR data were in agreement with those reported 
for BTH-II0204-207:A, a terphenyl compound first reported in 2011 by Beggins et al.25 
from the pathogenic bacterium Burkholderia pseudomallei. 
9 
O
O
OCH3
H3CO
 
OR1
OH
OR2
 
1 2 R1 = H  R2 = CH3 5 R1 = CH3  R2 = H 
3
1
5
1'
4'
1''
4"O
O
OCH3
 
O
O
OCH3
1
3
5
1''
4''
4'  
3 4 
Figure 1. Structures of compound 1-4. 
Compound 3 (6.2 mg) was obtained as an orange powder. The molecular formula 
was determined as CR19RHR14ROR3 Rvia HRESIMS, establishing an index of hydrogen 
deficiency of 13. The UV maxima (198, 235, and 331 nm) and NMR data suggested 
structural similarity with compound 1, although a key difference was the loss of structural 
symmetry. Relative to 1, compound 3 also lacked one methoxy moiety, as supported by a 
30 amu difference in the HRMS data. 1H NMR data (Table 1) revealed the presence of 10 
aromatic protons (δRHR 7.45-7.52 for H-2' to H-6' and δRHR 7.33-7.42 for H-2'' to H-6''), 
suggesting two mono substituted benzene rings, one olefinic proton (δRHR 6.88, H-6), and 
one methoxy group (δRHR 3.80, 3-OCHR3R). The 13C NMR data revealed the presence of 19 
carbons, consistent with the molecular formula and indicative of two carbonyls, which 
were assigned as quinone carbons (δRCR 187.4 and 183.3, for C-1 and C-4, respectively), 
four olefinic carbons (δRC R132.7, 155.4, 144.5, and 133.0, for C-2, C-3, C-5, and C-6, 
respectively), and 10 aromatic carbons (δRCR 130.7, 128.2, 129.0, 128.2, 130.7, 129.4, 
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128.8, 130.3, 128.8, and 129.4, for C-2', C-3', C-4', C-5', C-6', C-2'', C-3'', C4'', C-5'', and 
C-6'', respectively). Thus far, the spectroscopic data accounted for 12 of the 13 degrees of 
unsaturation, and hence, the 13th degree completed the quinone ring. COSY data 
identified two spin systems, which corresponded to the aromatic protons of the two 
phenyl rings. An HMBC correlation was observed from 3-OCH3 to C-3, indicating the 
connectivity of the methoxy group. HMBC correlations from H-6 to C-4, C-2, and C-1' 
were observed. NOESY correlations were observed from the olefinic proton H-6 to the 
equivalent C-2'/C-6' and from the 3-OCH3 to the equivalent C-2''/C-6'' (Figure 2b). The 
last structure elucidation hurdle was to verify whether the central ring was an ortho or 
para quinone, but the spectroscopic data were inconclusive, since the observed HMBC 
and NOESY correlations for the H-3 and the 3-OCH3 were equally valid for either 
substitution pattern. What increased the dilemma of the substitution pattern were 
contradictory NMR data that were published by two different research groups for a 
synthetic26 and a natural27 compound with the same molecular formula (compound 4). 
Our NMR data were in agreement with those reported by Singh and co-workers, except 
for one carbon where the 13C NMR data differed by about 12 ppm.27 Sawayama et al.26 
reported the synthesis of 4, where clear differences were observed between the NMR data 
of synthetic and natural 4, and they stated that reexamination of the structure of natural 4 
was “underway by Dr. S. B. Singh.”  However, since this reexamination has not been 
reported yet, compound 3 was crystallized from ethyl acetate at room temperature to give 
monoclinic crystals, and single crystal X-ray diffraction established the structure of 3 
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with the carbonyl carbons para to each other (Figure 2a). To be consistent with the 
literature, the trivial name betulinan C was ascribed to 3. 
 
Table 1. 1H (500 MHz) and 13C (125 MHz) NMR Data for 
Betulinan C (3) in CDCl3 
position δC, type δH (J in Hz) 
1 187.4, C -- 
2 132.7, C -- 
3 155.4, C -- 
4 183.3, C -- 
5 144.5, C -- 
6 133.0, CH 6.88, s 
1' 128.8, C -- 
2', 6' 129.4, CH 7.52, dd (8.0, 1.7) 
3', 5' 128.8, CH 7.45, m 
4' 130.3, CH 7.45, m 
1'' 130.0, C -- 
2'', 6'' 130.7, CH 7.33, dd (8.0, 1.7) 
3'', 5'' 128.2, CH 7.42, m 
4'' 129.0, CH 7.40, m 
3-OCH3   61.67, CH3 3.80, s 
 
    
O
O
OCH3
1
35
1'
4'
1''
4''
HMBC
NOESY
 
 
 
 
 
Figure 2. (a) X-ray crystallographic structure with 50% probability ellipsoids. (b) key 
HMBC and NOESY correlations of 3. 
(b) (a) 
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Compounds structurally related to 1-3 have been identified as phosphosdiesterase 
(PDE) inhibitors. Terferol (5), which was isolated from Streptomyces showdoensis SANK 
65080, possessed inhibitory activity against cyclic adenosine 3',5'-monophosphate 
phosphodiesterase (cAMP-PDE) and cyclic guanosine 3',5'-monophosphate 
phosphodiesterase (cGMP-PDE).28 The concentrations of 5 required for 50% inhibition 
of cAMP-PDE and cGMP-PDE were 0.82 and 0.96 μM, respectively.28 Moreover, 
Biggins et al.25 evaluated two terferol related compounds, BTH-II0204-207:A (2) and 
BTH-II0204-207:C, for PDE inhibition activity against 11 PDE families. The latter was 
inactive, while 2 showed activity against PDE11 as well as four out of the five PDE4s 
that were examined. PDE4 is an essential regulator of the secondary messenger cAMP in 
numerous cell types, and the reduction in cAMP degradation by several inhibitors, such 
as rolipram, piclamilast, roflumilast, cilomilast, and tetomilast, has suggested a broad 
range of clinical applications for the treatment of asthma and chronic obstructive 
pulmonary disease (COPD),29,30 some types of brain tumors,31,32 and other inflammatory 
diseases.33 In 2011, roflumilast (Daliresp) was approved by the U.S. FDA as the first 
selective PDE4 inhibitor to reduce COPD exacerbations.34 Moreover, abnormal 
regulation of cAMP and/or cGMP metabolism upon altered expression and activity of 
PDE isoforms has been implicated in the pathogenesis of various types of cancer, 
including prostate cancer, colon cancer, hematological malignancies, melanoma, and 
brain tumors.35,36 Based on these reports, the effect of 1-3 on the activity of recombinant 
human PDE4B237 were evaluated; PDE4B is the predominant isoform present in human 
monocytes and neutrophils and is involved mainly in inflammation.38 Of these, 3 was the 
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most potent with an IC50 value of 17 µM, followed by compounds 2 and 1 with IC50 
values of 31 and 44 µM, respectively (Figure 3; Table 2). 
 
 
Figure 3. Plots of the effect of compounds 1-3 and rolipram (positive control) on 
PDE4B2 activity. Substrate Conc. = 100 nM (cAMP). 
 
Table 2. PDE4B2 Inhibition Activity and Docking Results of Compounds 1-3 
compound PDE4B2 inhibition IC50 (µM) 
Docking score 
(kcal/mol) 
Docking score 
rank 
betulinan A (1) 44 −8.071 4 
BTH-II0204-207:A (2) 31 −8.277 3 
betulinan C (3) 17 −8.732 2 
roliprama 0.4 −11.396 1 
apostive control    
 
Molecular docking and other computational approaches are being used increasingly 
to explore the ligand-binding interactions of PDE4 inhibitors.39-42 As such, compounds 1-
14 
3 were docked into the crystal structure of human PDE4B using Glide Extra 
Precision.43,44 The docking protocol was verified by testing its ability to reproduce the 
experimental binding mode of co-crystallized rolipram (Supporting Information Figure 
8). To this end, rolipram bound to the crystal structure was removed from the binding 
pocket and docked back into the cofactor binding site; the root-mean-square deviation 
between the predicted conformation and the observed X-ray crystallographic data was 1.1 
Å, indicating the capability of the docking protocol to reproduce the binding mode of 
rolipram (Supporting Information Figure 8). Compounds 1-3 were docked into the cAMP 
binding site of PDE4B. The docking scores calculated with Glide correlated with the 
biological activity (Table 2); compound 3 displayed the highest activity (IC50 value of 17 
µM) and also the top-ranked docking score (-8.732 kcal/mol). In contrast, compound 1 
had the lowest activity (IC50 value of 44 µM) and showed the lowest docking score (-
8.071 kcal/mol). Finally, the pyrrolidinone rolipram was included, not only for the 
docking protocol validation, but also as a positive control in the enzymatic assay; 
rolipram was top ranked in both docking score and in vitro activity. 
Compounds 1-3 and rolipram displayed a similar binding mode (Figures 4 and 9). 
The two predicted hydrogen bonds between the free amino group of Gln443 and the 
cyclopentyloxy and methoxyphenyl groups of rolipram were in agreement with the 
observations derived from the crystallographic structure of PDE4B in complex with 
rolipram. As shown, Glide found a similar hydrogen bond with Gln443 and the carboxyl 
group for the most active compound 3 (Figures 4c and 4d); favorable π interactions with 
Phe446 in the binding pocket were also observed. Compounds 1 and 2 did not show 
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hydrogen bonds with Gln433, but similar π interactions were predicted (Figures 4a, 4b 
and 9). Taken together, these observations suggested that the binging modes predicted 
with Glide for compounds 1-3 were reasonable. 
 
  (a) 
 
(b) 
 
  (c) 
 
 
 
(d) 
 
 
 
Figure 4. Binding conformation of 1 (a), 2 (b) and 3 (c) predicted by Glide. 
Crystallographic rolipram (maroon) is shown as a reference with hydrogen bonds 
displayed as yellow/black dashes. Nonpolar hydrogen atoms are omitted. (d) Two-
dimensional interaction map of the optimized docking model of compound 3 in the 
cAMP binding pocket of PDE4B. Amino acid residues within 4.5 Å of the ligand are 
displayed. Blue arrows indicate hydrogen bonding to amino acid side chain atoms. 
 
Compounds 1-3 were assayed for cytotoxicity and antimicrobial activity. When 
tested against the three cancer cell lines MCF-7, H460, and SF268 (Supporting 
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Information Table 4), compounds 2 and 3 showed moderate cytotoxicity while 1 was 
inactive. Compounds 2 and 3 were equipotent against S. aureus with MIC values of 25 
µg/mL, while none of the compounds showed activity against C. albicans. 
In conclusion, three compounds (1-3) were isolated and characterized from the 
fungus MSX47445. The structure of the new paraquinone, 3, was assigned unequivocally 
by NMR and single crystal X-ray diffraction. The effect of compounds 1-3 on the activity 
of PDE4B was assessed both in vitro and in silico; compound 3 was the most potent, 
being approximately a half order of magnitude less potent than the positive control, 
rolipram. Further studies are ongoing to expand the knowledge base of this class of 
compounds, particularly given their compact structures. 
Experimental Section 
General Experimental Procedures. UV and IR spectra were acquired on a Varian 
Cary 100 Bio UV-Vis spectrophotometer and a Perkin-Elmer Spectrum One with 
Universal ATR attachment, respectively. NMR experiments were conducted in either 
CDCl3, acetone-d6 or DMSO-d6 with TMS as a reference via a JEOL ECA-500, 
operating at 500 MHz for 1H and 125 MHz for 13C. HRESIMS was performed on a 
Thermo LTQ Orbitrap XL mass spectrometer equipped with an electrospray ionization 
source. UPLC was carried out on a Waters Acquity system with data collected and 
analyzed using Empower software. HPLC was carried out using a Varian Prostar HPLC 
system equipped with ProStar 210 pumps and a Prostar 335 photodiode array detector 
(PDA), with data collected and analyzed using Galaxie Chromatography Workstation 
software (version 1.9.3.2). For preparative HPLC, a Phenomenex Synergi Max-RP 80 (4 
17 
µm; 250 × 21.2 mm) column was used at a 21 mL/min flow rate, while for the semi-
preparative HPLC, a Phenomenex Gemini-NX C18 (4 µm; 250 × 10 mm) column was 
used at a 4.7 mL/min flow rate. For UPLC, a Waters BEH C18 column (1.7 µm; 50 × 2.1 
mm) was used with a 0.6 mL/min flow rate. Flash chromatography was performed on a 
Teledyne ISCO CombiFlash Rf using a 40 g Silica Gold column and monitored by UV 
and evaporative light-scattering detectors. X-ray crystallography data were acquired 
using a Bruker APEX CCD diffractometer (MoKα radiation, graphite monochromator). 
All other reagents and solvents were obtained from Fisher Scientific and were used 
without further purification.  
Producing Organism and Fermentation. Mycosynthetix fungal strain 47445 was 
isolated from highly decomposed woody debris in 1990. The growth conditions were as 
described previously19,22 and outlined in the supplementary materials. For molecular 
identification, the internal transcribed spacer regions 1 & 2 and 5.8S nrDNA (ITS) were 
sequenced, since this region of the ribosomal RNA operon has been proposed as a 
barcode marker for fungi.45 Detailed methodology for DNA extraction, PCR 
amplification, sequencing, and phylogenetic analyses are outlined in the supplementary 
materials. The combined ITS and LSU sequence was deposited in the GenBank 
(accession no JX310275). The analyses of both the rRNA regions (ITS and D1/D2 of the 
LSU) suggested that MSX47445 was a member of the Chaetothyriales, Ascomycota and 
shares phylogenetic affinities with the mitosporic fungus Cyphellophora sp. 
Extraction and Isolation. To the large-scale solid fermentation culture of 
MSX47445, 500 mL of 1:1 MeOH-CHCl3 were added. The culture was chopped with a 
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spatula and shaken overnight (~16 h) at ∼100 rpm at rt. The sample was filtered with 
vacuum, and the remaining residues were washed with 100 mL of 1:1 MeOH-CHCl3. To 
the filtrate, 900 mL CHCl3 and 1500 mL H2O were added; the mixture was stirred for 2 h 
and then transferred into a separatory funnel. The bottom layer was drawn off and 
evaporated to dryness. The dried organic extract was re-constituted in 300 mL of 1:1 
MeOH-CH3CN and 200 mL of hexanes. The biphasic solution was stirred for an hour 
and then transferred to a separatory funnel. The MeOH-CH3CN layer was drawn off and 
evaporated to dryness under vacuum. The defatted material (1.2 g, orange red) was 
dissolved in a mixture of CHCl3-MeOH, adsorbed onto Celite 545, and fractionated via 
flash chromatography using a gradient solvent system of hexane-CHCl3-MeOH at a 40 
mL/min flow rate and 53.3 column volumes over 63.9 min to afford seven fractions. 
Fraction 2 eluted with 100% CHCl3 (~247 mg) was subjected to preparative HPLC using 
an isocratic system of 55:45 CH3CN-H2O over 30 min at a flow rate of 4.7 mL/min to 
yield seven sub-fractions. Sub-fraction 5 yielded compound 1 (30.2 mg), which eluted at 
~22.5 min. Sub-fraction 2 was subjected to semipreprative HPLC and yielded compounds 
2 (12.1 mg) and 3 (6.2 mg), which eluted at 9.5 and 19.0 min, respectively. UPLC was 
used to evaluate the purity of 1-3 using a gradient solvent system that initiated with 20:80 
CH3CN-H2O to 100% CH3CN over 4.5 min; all compounds were >97% pure 
(Supporting Information Figure 5). 
Betulinan C (3): orange powder; UV (MeOH) λmax (log ε) 330 (3.62), 235 (4.14), 
203 (4.32) nm; IR (diamond) vmax 1661, 1640, 1593, 1330, 1267, 1090, 1072, 935, 889, 
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849, 809, 776, 766 cm-1; 1H NMR (CDCl3, 500 MHz) and 13C NMR (CDCl3, 125 MHz), 
see Table 1; HRESIMS m/z  291.1017  [M + H]+ (calcd for C19H14O3 291.1016). 
X-ray Crystallography. Crystallographic data for compound 3 has been deposited 
with the Cambridge Crystallographic Data Centre, deposition number 904704. 
Compound’s 3 crystals were grown in ethyl acetate at rt. X-ray crystal structure analysis 
of 3 were as follows: formula C19H13O3, MW = 290.31, block-shaped yellow crystal, a = 
14.6693 (18) Å, b = 7.3806 (9) Å, c = 14.3582 (18) Å, β = 115.259 (1)°, T = 193 (2) K, Z 
= 4, monoclinic, space group P2(1)/c, GOF = S = 1.043, V = 1405.9 (3) Å3, R1 (3088 
reflections, I>2σ(I)) = 0.0521, wR2 (all 3719 reflections) = 0.1476, λ = 0.71073 Å.  
Cytotoxicity Assay. The cytotoxicity measurements against the MCF-746 human 
breast carcinoma (Barbara A. Karmanos Cancer Center), NCI-H46047 human large cell 
lung carcinoma (HTB-177, American Type Culture Collection (ATCC), and SF-26848 
human astrocytoma (NCI Developmental Therapeutics Program) cell lines were 
performed as described previously.49,50 
Antimicrobial Assay. The compounds were screened for antimicrobial activity 
using an agar plate diffusion assay as described previously.18 
Phosphodiesterase Inhibitor Assay. The PDE inhibitor assay was performed at 
BPS Bioscience Inc. as described previously.13 Detailed experimental procedures are 
provided in the Supporting Information. 
Molecular Modeling. Compounds 1-3 were prepared using the LigPrep 2.4 module 
of Maestro 9.1 (Schrödinger, LLC). The crystal structure of human PDE4B in complex to 
the inhibitor rolipram was retrieved from the Protein Data Bank (PDB entry 1RO6).51 
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Docking was performed with the cAMP catalytic domain using Glide (Grid-Based 
Ligand Docking with Energetics; Schrödinger, LLC) program, version 5.6.44 The Protein 
Preparation Wizard module of Maestro was used to prepare the protein.52 During protein 
preparation, H2O molecules were deleted. For docking, the scoring grids were centered 
on the crystal structure of rolipram using the default bounding sizes. All structures were 
docked and scored using Glide.44 The best docked poses were selected as the ones with 
the lowest Glide Score; the more negative the Glide Score, the more favorable the 
binding. 2D interactions maps were generated with Discovery Studio 3.1 from Accelrys 
Software Inc. 
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Producing Organism and Fermentation. The culture was stored on a malt extract 
slant and was transferred periodically. A fresh culture was grown on a similar slant, and a 
piece was transferred to a medium containing 2% soy peptone, 2% dextrose, and 1% 
yeast extract (YESD media). Following incubation (7 d) at 22 °C with agitation, the 
culture was used to inoculate 50 mL of a rice medium, prepared using rice to which was 
added a vitamin solution and twice the volume of rice with H2O, in a 250 mL Erlenmeyer 
flask. This was incubated at 22 °C until the culture showed good growth (approximately 
14 d). The scale-up culture was grown in a 2.8 L Fernbach flask containing 150 g of rice 
and 300 mL of H2O and was inoculated using a seed culture grown in YESD medium. 
This was incubated at 22 °C for 14 d. 
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For extraction of genomic DNA of fungal strain MSX47445, mycelium from axenic 
cultures grown in YESD broth was scraped with a sterile scalpel and ground to a fine 
powder in liquid N2 using a mortar and pestle. Approximately 400 µL of AP1 buffer 
from the DNAeasy Plant Mini Kit (QIAGEN Inc.) was added to the mycelial powder, and 
DNA was extracted following the manufacturer’s instructions. The DNA was eluted in 
approximately 25–30 µL distilled H2O. The complete ITS region, along with the partial 
region of divergent domains D1/D2 of the large subunit of the 28S nuclear ribosomal 
DNA (LSU), were amplified with ITS1F and LR3 by PCR using puReTaq™ Ready-To-
Go PCR beads (Amersham Biosciences Corp.). The PCR products were sequenced 
subsequently in a 11 µL sequencing reaction with BigDye Terminators v3.1 (Applied 
Biosystems) using ITS primers ITS1F and ITS453,54 and LSU primers LROR and 
LR3.55,56 For PCR, the following protocol was used: initial denaturation at 95 °C for 5 
min, followed by 35 or 40 cycles of 95 °C for 30 s, 41 or 50 °C for 15 s, and 72 °C for 1 
min with a final extension step of 72 °C for 10 min. To enhance the PCR reactions, 2.5 
µL of BSA (bovine serum albumin, New England Biolabs) and/or 2.5 µL of DMSO were 
added. The PCR products were purified to remove excess primers, dNTPs, and 
nonspecific amplification products with the QIAquick PCR Purification Kit (QIAGEN 
Inc.). Sequences were generated on an Applied Biosystems 3730XL high-throughput 
capillary sequencer at the University of Illinois Urbana-Champaign Biotech facility. 
The complete ITS sequence, including both spacers and the 5.8S region of 
MSX47445 (~644 base pairs), was compared with GenBank’s database57 using the Blastn 
search.58 The Blast search revealed Cyphellophora eucalypti Cheew & Crous 
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(GQ303274) as the closest match (query coverage of 100%, and a sequence similarity of 
89%). To be considered conspecific based on ITS data, studies of Ascomycota fungi have 
used a ≥ 97–98% or 99% cut off as a proxy for species level identification.59,60 Since, C. 
eucalypti, a member of Chaetothyriales, (Chaetothyriomycetidae, Eurotiomycetes, 
Ascomycota) was the closest match in the GenBank and shared 89% sequence similarity 
with the ITS sequence, MSX47445 had affinities only to the level of the order 
Chaetothyriales. The variable D1/D2 regions of LSU of MSX47445 (~ 600 bp) were 
subjected to a Blast search in GenBank. Blast search with the D1/D2 region also revealed 
C. eucalypti (GQ303305) as the closest match with MSX47445 (query coverage of 96% 
and a sequence similarity of 99%). These sequences were downloaded and a Maximum 
Likelihood (ML) analysis was performed to determine the phylogenetic affinities of 
MSX47445 with members of the Chaetothyriales. Multiple sequence alignment and 
phylogenetic analysis was performed following programs reviewed previously.61 Results 
of the ML phylogenetic analysis indicated that MSX47445 shared phylogenetic affinities 
with C. eucalypti but without significant bootstrap support values (See Supplementary 
Figure 10). 
Experimental Protocol for the Phosphodiesterase Inhibitor Assay. The PDE 
inhibitor assay was performed at BPS Bioscience Inc. A series of dilutions of the test 
compounds were prepared with 10% DMSO in assay buffer, and 5 µL of the dilution 
were added to a 50 µL reaction so that the final concentration of DMSO was 1% in all of 
the reactions. The enzymatic reactions were conducted at rt for 60 min in a 50 µL mixture 
containing PDE assay buffer, 100 nM FAM-cAMP, PDEB2 enzyme and the test 
23 
compound. After the enzymatic reaction, 100 µL of a binding solution (1:100 dilution of 
the binding agent with the binding agent diluent) were added to each reaction, and the 
reaction was performed at rt for 60 min. Fluorescence intensity was measured at an 
excitation of 485 nm and an emission of 528 nm using a Tecan Infinite M1000 
microplate reader.  
24 
 
  
Figure 5. UPLC chromatograms of compounds 1-3 (λ 210 nm). 
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Figure 6. 1H NMR (500 MHz, CDCl3) of betulinan C (3). 
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Figure 7. 13C NMR (125 MHz, CDCl3) of betulinan C (3).
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Figure 8. Comparison between the binding position of rolipram within the crystal 
structure (grey) and the binding mode predicted by Glide (orange). 
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(a) 
 
(b) 
 
                                           (c) 
 
Figure 9. Two-dimensional interaction map of the optimized docking model of compound 
1 (a), 2 (b), and rolipram (c) in the cAMP binding pocket of PDE4B. Amino acid residues 
within 4.5 Å of the ligand are displayed. Blue and green arrows indicate hydrogen 
bonding to amino acid side chain and main chain atoms, respectively. 
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Figure 10. Phylogram of the most likely tree (-lnL = 4401.180) from a RAxML analysis 
of 53 taxa based on partial region of the 28S large subunit nrDNA (1296 bp). Numbers 
refer to RAxML bootstrap support values ≥ 70% based on 1000 replicates. MSX47445 is 
shown in bold.  
Note: MSX47445 shows phylogenetic affinities to Cyphellophora eucalypti (GQ303305) 
but without significant bootstrap support.  
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Table 3. Cytotoxicity and Antimicrobial Activities of Compounds (1-3) 
Compound 
Cytotoxicity IC50 (μM) MIC (µg/mL) 
MCF-7 H460 SF268 C. albicans S. aureus 
betulinan A (1) 100.0 101.2 79.7 >150 >150 
BTH-II0204-207:A (2) 39.0 21.8 38.8 >150 25 
betulinan C (3) 26.1 19.5 32.8 100 25 
camptothecina 0.1 0.0 0.0 --- --- 
amphotericin Ba --- --- --- <0.025 --- 
novobiocina --- --- --- --- <0.025 
apositive controls 
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CHAPTER III 
 
WAOL A, TRANS-DIHYDROWAOL A, AND CIS-DIHYDROWAOL A: 
POLYKETIDE-DERIVED γ-LACTONES FROM A VOLUTELLA SPECIES 
 
Tamam El-Elimat, Mario Figueroa, Huzefa A. Raja, Audrey F. Adcock, David J. 
Kroll, Steven M. Swanson, Mansukh C. Wani, Cedric J. Pearce, Nicholas H. 
Oberlies. Tetrahedron Letters 2013, 54, 4300-4302. 
 
An organic extract of a filamentous fungus (MSX58801), identified as a Volutella 
sp. (Hypocreales, Ascomycota), displayed moderate cytotoxic activity against NCI-H460 
human large cell lung carcinoma. Bioactivity-directed fractionation led to the isolation of 
three γ-lactones having the furo[3,4-b]pyran-5-one bicyclic ring system [waol A (1), 
trans-dihydrowaol A (2), and cis-dihydrowaol A (3)]. The structures were elucidated 
using a set of spectroscopic and spectrometric techniques; the absolute configuration of 2 
was established via a modified Mosher’s ester method. Compounds 1 and 2 were 
evaluated for cytotoxicity against a human cancer cell panel. 
 
In pursuit of structurally diverse anticancer leads from nature,11,17 our group has 
been investigating filamentous fungi, particularly the Mycosynthetix library, representing 
over 55,000 accessions.18-22,62,63 Fungi represent an exciting reservoir of bioactive natural 
products, as they are an underexplored and renewable resource.8,13,23
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An organic extract of the filamentous fungus MSX58801, which was isolated from 
leaf litter in 1991, displayed moderate cytotoxic activity against NCI-H460 human large 
cell lung carcinoma (~86% inhibition of cell growth when tested at 20 µg/mL).19 
Bioactivity-directed fractionation using flash chromatography followed by preparative 
RP-HPLC resulted in the isolation of three γ-lactones (1-3) containing a furo[3,4-
b]pyran-5-one bicyclic ring system, with >95% purity for compounds 1 and 2 according 
to UPLC (Figure 14, Supplementary data). Compounds 1 and 2 were evaluated for 
cytotoxicity against a human cancer cell panel. 
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Figure 11. Structures of compounds 1-3. 
Compound 1 (2.46 mg), which was obtained as a colorless oil, had a molecular 
formula of C13H16O4 as determined by HRESIMS. The NMR (Figure 15, Supplementary 
data), HRMS, and optical rotation data identified 1 as the known compound, waol A (FD-
211; Figure 11). First isolated in 1995 from a fermentation of Myceliophthora lutea TF-
0409,64 the structure of 1 was revised in 2003.65,66 
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Figure 12. Key HMBC, COSY, and NOESY correlations of 2 and 3. 
Compound 2 (9.67 mg) was also obtained as a colorless oil.67 The molecular formula 
was determined as C13H18O4 via HRESIMS, establishing an index of hydrogen 
deficiency of 5. The NMR data suggested structural similarity with compound 1. 
However, compound 2 lacked the olefinic proton at δH 6.90, which was replaced by three 
aliphatic protons (δH 1.79, 2.43, and 2.91). These data suggested a difference between 1 
and 2 of a double bond, as supported by a 2 amu difference in the HRMS data. The 1H 
NMR data of 2 revealed the presence of four olefinic protons, corresponding to two 
trans-disubstituted olefins (δH 5.52, ddq, J = 15.5, 8.0, 1.7; 5.55, ddq, J = 15.5, 5.2, 1.7; 
5.91, dqd, J = 15.5, 6.9, 1.7; and 5.99, dq, J = 15.5, 6.9, for H-1′′, H-1′, H-2′, and H-2′′, 
respectively), four oxymethines (δH 3.48, dd, J = 12.0, 8.6; 3.84, bq, J = 2.9; 4.03, ddd, J 
= 5.2, 2.9, 1.7; and 4.67, dd, J = 8.6, 8.0, for H-7a, H-3, H-2, and H-7, respectively), one 
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methine (δH 2.91, ddd, J = 12.6, 12.0, 3.4, for H-4a), one methylene (δH 1.79, ddd, J = 
13.2, 12.6, 2.9; and 2.43, ddd, J = 13.2, 3.4, 2.9, for H-4α and H-4β, respectively), two 
equivalent methyls (δH 1.77, dd, J = 6.9, 1.7, for H-3′ and H-3′′), and one exchangeable 
proton (δH 1.84, for 3-OH). The 13C NMR data revealed 13 carbons, consistent with the 
HRMS data and indicative of one carbonyl (δC 173.5 for C-5), four olefinic carbons (δC 
125.7, 126.4, 130.6, and 134.3, for C-1′′, C-1′, C-2′, and C-2′′, respectively), five 
methines (δC 39.0, 66.3, 81.2, 82.1, and 82.4 for C-4a, C-3, C-2, C-7a, and C-7, 
respectively), one methylene (δC 30.0 for C-4), and two methyls (δC 18.1 and 18.2 for C-
3′ and C-3′′, respectively) (see Supplementary Figures 16 and 17 for the 1H and 13C NMR 
spectra and Table 4). The two double bonds and the carbonyl group accounted for three 
degrees of unsaturations, leaving the remaining two accommodated by the bicyclic ring 
system. COSY data identified one spin system as H3-3′/H-2′/H-1′/H-2/H-3/H2-4/H-4a/H-
7a/H-7/H-1′′/H-2′′/H3-3′′ (Figure 12a). The following key HMBC correlations were 
observed: H3-3′→C-1′, H3-3′′→C-1′′, H-2→C-2′, H-7→C-2′′, H-3→C-4a, H-7a→C-4, 
H-4a→C-7, and H-4a→C-5 (Figure 12a). NOESY correlations from H-1′′ to H-7a, from 
H-7a to H-2, and from H-2 to H-3 and H-2′ indicated that H-1′′, H-7a, H-2, H-3, and H-2′ 
were all on the same face. Alternatively, NOESY correlations observed from H-4a to H-7 
indicated that these two protons were on the same side of the molecule but opposite to the 
previous set (Figure 12b). Comparing all of these data with those for 1 yielded the 
structure of 2 (Figure 11), which was ascribed the trivial name trans-dihydrowaol A. The 
absolute configuration of 2 was assigned via a modified Mosher’s ester method,68 
establishing the configuration as 2R, 3R, 4aR, 7S, and 7aR (Figure 13).69 
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Figure 13. ΔδH values [Δδ (in ppm) = δS − δR] obtained for (S)- and (R)-MTPA esters (2a 
and 2b, respectively) of trans-dihydrowaol A (2) in pyridine-d5. 
 
Compound 3 (1.45 mg) was obtained as a colorless oil.70 The molecular formula was 
determined as C13H18O4 via HRESIMS, and was the same as compound 2. The NMR 
data (Table 5 and Figures 18 and 19) suggested structural similarity with 2. Key 
differences were a coupling constant of 0.6 Hz between H-4a (δH 2.58, ddd, J = 7.5, 2.3, 
0.6) and H-7a (δH 4.17, dd, J = 4.6, 0.6) in 3 vs 12 Hz in 2, and a NOESY correlation 
from H-4a to H-7a in 3 vs H-4a to H-7 in 2 (Figure 12d). These data implied a 
pseudoaxial/pseudoequatorial cis orientation of H-4a/H-7a. NOESY correlations were 
also observed from H-2 to H-7a and H-4a, and from H-4a to H-3, indicating that those 
protons were on the same face (Figure 12d). These data suggested an inversion in the 
configuration at C-4a in 3 relative to 2, establishing the structure of 3 as an epimer of 2 
(Figure 11). The trivial name, cis-dihydrowaol A (3), was ascribed to this compound. The 
relative configuration of 3 was assigned by comparison with 2 as 2R, 3R, 4aS, 7S, and 
7aR. An attempt to establish the absolute configuration via a modified Mosher’s ester 
method68 was unsuccessful. 
 
 
36 
Table 4. Cytotoxicity of Compounds 1 and 2 Against Two Human Tumor 
Cell Linesa  
 
compound 
IC50 values in µM 
MDA-MB-435b SW-620c 
waol A (1) 39.6 13.8 
trans-dihydrowaol A (2) >40 >40 
aPositive controls were vinblastine and bortezomib. Vinblastine was tested at 
concentrations of 3 ng/mL and 1 ng/mL: MDA-MB-435 cells had 37% and 99% 
viable cells; SW620 cells had 76% and 90% viable cells; respectively. 
Bortezomib was tested at concentrations of 5 nM and 2.5 nM: MDA-MB-435 
cells had 90% and 91% viable cells; SW620 cells had 79% and 71% viable cells; 
respectively. 
bmelanoma and ccolon tumor cell lines were tested using published protocols.19,71 
 
Compounds 1 and 2 were tested against two cancer cell lines, MDA-MB-435 
(human melanoma) and SW-620 (human colon cancer), using methods described 
previously;19,71 due to paucity of sample, compound 3 was not tested. While compound 1 
showed moderate cytotoxic activity against the SW-620 cancer cell line, compound 2 was 
inactive against both cancer cell lines (Table 4), suggesting the importance of the double 
bond for cytotoxicity. Compound 1 was reported by Nozawa et al64 to have broad 
spectrum activity against cultured tumor cell lines, including adriamycin-resistant HL-60 
cells. Several compounds having the furo[3,4-b]pyran-5-one bicyclic ring system have 
been reported from fungi with diverse biological activities, including antibacterial and 
cytotoxic activities.72-77 
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Supplementary Data 
 
General Experimental Procedures. Optical rotation data were acquired on a 
Rudolph Research Autopol III polarimeter. NMR experiments were conducted in CDCl3 
with TMS as a reference via a JEOL ECA-500, operating at 500 MHz for 1H and 125 
MHz for 13C. HRESIMS was performed on a Thermo LTQ Orbitrap XL mass 
spectrometer equipped with an electrospray ionization source. UPLC was carried out on a 
Waters Acquity system with data collected and analyzed using Empower software. HPLC 
was carried out using a Varian Prostar HPLC system equipped with ProStar 210 pumps 
and a Prostar 335 photodiode array detector (PDA), with data collected and analyzed 
using Galaxie Chromatography Workstation software (version 1.9.3.2). For preparative 
HPLC, a Phenomenex Gemini-NX C18 (5 µm; 250 × 21.2 mm) column was used at a 
21.24 mL/min flow rate. For UPLC, a Waters BEH C18 column (1.7 µm; 50 × 2.1 mm) 
was used with a 0.5 mL/min flow rate. Flash chromatography was performed on a 
Teledyne ISCO CombiFlash Rf using a 12 g Silica Gold column and monitored by UV 
and evaporative light-scattering detectors. All other reagents and solvents were obtained 
from Fisher Scientific and were used without further purification.  
Producing Organism and Fermentation. Mycosynthetix fungal strain 58801 was 
isolated from leaf litter in 1991. The culture was stored on a malt extract slant and was 
transferred periodically. A fresh culture was grown on a similar slant, and a piece was 
transferred to a medium containing 2% soy peptone, 2% dextrose, and 1% yeast extract 
(YESD media). Following incubation (7 d) at 22 °C with agitation, the culture was used 
to inoculate 50 mL of a rice medium, prepared using rice to which was added a vitamin 
 
38 
solution and twice the volume of rice with H2O, in a 250 mL Erlenmeyer flask. This was 
incubated at 22 °C until the culture showed good growth (approximately 14 d). The scale-
up culture was grown in a 2.8 L Fernbach flask containing 150 g of rice and 300 mL of 
H2O and was inoculated using a seed culture grown in YESD medium. This was 
incubated at 22 °C for 14 d. 
Fungal strain MSX58801 was characterized using molecular data from the internal 
transcribed spacer region of the rRNA gene (ITS). The ITS region has been proposed as a 
barcode marker for fungal species identification.45 The ITS region (ITS1-5.8S-ITS2) was 
amplified using illustra Ready-To-Go™ PCR Beads (GE Healthcare, Waukesha, WI) 
with a combination of ITS1F/ITS1 and ITS4 primers,53,54 using the following thermo-
cycler conditions: initial denaturing at 94 ºC for 5 min; 39 cycles of denaturing at 94 ºC 
for 30 s, annealing at 50 ºC for 15 s; extension at 72 ºC for 1 min; and a final extension 
step of 72 ºC for 10 min. Purified PCR products were sequenced in 11 μL sequencing 
reactions with BigDye Terminators v. 3.1 (Applied Biosystems, Foster City, CA) in 
combination with the following ITS primers: ITS1F/ITS5 and ITS4 at the University of 
Illinois Biotech facility. The ITS sequence was then subjected to a BLAST search using 
NCBI GenBank database. Based on this, the closest hits were members of the genus 
Volutella, Ascomycota [Volutella consors (Ellis & Everh.) Seifert, Gräfenhan & 
Schroers., GenBank FN598959; Identities = 432/443 (98%); Gaps = 4/443 (0%), 
Volutella sp., GenBank EF029211.1; Identities = 538/556 (97%); Gaps = 7/556 (1%)]. 
Volutella is a mitosporic fungus that has been poorly studied in the light of molecular 
phylogenetic analyses and includes about 120 described species.78 The top BLAST 
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matches were subsequently downloaded, including the type species V. ciliata (Alb. & 
Schw.: Fr.) Fr., and a maximum likelihood (ML) analysis61 was performed using methods 
outlined earlier.79 The ML analysis placed MSX58801 within a well-supported clade 
(based on 1000 ML bootstrap replicates) consisting of Volutella sp., and it was sister to a 
clade containing species of V. ciliata (Figure 20). Therefore, based on results of the 
BLAST search and ML phylogenetic analysis, the strain MSX58801 was identified as a 
Volutella sp. (Ascomycota; Pezizomycotina; Sordariomycetes; Hypocreomycetidae; 
Hypocreales; Nectriaceae). The sequence data for MSX58801 was deposited in GenBank 
(accession no KC963031). 
Extraction and Isolation. Six large scale fermentation cultures (LS-1 to LS-6) of 
the fungus MSX58801 were processed during the course of this project due to the 
challenges associated with getting the fungus to reliably produce the target compounds. 
Compound 2 was detected in LS-1, LS-3, and LS-4, compound 3 was detected only in 
LS-1, while compound 1 was detected in LS-3 and LS-4. None of the target compounds 
were detected in LS-2, LS-5, and LS-6. To each large-scale solid fermentation culture of 
MSX58801, 500 mL of 1:1 MeOH-CHCl3 were added. The culture was chopped with a 
spatula and shaken overnight (~16 h) at ∼100 rpm at rt. The sample was filtered with 
vacuum, and the remaining residues were washed with 100 mL of 1:1 MeOH-CHCl3. To 
the filtrate, 900 mL CHCl3 and 1500 mL H2O were added; the mixture was stirred for 2 h 
and then transferred into a separatory funnel. The bottom layer was drawn off and 
evaporated to dryness. The dried organic extract was re-constituted in 300 mL of 1:1 
MeOH-CH3CN and 200 mL of hexanes. The biphasic solution was stirred for an hour 
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and then transferred to a separatory funnel. The MeOH-CH3CN layer was drawn off and 
evaporated to dryness under vacuum. Each defatted material (860, 620, and 1000 mg, for 
LS-1, 3, and 4, respectively, which were found to produce the target compounds) was 
dissolved in a mixture of CHCl3-MeOH, adsorbed onto Celite 545, and fractionated via 
flash chromatography using a gradient solvent system of hexane-CHCl3-MeOH at a 40 
mL/min flow rate and 53.3 column volumes over 63.9 min to afford 5 fractions. Fraction 
3, which eluted with 100% CHCl3, was subjected to preparative HPLC using a gradient 
solvent system that initiated with 30:70 of CH3CN-H2O to 50:50 over 30 min at a flow 
rate of 21.24 mL/min to yield three sub-fractions. Sub-fractions 1, 2, and 3 which eluted 
at 13.0, 14.0 and 15.3 min, yielded compounds 3 (1.45 mg), 2 (9.67 mg) and 1 (2.46 mg), 
respectively. UPLC was used to evaluate the purity of the isolated compounds using a 
gradient solvent system that initiated with 20:80 CH3CN-H2O to 100% CH3CN over 4.5 
min; compounds 1 and 2 were >95% pure. 
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Figure 14. UPLC chromatograms of compounds 1 and 2 (ELSD detection) demonstarting 
>95% purity. 
O
O
O
HO
H
Waol A (1) 
O
O
O
HO
H
H
trans-Dihydrowaol A (2) 
 
 
42 
 
Figure 15. 1H NMR spectrum of waol A (1) [500 MHz, CDCl3]. 
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Figure 16. 1H NMR spectrum of trans-dihydrowaol A (2) [500 MHz, CDCl3]. 
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Figure 17. 13C NMR spectrum of trans-dihydrowaol A (2) [125 MHz, CDCl3]. 
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Figure 18. 1H NMR spectrum of cis-dihydrowaol A (3) [500 MHz, CDCl3]. 
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Figure 19. 13C NMR spectrum of cis-dihydrowaol A (3) [125 MHz, CDCl3]. 
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Figure 20. Phylogram of the most likely tree (-lnL = 1561.75) from a PHYML analysis of 
29 taxa based on ITS nrDNA sequence data (556 bp). Numbers refer to PHYML 
bootstrap support values ≥ 70% based on 1000 replicates. MSX58801 identified as 
Volutella sp. (highlighted in green). Bar indicates nucleotide substitution per site.
 
 
48 
Table 5. NMR Data for trans-Dihydrowaol A (2) and cis-Dihydrowaol A (3) [500 MHz for 1H, 125 MHz for 
13C; Chemical Shifts in δ, Coupling Constants in Hz, CDCl3] 
 
position 
2 3 
δC, type δH, mult (J in Hz) δC, type δH, mult (J in Hz) 
2 81.2, CH 4.03, ddd (5.2, 2.9, 1.7) 77.5, CH 3.82, ddd (5.7, 2.3, 1.2) 
3 66.3, CH 3.84, bq (2.9) 65.3, CH 3.71, ddd (3.4, 2.3, 1.2) 
4α 30.0, CH2 1.79, ddd (13.2, 12.6, 2.9) 27.9, CH2 2.02, ddd (14.9, 7.5, 3.4) 
4β  2.43, ddd (13.2, 3.4, 2.9)  2.57, ddd (14.9, 2.3, 1.2) 
4a 39.0, CH 2.91, ddd (12.6, 12.0, 3.4) 34.3, CH 2.58, ddd (7.5, 2.3, 0.6) 
5 173.5, C -- 177.2, C -- 
7 82.4, CH 4.67, dd (8.6, 8.0) 83.8, CH 4.97, ddd (5.7, 4.6, 1.7) 
7a 82.1, CH 3.48, dd (12.0, 8.6) 77.9, CH 4.17, dd (4.6, 0.6) 
1' 126.4, CH 5.55, ddq (15.5, 5.2, 1.7) 127.6, CH 5.54, ddq (15.5, 5.7, 1.7) 
2' 130.6, CH 5.91, dqd (15.5, 6.9, 1.7) 129.8, CH 5.85, dqd (15.5, 6.9, 1.2) 
3' 18.1, CH3 1.77, dd (6.9, 1.7) 18.1, CH3 1.74, dd (6.9, 1.7) 
1′′ 125.7, CH 5.52, ddq (15.5, 8.0, 1.7) 124.7, CH 5.43, ddq (15.5, 5.7, 1.7) 
2'' 134.3, CH 5.99, dq (15.5, 6.9) 130.2, CH 5.85, dqd (15.5, 6.9, 1.7) 
3'' 18.2, CH3 1.77, dd (6.9, 1.7) 17.9, CH3 1.72, dd (6.9, 1.7) 
3-OH − 1.84, br s − 1.76, br s 
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CHAPTER IV 
 
SORBICILLINOID ANALOGUES WITH CYTOTOXIC AND SELECTIVE ANTI- 
ASPERGILLUS ACTIVITIES FROM SCYTALIDIUM ALBUM 
 
Tamam El-Elimat, Mario Figueroa, Huzefa A. Raja, Steven M. Swanson, Joseph O. 
Falkinham III, David M. Lucas, Mansukh C. Wani, Cedric J. Pearce, and Nicholas 
H. Oberlies. This chapter is intended for submission to Journal of Antibiotics (2014). 
 
As part of an ongoing project to explore filamentous fungi for anticancer and 
antibiotic leads, eleven bioactive compounds were isolated and identified from an organic 
extract of the fungus Scytalidium album (MSX51631) using bioactivity-directed 
fractionation against a human cancer cell panel. Of these, eight were a series of 
sorbicillinoid analogues (1-8), of which four were new [scalbucillin A (2), scalbucillin B 
(3), scalbucillin C (6) and scalbucillin D (8)], two were phthalides (9-10), and one was 
naphthalenone (11). Compounds (1-11) were tested in the MDA-MB-435 (melanoma) 
and SW-620 (colon) cancer cell lines. Compound 1 was the most potent with IC50 values 
of 1.5 µM, respectively, followed by compound 5, with IC50 values of 2.3 and 2.5 µM at 
72 h. Compound 1 showed a 48-h IC50 value of 3.1 µM when tested against the 
lymphocytic leukemia cell line OSU-CLL. Compounds 1 and 5 showed selective and 
equipotent activity against Aspergillus niger with minimum inhibitory concentration 
values of 0.05 and 0.04 µg/ml (0.20 and 0.16 µM), respectively. The in vitro hemolytic 
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activity against sheep erythrocytes of compounds 1 and 5 was investigated and were 
found to provoke 10% hemolysis at 45 and 37.5 µg/ml, respectively. 
 
Introduction 
Bioactivity-directed purification studies of filamentous fungi from the 
Mycosynthetix library, representing over 55,000 accessions, have yielded structurally 
diverse cytotoxic secondary metabolites.17,62,63,80-82 As part of these, the organic extract of 
a solid phase culture of a fungus identified as Scytalidium album (MSX51631), which 
was isolated in 1990 from Cobb county, Georgia, USA, showed promising cytotoxic 
activities against the SW-620 (colon) and MDA-MB-435 (melanoma) cancer cell lines. 
Bioactivity-directed fractionation resulted in the isolation and identification of eight 
sorbicillinoid analogues (1-8), of which four were new [scalbucillin A (2), scalbucillin B 
(3), scalbucillin C (6) and scalbucillin D (8)] and four were known [5'-formyl-2'-
hydroxyl-4'-methoxy-(E,E)-sorbophenone (1), 1-(2'-hydroxy-4'-methoxy-5'-
methylphenyl)-2,4-E,E-hexadien-1-one (4), 5′-formyl-2′-hydroxy-4′-methoxy-(E)-4-
hexenophenone (5), and 1-(2'-hydroxy-4'-methoxy-5'-hydroxymethylphenyl)-E-4-hexen-
1-one (7)]. Also isolated were two phthalides [5,7-dimethoxyphthalide (9) and 4,6-
dimethoxyphthalide (10)] and one naphthalenone [isosclerone (11)]. Compounds 1-11 
were evaluated for cytotoxicity against a human cancer cell panel and for antimicrobial 
activity in an array of bacteria and fungi. The hemolytic activity of compounds 1, 3, and 
5 was measured against sheep red blood cells. Compounds 1 and 5 were further evaluated 
for growth inhibitory activity against a B-lymphocytic leukemia cell line, OSU-CLL.83 
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Overall, the growth inhibitory activity of the primary organic extract was attributed to 
compounds 1 and 5. 
Results and Discussion 
Two solid-substrate large-scale cultures of the fungus Scytalidium album were 
extracted with 1:1 CHCl3-MeOH and partitioned with water. The vacuum-dried organic 
extract was then defatted with 1:1 CH3CN/MeOH-hexane. The resulting CH3CN/MeOH-
soluble extract showed cytotoxic activity against the SW-620 and MDA-MB-435 cancer 
cell lines (~83% and 71% inhibition of cell growth when tested at 20 µg/ml, respectively) 
and was subjected to fractionation using flash chromatography. Active fractions on the 
two cancer cell lines were purified using reversed-phase preparative and semi-preparative 
HPLC to yield compounds 1-11 with >95% purity as evidenced by UPLC 
(Supplementary Figure 23). 
A series of eight sorbicillinoid analogues (1-8), of which four were new, all 
possessing the carbon skeleton of the known antibiotic, sorbicillin,84 were isolated and 
identified in this study. The NMR, HRMS, and UV data identified 1 (13.87 mg) and 5 
(3.25 mg) as the known 5'-formyl-2'-hydroxyl-4'-methoxy-(E,E)-sorbophenone and 5′-
formyl-2′-hydroxy-4′-methoxy-(E)-4-hexenophenone, respectively. Both of these were 
isolated in 1973 from the fungus Scytalidium sp. FY strain.85 In an analogous manner, 
compounds 4 (5.89 mg) and 7 (8.21 mg) were identified as the known 1-(2'-hydroxy-4'-
methoxy-5'-methylphenyl)- E,E-2,4-hexadien-1-one, and 1-(2'-hydroxy-4'-methoxy-5'-
hydroxymethylphenyl)-E-4-hexen-1-one, respectively. Both 4 and 7 were isolated in 
2006 from a fungicolous isolate of the genus Phaeoacremonium.86 Characterization data 
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for all isolates compared favorably with the literature (See Supplementary Figures 24, 27, 
28, and 30 for 1H and 13C NMR spectra of compounds 1, 4, 5, and 7, respectively).  
Four new sorbicillinoid analogues (2, 3, 6, and 8) were isolated as well, and their 
structures were identified by comparison of HRMS and NMR data with each other and 
with structurally related known compounds. Compound 2 (1.77 mg) was obtained as a 
yellow powder. The molecular formula was determined as C14H14O5 via HRESIMS 
along with 1H, 13C, and edited-HSQC data (Tables 6 and 8, Supplementary Figure 25), 
establishing an index of hydrogen deficiency of 8. Inspection of the HRMS and NMR 
data suggested 2 as a sorbicillinoid analogue with structural similarity with 1. For 
example, compound 2 showed the characteristic C1'-C6' sorbyl side chain, as noted by 
two conjugated double bonds with coupling constants consistent with an E, E 
configuration (JH-2/H-3 and JH-4/H-5 = 14.6 Hz) that were conjugated with a ketone 
carbonyl (δC 192.8) that was further conjugated with an aryl group. Additional 
similarities included NMR signals characteristic of six aromatic carbons and two singlet 
aromatic protons, suggesting a 1,2,4,5-tetrasubstituted benzene ring with two aromatic 
protons para to each other, a methoxy group, and a hydrogen-bonded phenolic proton. 
All of the benzene ring substituents were confirmed by HMBC correlations (Figure 22). 
Key differences between compounds 1 and 2 were the replacement of the singlet 
aldehyde proton and the carbonyl carbon in 1 (δH/δC 10.27/187.7) by a broad 
exchangeable proton and a carboxylic acid carbon in 2 (δH/δC 10.05/164.3). These data, 
along with an extra oxygen atom in 2 relative to 1, as supported by a 16 amu difference in 
the HRMS data, suggested that the aldehyde substituent at C-5' of the benzene ring in 1 
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was replaced by a carboxylic acid group in 2. The trivial name scalbucillin A was 
ascribed to 2. 
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Figure 21. Structure of compounds (1-11) isolated from S. album. 
Compound 3 (1.10 mg) was obtained as a yellow powder with a molecular formula 
of C14H16O4 as determined by HRESIMS and analysis of 1H NMR, 13C NMR, and 
edited-HSQC data (Tables 6 and 8, Supplementary Figure 26). Inspection of the NMR 
data suggested compound 3 as a sorbicillinoid analogue with structural similarity to 7. 
However, compound 3 lacked the four aliphatic protons H2-2 and H2-3 (δH 2.98 and 
2.41), which were replaced by two olefinic protons (δH 6.95 and 7.49) with a coupling 
constant consistent with an E configuration (JH-2/H-3 = 15.0 Hz). Conjugation of the C2-
C3 double bond with the ketone carbonyl resulted in an upfield shift of the chemical shift 
of C1 in 3 relative to 7. Further examination of the NMR data, including COSY and 
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HMBC spectra (Figure 22), yielded the structure of 3, which was ascribed the trivial 
name scalbucillin B. 
Compound 6 (9.97 mg) was obtained as a white powder. The chemical formula was 
determined as C15H18O5 by HRESIMS and analysis of 1H NMR, 13C NMR, and edited-
HSQC data (Tables 7 and 8, Supplementary Figure 29). Examining the NMR data 
suggested a sorbicillinoid analogue with structural similarity to 5 (Table 7). As in 5, 
compound 6 showed NMR signals consistent with a side chain containing two-coupled 
olefinic protons with a coupling constant that supported an E configuration (JH-4/H-5 = 
15.5 Hz). A chemical shift of the ketone carbonyl of 204.7 ppm indicated the lack of 
conjugation with the double bond. Furthermore, the presence of a three proton doublet of 
doublets (δH-6 1.65, dd, J = 6.3, 1.2 Hz) with a chemical shift and coupling constants 
consistent with an allylic position established the side chain of compound 6 (Figure 21). 
Additional similarities included NMR data characteristic of a 1,2,4,5-tetrasubstituted 
benzene ring with two sharp singlet aromatic protons, indicating positions para to each 
other. A sharp singlet proton (δH 13.05), which did not show single bond coupling to a 
carbon as evidenced from the edited HSQC experiment, indicated a phenolic proton ortho 
to the side chain and hydrogen-bonded with the carbonyl carbon. Key differences 
between compounds 5 and 6 include replacement of the aldehyde proton in 5 (δH 10.26) 
by a methoxy functionality in 6 (δH/δC 3.88/52.2) and replacement of the aldehyde 
carbon (δC 187.5) by an ester functionality (δC 165.4). These data, along with a 30 amu 
difference in the HRMS data of compounds 5 and 6, indicated replacement of the 
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aldehyde in 5 by a methyl ester in 6.  The trivial name scalbucillin C was ascribed to 
compound 6.  
Compound 8 (2.47 mg), which was obtained as a white powder, had a molecular 
formula of C14H18O3 as determined by HRESIMS and analysis of 1H NMR, 13C NMR 
and edited-HSQC data (Tables 7 and 8, Supplementary Figure 31). The NMR data of 8 
indicated a sorbicillinoid analogue with structural similarity to 4. However, 8 lacked the 
H-2 and H-3 olefinic protons, which were replaced by four aliphatic protons (δH 2.95 and 
2.40 for H2-2 and H2-3, respectively). This resulted in a downfield shift of C1 in 8 (δC 
204.2), relative to that in 4 (δC 192.3), since the latter conjugates with the C2-C3 double 
bond. Further analysis of the NMR data including COSY and HMBC experiments 
(Figure 22), yielded the structure of 8, which was ascribed the trivial name scalbucillin D. 
In addition to compounds 1-8, two known phthalides [5,7-dimethoxyphthalide 
(9)87,88 and 4,6-dimethoxyphthalide (10)89,90], and one known naphthalenone [isosclerone 
(11)]91 were isolated and identified by comparison of NMR, HRMS, and optical rotation 
data (for compound 11) to the literature. This is the first report of 10 from a fungal 
source. 
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Figure 22. Key HMBC and COSY correlations of compounds 2, 3, 6, and 8. 
Table 6. 1H NMR Data for Compounds 2 and 3 (in CDCl3, 700 MHz, 
Chemical Shifts in δ, Coupling Constants in Hz) 
 
position 
2 3 
δH, Mult. (J in Hz) δH, Mult. (J in Hz) 
2 7.05, d (14.6) 6.95, d (15.0) 
3 7.54, dd (14.6, 9.9) 7.49, dd (15.0, 10.6) 
4 6.39, m 6.34, m 
5 6.38, dq (14.6, 5.1) 6.31, dq (15.0, 6.4) 
6 1.94, d (5.1) 1.92, dd (6.4, 0.6) 
3ʹ 6.58, s 6.46, s 
6ʹ 8.74, s 7.71, s 
7ʹ ― 4.64, d (6.1) 
8ʹ 4.12, s 3.90, s 
9' ― ― 
2ʹ-OH 13.87, s 13.58, s 
7ʹ-OH 10.05, bs 2.02, t (6.1) 
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Table 7. 1H NMR Data for Compounds 6 and 8 (in CDCl3, 500 MHz, 
Chemical Shifts in δ, Coupling Constants in Hz) 
 
position 
6 8 
δH, Mult. (J in Hz) δH, Mult. (J in Hz) 
2 3.02, dd (7.5, 6.9) 2.95, dd (8.0, 7.5) 
3 2.41, ddd (7.5, 6.9, 6.3) 2.40, ddd (8.0, 7.5, 5.2) 
4 5.49, dtq (15.5, 6.3, 1.2) 5.49, dtq (15.5, 5.2, 0.6) 
5 5.50, dq (15.5, 6.3) 5.50, dq (15.5, 5.2) 
6 1.65, dd (6.3, 1.2) 1.65, dd (5.2, 0.6) 
3ʹ 6.47, s 6.37, s 
6ʹ 8.37, s 7.44, s 
8ʹ 3.88, s 3.84, s 
9' 3.93, s ― 
2ʹ-OH 13.05 12.79, s 
 
Table 8. 13C NMR Data for Compounds 2, 3, 6 and 8 (in CDCl3, 175 
MHz for 2 and 3 and 125 MHz for 6 and 8, Chemical Shifts in δ) 
 
position 2 3 6 8 
1 192.8 192.4 204.7 204.2 
2 120.6 121.4 38.0 38.0 
3 146.9 145.1 27.2 27.5 
4 130.4 130.4 129.2 129.6 
5 143.5 141.8 126.6 126.2 
6 19.1 19.0 18.0 18.0 
1ʹ 115.1 113.3 112.9 112.7 
2ʹ 169.6 166.5 167.9 164.0 
3ʹ 100.5 99.7 100.5 99.0 
4ʹ 163.1 163.8 165.5 164.3 
5ʹ 109.2 120.7 111.6 118.1 
6ʹ 137.2 129.9 135.9 131.1 
7ʹ 164.3 61.2 165.4 15.8 
8ʹ 57.2 55.8 52.2 55.8 
9' ― ― 56.5 ― 
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The cytotoxicity of compounds (1-11) were measured against MDA-MB-435 and 
SW-620 cancer cell lines. Compound 1 was the most potent with IC50 values 
(concentrations that inhibit growth by 50% relative to untreated cells) of 1.5 and 0.5 µM, 
respectively, followed by compound 5, with IC50 values of 2.3 and 2.5 µM, respectively 
(Table 9). Testing of closely related analogues permitted preliminary conclusions 
regarding structure-activity relationships, particularly the importance of the aldehyde 
group at 5´. Replacing the aldehyde with a carboxylic acid rendered the compounds 
inactive, as in 2. A second important structural feature was the requirement of the intact 
sorbyl side chain for biological activity. Compound 5, with a reduced C2-C3 double 
bond, was less active by 1.5 and 5 fold in comparison with 1 when measured against the 
MDA-MB-435 and SW-620 cancer cell lines, respectively. This latter observation was 
supported by moderate growth inhibitory activity with compounds 3 and 4 that was not 
present in compounds 7 and 8, which differ only by reduction of the same double bond. 
Interestingly, compound 1 was similarly active against the B-lymphocytic leukemia cell 
line OSU-CLL as compared to the solid tumor cell lines (48-hr IC50 of 3.1 µM), but 
compound 5 lacked significant activity in this context. Compound 1, which was isolated 
previously from the fungus Scytalidiun album,85,92 displayed cytotoxic activity when 
tested against 9KB as reported by the National Cancer Institute (NSC 174259), with ED50 
(dose that inhibits growth to 50% of the control growth by 3 days after addition of the 
drug) value of 0.3 µg/mL.92 Neither the researchers’ own activity data of compound 1 nor 
the NCI data were published (Personal communication with Dr. David Newman, 
National Cancer Institute).   
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Table 9. Activity of Compounds 1-11 Against Two 
Human Tumor Cell Lines 
 
compounda 
IC50 values in µMb 
MDA-MB-435c SW-620c 
1 1.5 0.5 
3 67.9 16.0 
4 65.2 15.1 
5 2.3 2.5 
aCompounds 2 and 6-11 were inactive. 
bIC50 values were determined as the concentration required 
to inhibit growth to 50% of control with a 72 h incubation. 
cPositive control was vinblastine tested at concentration of 1 
nM in MDA-MB-435 cells and 10 nM in SW620 cells, 
which had 48% and 30% viable cells, respectively. 
 
The antimicrobial activity of the isolated compounds (1-11) was evaluated against a 
panel of bacteria and fungi (Table 10). Compounds 1 and 5 showed selective and 
equipotent activity against the filamentous fungus Aspergillus niger with MIC values of 
0.05 and 0.04 µg/ml, respectively, followed by compound 3 with an MIC value of 0.60 
µg/ml. Relative to amphotericin B, a clinically used agent that was used as a positive 
control, compounds 1 and 5 were more potent by more than two orders of magnitude. A 
hemolytic assay was used to assess the toxicity of compounds 1, 3, and 5 towards sheep 
red blood cells in vitro. Compounds 1, 3, and 5 resulted in 10% hemolysis of sheep red 
blood cells at 45.0, 52.5, and 37.5 µg/ml, respectively, with safety factors (calculated as 
the 10% hemolysis concentration over MIC) of 900.0, 87.5, and 937.5, respectively 
(Table 10). Antifungal activities in disk assays against A. flavus and F. verticillioides of 
compounds 1 and 7 were reported previously by Reátegui et al.86 In the current study, 
compound 7 showed no activity in the tested fungal strains. 
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Table 10. Antifungal and Hemolytic Activity of Compounds 1, 3, and 5 
compound 
Minimal inhibitory concentration (µg/ml) 10% Hemolysis 
(µg/ml)a 
Safety 
factorb C. albicans C. neoformans A. niger 
1 >53 >53 0.05 52.5 1050 
3 >38 >38 0.60 37.5 62.5 
5 >45 >45 0.04 45.0 1125 
Amphotericin Bc 16 8 31 NT NA 
Triton X-100c NT NT NT 0.40 NA 
aHemolytic activity is the concentartion required to provoke 10% hemolysis. 
bSafety factor was calculated as the concentration inducing 10% hemolysis over MIC 
against A. niger. 
cPositive controls. 
Abbreviations: NT, not tested. NA, not available. 
 
Conclusions 
A series of eight sorbicillinoid analogues (1-8), of which four were new, along with 
two phthalides (9-10), and one naphthalenone (11), were isolated from the fungus 
Scytalidium album (MSX51631). Although the sorbicillinoid family encompasses over 50 
members, only 4 sorbicillin-type phenolics, as described by Harned et al,84 have been 
isolated previously from natural sources. This study served to double that to eight related 
analogues; it is not clear, however, if these compounds are produced by the same 
biosynthetic route that leads to sorbicillin.84 This report expands significantly upon the 
structure-activity relationship of these compounds in cytotoxicity assays, establishing the 
importance of the aldehyde moiety at the 5' position and the conjugated sorbyl side chain. 
Whether the aldehyde was oxidized to the carboxylic acid (such as compound 2), or 
reduced to the primary alcohol (such as compound 3), the growth inhibitory was 
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diminished, suggesting the reaction of the aldehyde-containing compounds with DNA or 
proteins to form Schiff base adducts.93,94 
Similarly, when the aldehyde was retained but the sorbyl side chain was reduced, as 
in compound 5 versus 1, the growth inhibitory activity was reduced by 1.5-5 fold in solid 
tumor cell lines, and at least ten-fold in a B-lymphocytic cell line (IC50 of 5 not reached 
in these cells). This is in clear contrast to the activities of compounds 1 and 5 against A. 
niger, in which they are effectively equipotent. This difference suggests that the saturated 
sorbyl side chain is important for the biologic activity of compound 1 only in mammalian 
cells. This interesting observation may not only provide clues as to mechanism of action 
of this class of agents, it also suggests that compound 5 may be a potential candidate for 
drug development as an antifungal, as it may not elicit substantial negative effects in 
normal cells.  This hypothesis is supported by the relatively high safety factor of 
compound 5 (as well as 1) with regards to hemolysis of sheep red blood cells. In addition 
to compounds 1 and 5, compound 3 also showed selective potency against A. niger, with 
a similarly low toxicity toward sheep red blood cells in vitro but a lower safety factor 
(i.e., higher MIC). 
The discovery of strong, narrow-spectrum anti-A. niger activity underscores the 
utility of subjecting natural products to as wide a screen as possible to detect biological 
activity. Aspergillus species are highly invasive to human beings and continue to present 
safety challenges for agricultural products and food, the exploration of novel structures 
for potential application in these settings is a high priority. The exceptional potency and 
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apparent selectivity of several of the compounds isolated here strongly supports further 
exploration of this class of secondary metabolites. 
Methods 
General. UV spectra were obtained using a Varian Cary 100 Bio UV-Vis 
spectrophotometer (Varian Inc., Walnut Creek, CA, USA). NMR data were collected 
using either a JEOL ECA-500 NMR spectrometer operating at 500 MHz for 1H and 125 
MHz for 13C, or a JEOL ECS-400 NMR spectrometer equipped with a high sensitivity 
JEOL Royal probe and a 24-slot autosampler operating at 400 MHz for 1H and 100 MHz 
for 13C (both from JEOL Ltd., Tokyo, Japan), or an Agilent 700 MHz NMR spectrometer 
(Agilent Technologies, Inc., Santa Clara, CA, USA), equipped with a cryoprope, 
operating at 700 MHz for 1H and 175 MHz for 13C. Residual solvent signals were utilized 
for referencing. High resolution mass spectra (HRMS) were obtained using a Thermo 
LTQ Orbitrap XL mass spectrometer equipped with an electrospray ionization source 
(Thermo Fisher Scientific, San Jose, CA, USA). A Waters Acquity UPLC system 
(Waters Corp., Milford, MA, USA) utilizing a Waters BEH C18 column (1.7 µm; 50 × 
2.1 mm) was used to check the purity of the isolated compounds with data collected and 
analyzed using Empower software. Phenomenex Gemini-NX C18 analytical (5 µm; 250 × 
4.6 mm), preparative (5 µm; 250 × 21.2 mm), and semipreparative (5 µm; 250 × 10.0 
mm) columns (all from Phenomenex, Torrance, CA, USA) and a YMC ODS-A analytical 
(5 µm; 150 × 4.6 mm), preparative (5 µm; 250 × 20 mm), and semipreparative (5 µm; 
250 × 10.0 mm) columns (all from YMC America, Inc., Allentown, PA, USA) were used 
on a Varian Prostar HPLC system equipped with ProStar 210 pumps and a Prostar 335 
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photodiode array detector (PDA), with data collected and analyzed using Galaxie 
Chromatography Workstation software (version 1.9.3.2, Varian Inc.). Flash 
chromatography was conducted on a Teledyne ISCO CombiFlash Rf using Silica Gold 
columns and monitored by UV and evaporative light-scattering detectors (both from 
Teledyne Isco, Lincoln, NE, USA). 
Fungal Strain Isolation and Identification. Mycosynthetix fungal strain 
MSX51631 was collected in 1990 from Cobb County, Georgia, USA. Molecular 
techniques were used to identify the strain by sequencing the nuclear internal transcribed 
spacers and intervening 5.8S gene45 along with the D1/D2 regions of the adjacent nuclear 
ribosomal large subunit.95,96 DNA extraction, PCR amplification, sequencing, and 
phylogenetic analyses were conducted as described previously.63,81,97-99 The ITS region 
was used for species-level identification using the pairwise sequence alignment option on 
the Fungal Barcoding webpage (http://www.fungalbarcoding.org/).96 This function allows 
performing online alignment between an input (query) sequence and the available 
sequences in the database, which comprise different curated global fungal databases, 
including, Q-bank Fungi database (http://www.q-bank.edu/Fungi); CBS-KNAW Fungal 
Biodiversity Centre (http://www.cbs.knaw.nl/Collections); Molecular Mycology 
Research Laboratory (http://www.mycologylab.org/); Portuguese Yeast Culture 
Collection (http://pycc.bio-aware.com/); and NCBI GenBank. The search returns the 
best-matching piecewise (local) or global alignments of two query sequences. 
Identifications were performed in a monophasic way; in which sequences were compared 
to produce a global similarity or probability coefficient between the unknown sequence 
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and the reference sequence database (http://www.fungalbarcoding.org/). Based on the 
results of the pairwise sequence alignment, the closest genus and species that matched the 
ITS sequence of the strain MSX51631 were representatives of Scytalidium album 
(isotype sequence; CBS 372.65) (identities = 482/485 (99.3%), gaps = 0), the other 
closest matches included those of Ascomycota sp. olrim237 (AY787735; identities = 
470/470 (100%), gaps = 0), Ascomycota sp. olrim349 (HM036638; identities = 454/454 
(100%), gaps = 0). Pairwise sequence alignment was also performed with combined ITS-
LSU region, which suggested that the closest match of the query sequence was 
Scytalidium album (isotype sequence; CBS 372.65) (identities = 927/942 (98%), gaps = 6 
(0.7%). 
A combined ITS-LSU rDNA complete linkage tree was generated using pairwise 
sequence alignment search on the Fungal Barcoding webpage (Supplementary Figure 
35). Therefore, the strain MSX51631 was identified as having affinities to Scytalidium 
album L. Beyer & Klingström. (Helotiales, Leotiomycetidae, Leotiomycetes, 
Pezizomycotina, Ascomycota). The combined ITS-LSU sequence will be deposited in the 
GenBank (accession no XXXX). 
Fermentation, Extraction and Isolation. Storage conditions, fermentation, and 
extraction procedure of the fungal strain MSX51631 were as described previously.19,62,63 
Briefly, cultures of strain MSX51631 were grown in 2.8-l Fernbach flasks (Corning, Inc., 
Corning, NY, USA) containing 150 g rice and 300 ml H2O. A seed culture grown in 
YESD medium was used as an inoculum. Following incubation at 22 °C for 14 d, the 
solid culture was extracted by adding a 500 ml mixture of 1:1 MeOH-CHCl3. The culture 
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was cut into small pieces using a spatula and shaken for about 16 h at ~125 rpm at rt, 
followed by vacuum filtration. The remaining residues were washed with 100 ml of 1:1 
MeOH-CHCl3. To the filtrate, 900 ml CHCl3 and 1500 ml H2O were added; the mixture 
was stirred for ½ h and then transferred into a separatory funnel. The bottom layer was 
drawn off and evaporated to dryness. The dried organic extract was re-constituted in 100 
ml of 1:1 MeOH-CH3CN and 100 ml of hexanes. The biphasic solution was shaken 
vigorously and then transferred to a separatory funnel. The MeOH-CH3CN layer was 
drawn off and evaporated to dryness under vacuum. The defatted material (~750 mg) was 
dissolved in a mixture of CHCl3-MeOH, adsorbed onto Celite 545, and fractionated via 
flash chromatography using a gradient solvent system of hexane-CHCl3-MeOH at a 30 
ml/min flow rate and 61.0 column volumes over 34.1 min to afford five fractions. 
Fraction 2 (~315.97 mg) was subjected to preparative reversed phase HPLC over a 
Phenomenex Gemini-NX C18 preparative column using a gradient system of 50:50 to 
70:30 over 50 min to 100:00 of CH3CN-H2O (acidified with 0.1% formic acid) at a flow 
rate of 21 ml/min to yield thirteenth sub-fractions. Sub-fractions 2 and 7 yielded 
compounds 11 (0.46 mg) and 3 (0.55 mg), which eluted at ~6.5 and ~27.5 min, 
respectively. Sub-fractions 8-11 were subjected to further purifications. Sub-fraction 8 
(3.23 mg) was subjected to semi-preparative HPLC purification over a Phenomenex 
Gemini-NX C18 column using a gradient system of 50:50 to 60:40 of CH3CN-H2O 
(acidified with 0.1% formic acid) over 15 min at a flow rate of 4.72 ml/min to yield 
compounds 2 (0.75 mg) and 7 (1.65 mg), which eluted at ~8.2 and ~10.5 min, 
respectively. Sub-fraction 9 (9.14 mg) was subjected to semi-preparative HPLC 
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purification using a Phenomenex Gemini-NX C18 and a gradient system of 70:30 to 
80:20 of CH3OH-H2O (acidified with 0.1% formic acid) over 20 min at a flow rate of 
4.72 ml/min to yield compound 1 (3.10 mg) that eluted at ~12.5 min. Sub-fraction 10 
(14.2 mg) was subjected to preparative HPLC purification using a YMC ODS-A column 
and an isocratic solvent system of 60:40 of CH3OH-H2O (acidified with 0.1% formic 
acid) at a flow rate of 15 ml/min to yield compounds 1 (5.21 mg), 5 (4.16 mg), and 6 
(1.83 min), which eluted at ~80.2, ~91.5, and ~106.3 min, respectively. Sub-fraction 11 
(146.52 mg) was subjected to preparative HPLC purification using a Phenomenex 
Gemini-NX C18 and a gradient system of 60:40 to 100:00 of CH3CN-H2O (acidified with 
0.1% formic acid) over 30 min at a flow rate of 21.24 ml/min to yield compounds 1 (3.33 
mg) and 4 (3.10 mg), which eluted at ~11.0 and ~16.3 min, respectively. To obtain purity 
over 95% as measured by UPLC, compounds 5-6 were further purified using 
semipreparative reversed phase HPLC.  
Another two large scale cultures of MSX51631 were extracted, combined, and 
fractionated as described above. The MeOH-CH3CN fraction (1.77 g) was subjected to 
fractionation using flash chromatography and a gradient solvent system of hexane-
CHCl3-MeOH at a 40 ml/min flow rate and 53.3 column volumes over 63.9 min to afford 
four fractions. Fraction 2 (~868.95 mg) was subjected to extensive purifications using 
preparative and semipreparative reversed phase HPLC and yielded additional amounts of 
compounds 1-7, which were isolated from the first processed large scale of MSX51631, 
along with compounds 8 (2.47 mg), 9 (5.54 mg), and 10 (7.91 mg). 
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Scalbucillin A (2): Compound 2 was isolated as a yellow solid (1.77 mg); UV 
(MeOH) λmax (log ε) 349 (3.57), 309 (3.64), 247 (3.51), 222 (3.47) nm; 1H NMR (CDCl3, 
700 MHz) and 13C NMR (CDCl3, 175 MHz), see Tables 6 and 8 and Supplementary 
Figure 25; HRESIMS m/z  263.0910  [M + H]+ (calcd for C14H15O5 263.0914). 
Scalbucillin B (3): Compound 3 was isolated as a yellow solid (1.10 mg); UV 
(MeOH) λmax (log ε) 349 (3.22), 310 (3.31), 231 (3.22) nm; 1H NMR (CDCl3, 700 MHz) 
and 13C NMR (CDCl3, 175 MHz), see Tables 6 and 8 and Supplementary Figure 26; 
HRESIMS m/z  249.1115  [M + H]+ (calcd for C14H17O4 249.1121). 
Scalbucillin C (6): Compound 6 was isolated as a white solid (9.97 mg); UV 
(MeOH) λmax (log ε) 312 (3.56), 275 (3.71), 246 (3.71) nm; 1H NMR (CDCl3, 500 MHz) 
and 13C NMR (CDCl3, 125 MHz), see Tables 7 and 8 and Supplementary Figure 29; 
HRESIMS m/z  279.1221  [M + H]+ (calcd for C15H19O5 279.1227). 
Scalbucillin D (8): Compound 8 was isolated as a white solid (2.47 mg); UV 
(MeOH) λmax (log ε) 324 (3.61), 275 (3.65), 237 (3.62) nm; 1H NMR (CDCl3, 500 MHz) 
and 13C NMR (CDCl3, 125 MHz), see Tables 7 and 8 and Supplementary Figure 31; 
HRESIMS m/z  235.1323  [M + H]+ (calcd for C14H18O3 235.1329). 
Cytotoxicity Assays. Compounds (1-11) were tested against the MDA-MB-435100 
human melanoma (HTB-129, ATCC) and the SW-620101 human colorectal 
adenocarcinoma (CCL-227, ATCC) cell lines as described previously.19 Compounds 1 
and 5 were also tested against the B-lymphocytic cell line OSU-CLL83 using CellTiter 96 
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reagents according to the manufacturer’s instructions (Promega, Madison WI). The 48-hr 
IC50 of compound 1 was calculated using Prism software (GraphPad, La Jolla, CA).  
Antimicrobial Assay. Minimal inhibitory concentrations (MICs) of compounds (1-
11) against a panel of bacteria and fungi were measured as described previously.18,102,103 
All measurements were made in duplicate. 
Hemolytic Assay. Hemolytic activity of compounds 1, 3, and 5 was measured 
against sheep red blood cells as described elsewhere.104 
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Supporting Information 
 
 
 
 
Figure 23. UPLC chromatograms of compounds 1-11 (λ 254 nm) demonstarting >95% 
purity. Acquity UPLC system; ACQUITY UPLC BEH C18 1.7 μm 2.1 × 50 mm column; 
gradient CH3CN/H2O 20 to 100% over 4.5 min; Injection volume 3 μl. 
 
  
(1) (2) 
(3) (4) 
(5) (6) 
(7) (8) 
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Figure 23 (continued). UPLC chromatograms of compounds 1-11 (λ 254 nm) 
demonstarting >95% purity. Acquity UPLC system; ACQUITY UPLC BEH C18 1.7 μm 
2.1 × 50 mm column; gradient CH3CN/H2O 20 to 100% over 4.5 min; Injection volume 
3 μl. 
(9) (10) 
(11) 
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Table 11. Antimicrobial Activities of Compounds (1-11) 
compound 
Minimal inhibitory activity (µg/mL) 
M. 
luteus 
S. 
aureus E. coli 
M. 
smegmatis 
S. 
cerevisiae 
C. 
albicans 
C. 
neoformans A. niger 
1 >53 >53 >53 >53 >53 >53 >53 0.05 
2 >108 >108 >108 >108 >108 >108 >108 >108 
3 >38 >38 >38 >38 >38 >38 >38 0.60 
4 >118 >118 >118 >118 >118 >118 >118 >118 
5 >45 >45 >45 >45 >45 >45 >45 0.04 
6 >105 >105 >105 >105 >105 >105 >105 >105 
7 >105 >105 >105 >105 >105 >105 >105 >105 
8 >85 >85 >143 >143 >143 >143 >143 >143 
9 >85 >85 >145 >145 >145 >145 >145 >145 
10 >85 >85 >85 >85 >85 >85 >85 >85 
11 >105 >105 >105 >105 >105 >105 >105 >105 
Ampicillina 4 0.2 >250 >250 >250 >250 >250 >250 
Rifamycina 0.06 0.2 31 4 >250 >250 >250 >250 
Amphotericin Ba >250 0.2 >250 >250 3.9 16 8 31 
aPositive controls 
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Figure 24. 1H and 13C NMR spectrra of compound 1 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 25. 1H and 13C NMR spectra of compound 2 [700 MHz for 1H and 175 MHz for 13C, CDCl3]. 
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Figure 26. 1H and 13C NMR spectra of compound 3 [700 MHz for 1H and 175 MHz for 13C, CDCl3]. 
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Figure 27. 1H and 13C NMR spectra of compound 4 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
1-(2'-hydroxy-4'-methoxy-5'-methylphenyl)-
E,E-2,4-hexadien-1-one (4)
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 Figure 28. 1H and 13C NMR spectra of compound 5 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 29. 1H and 13C NMR spectra of compound 6 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 30. 1H and 13C NMR spectra of compound 7 [400 MHz for 1H and 100 MHz for 13C, CDCl3]. 
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Figure 31. 1H and 13C NMR spectra of compound 8 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
Scalbucillin D (8)
OH
O
O
 
 
80 
 
Figure 32. 1H and 13C NMR spectra of compound 9 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 33. 1H and 13C NMR spectra of compound 10 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 34. 1H NMR spectrum of compound 11 [400 MHz, CDCl3]. 
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Figure 35. Complete linkage tree generated using complete ITS and partial region of the 
28S large subunit nrDNA (954 bp) using pairwise sequence alignment option using 
Fungal Barcoding website (http://www.fungalbarcoding.org). MSX51631 clusters in a 
clade (highlighted with dashed lines) with Scytalidium album as sister species.  
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CHAPTER V 
 
CYTOTOXIC POLYKETIDES FROM FUNGAL CO-CULTURE OF ASPERGILLUS 
VERSICOLOR AND SETOPHOMA TERRESTRIS 
 
Tamam El-Elimat, Mario Figueroa, Huzefa A. Raja, Tyler N. Graf, Audrey F. 
Adcock, David J. Kroll, Steven M. Swanson, Joseph O. Falkinham III, Mansukh C. 
Wani, Cedric J. Pearce, and Nicholas H. Oberlies. This chapter is intended for 
submission to Chemistry - A European Journal (2014). 
 
Sixteen polyketides belonging to diverse structural classes including 
monomeric/dimeric tetrahydroxanthones and resorcylic acid lactones were isolated from 
an organic extract of a fungal co-culture of Aspergillus versicolor and Setophoma 
terrestris (MSX45109) using bioactivity-directed fractionation as part of a search for 
anticancer leads from filamentous fungi. Of these, six were new: penicillixanthone B (5), 
blennolide H (6), 11-deoxy blennolide D (7), blennolide I (9), blennolide J (10), and 
pyrenomycin (16). The known compounds were: secalonic acid A (1), secalonic acid E 
(2), secalonic acid G (3), penicillixanthone A (4), paecilin B (8), aigialomycin A (11), 
hypothemycin (12), dihydrohypothemycin (13), pyrenochaetic acid C (14), and nidulalin 
B (15). The structures were elucidated using a set of spectroscopic and spectrometric 
techniques; the absolute configurations of compounds 1-10 were determined using CD 
spectroscopy combined with time-dependent density functional theory (TDDFT) 
calculations, while a modified Mosher’s ester method was used for compound 16. The 
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cytotoxic activities of compounds (1-15) were evaluated using the MDA-MB-435 
(melanoma) and SW-620 (colon) cancer cell lines. Compounds 1, 4, and 12 were the 
most potent with IC50 values ranging from 0.16 to 2.14 µM. When tested against a panel 
of bacteria and fungi, compounds 3 and 5 showed promising activity against the Gram-
positive bacterium Micrococcus luteus with MIC values of 5 and 15 µg/mL, respectively. 
 
Structurally diverse cytotoxic secondary metabolites have been isolated and 
identified from filamentous fungi of the Mycosynthetix library, representing over 55,000 
accessions, as part of ongoing bioactivity-directed studies for discovery of anticancer 
drug leads.17,19-22,62,63,80,82,105 As a continuation of such studies, the organic extract of a 
solid culture medium of a fungal co-culture of Aspergillus versicolor and Setophoma 
terrestris (MSX45109), which was isolated from plant material collected in a mangrove 
habitat in 1989, showed potent cytotoxic activities against the SW-620 (colon) and 
MDA-MB-435 (melanoma) cancer cell lines (~91% and 100% inhibition of cell growth 
when tested at 20 µg/mL, respectively). Bioactivity-directed fractionation resulted in the 
isolation and structural identification of sixteen polyketides belonging to diverse 
structural classes, of which six were new: penicillixanthone B (5), blennolide H (6), 11-
deoxy blennolide D (7), blennolide I (9), blennolide J (10), and pyrenomycin (16). The 
known compounds were: secalonic acid A (1), secalonic acid E (2), secalonic acid G (3), 
penicillixanthone A (4), paecilin B (8), aigialomycin (11), hypothemycin (12), 
dihydrohypothemycin (13), pyrenochaetic acid C (14), and nidulalin B (15). Compounds 
1-10 were identified as a series of monomeric/dimeric tetrahydroxanthones, an important 
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class of mycotoxins that are produced by a variety of microorganisms with remarkable 
biological activities.106,107 Ergochromes is a joint name for a group of structurally related 
compounds, including secalonic acids, ergoflavins, ergochrysins, and chrysergonic 
acid.107,108 They were isolated as homo/heterodimers of six monotetrahydroxanthones 
(hemisecalonic acids A-F).108 This class of biologically active mycotoxins, which have 
displayed  antitumor, antibacterial, and anti-HIV activities,109-112 was first isolated from 
ergot, Claviceps purpurea, in 1958.113 Of the six postulated monomeric 
tetrahydroxanthones (hemisecalonic acids A-F), only blennolide A and B, which are the 
monomer units of secalonic acids B and D, respectively, were isolated fairly recently.114 
In the current study, a series of new monomeric and homo/hetero dimeric 
tetrahydroxanthones were identified, which expanded the diversity of this class of natural 
products and updated the literature on structural elucidation and absolute configuration 
determination of structurally related compounds, and hence important for dereplication 
considerations.80 Interestingly, a recent and comprehensive study reported a similar series 
of compounds though with opposite absolute configuration.114 On the other hand, 
compounds 11-13 were characterized as a series of structurally related resorcylic acid 
lactones (RALs), a family of benzannulated macrolides that are produced by a variety of 
fungi with a wide range of biological activities, including antitumor, antifungal, 
antibiotic, and antiviral properties.115 The absolute configurations of compounds 1-10 
were determined using time-dependent density functional theory (TDDFT) calculations 
of CD spectra, while for 16 a modified Mosher’s ester method was used. The dimeric 
tetrahydroxanthone derivatives 1 and 4 and the RAL 12 showed potent inhibition of the 
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melanoma (MDA-MB-435) and colon (SW-620) cancer cell lines. Alternatively, 
compounds 3 and 5 showed promising activity against the Gram-positive bacterium 
Micrococcus luteus. 
Results and Discussion 
The organic extracts of a large-scale solid-substrate fungal co-culture of A. 
versicolor and S. terrestris (MSX45109) showed potent cytotoxic activity against the 
SW-620 and MDA-MB-435 cancer cell lines and was fractionated by silica gel flash 
chromatography to yield 5 fractions. The third fraction, which eluted with 10% MeOH-
CHCl3, showed potent cytotoxic activity on the two cancer cell lines, and as such, it was 
purified using reversed-phase preparative and semipreparative HPLC to yield compounds 
1-16. The purity of the isolated compounds was verified using UPLC (Figure 49). 
A total of sixteen polyketides were isolated and identified in this study. Compounds 
1-10 were identified as a series of monomeric (6-8), homodimeric (1-5), and 
heterodimeric (9 and 10) tetrahydroxanthones by comparison of HRMS, NMR, and CD 
data with each other and with structurally related compounds. Stereoisomeric compounds 
1 (35.10 mg), 2 (51.25 mg), and 3 (9.49 mg) were obtained as yellow powders with a 
molecular formula of C32H30O14 as determined by HRESIMS. The 1H and 13C NMR 
spectra of compounds 1 and 2 showed the presence of only 15 protons and 16 carbons, 
indicating that these compounds were symmetric, whereas 3 was asymmertic. A search of 
the Dictionary of Natural Products for the molecular formula and a UV range of 325-345 
nm resulted in 12 hits, 5 of which were excluded based on NMR data. The remaining 7 
hits were the secalonic acids A-G containing a 2,2'-linkage. The fact that compounds 1 
 
88 
and 2 were symmetric cut down the number of possibilities for compounds 1 and 2 into 
secalonic acids A, B, D, or E, while compound 3 could be either secalonic acid C, F, or 
G. Key differences between compounds 1 and 2 were the chemical shift values and 
splitting patterns of H-5, H-6, and H2-7. A proton doublet corresponding to H-5/H-5' (δH 
3.92, d, J = 11.2) in 1 was downfield shifted in 2 (δH 4.12, d, J = 1.2). These J values 
implied a pseudodiaxial trans orientation of H-5/H-6 in 1 and a 
pseudoaxial/pseudoequatorial cis orientation in 2 (Figures 51 and 52, Table 19). On the 
other hand, the 1H NMR spectrum of 3 showed similarity with the combined 1H NMR 
spectra of 1 and 2 by revealing two sets of protons that corresponded to two asymmetric 
monomers (Figure 41, Table 19). The 2,2'-linkage in 1-3 was confirmed by diagnostic 
HMBC cross correlations of H-3 and H-3' with C-2' and C-2, respectively. The absolute 
configurations of the 2,2'-secalonic acids have been determined by CD 
spectroscopy.116,117 The Cotton effect around 330 nm has been correlated with the 
configurations of C-10a and C-10a'. Negative Cotton effects at 332 nm in the CD spectra 
of compounds 1, 2, and 3, ∆ε = -38.8, -24.6, -31.2, respectively, indicated an S-
configuration at both C-10a and C-10a' (Figure 37). This allowed the assignment of the 
R-configuration at C-6 and C-6' based on the trans orientation of C-6/6' and C-10a/10a' 
substituents deduced from the biosynthetic route for the formation of stereoisomeric 
tetrahydroxanthone precursors of secalonic acids, with no exception so far in literature.118 
Combining all the data together suggested the absolute configuration as 
(5S,6R,10aS,5'S,6'R,10a'S), (5R,6R,10aS,5'R,6'R,10a'S), and (5R,6R,10aS,5'S,6'R,10a'S) 
for compounds 1-3, respectively. Consequently, compounds 1-3 were identified as 
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secalonic acid A,119 secalonic acid E,120 and secalonic acid G,121 respectively, in 
accordance with published data (Table 20). Most literature pertaining to these compounds 
dates back to the 1960s and 1970s, therefore to update the literature, the 1H and 13C NMR 
data for 1-3 were provided in the Supporting Information (Table 19, Figures 51-53). 
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Figure 36. Structures of compounds 1-16 
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Figure 36 (continued). Structures of compounds 1-16 
 
 
91 
 
 
Figure 37. ECD spectra of secalonic acids A (1), E (2), and G (3) in chloroform at 0.03 
mM concentration, cell length 2 cm. 
 
Compound 4 (5.39 mg) was obtained as a yellow powder. The chemical formula was 
determined as C32H30O14 by HRESIMS and analysis of 1H NMR, 13C NMR and edited-
HSQC data (Figure 54). The NMR data suggested an asymmetric secalonic acid analogue 
with structural similarity to 1 (Figure 54, Table 21). However, a key difference between 4 
and 1 was the linkage point of the monomeric units, being a 2,2' in 1 vs. 2,4' in 4, which 
rendered 4 asymmetric, as evidenced by diagnostic HMBC cross correlations of H-3 and 
H-3' with C-4' and C-4, respectively (Figure 50). The two monomeric moieties in 4 were 
assigned the same configuration as 1, as evidenced by a negative Cotton effect at 331 nm 
in the CD spectrum of 4, ∆ε = -24.8, and negative values of optical rotation for both 1 
and 4 (Figure 38, Table 20). The absolute configuration of 4 was established as 
(5S,6R,10aS,5'S,6'R,10a'S) by comparing experimental and calculated ECD spectra 
predicted by the time-dependent density functional theory (TDDFT) method (Figure 
39).122-125 The NMR and optical rotation data were in agreement with those reported for 
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penicillixanthone A.126 Interestingly, compound 4 was reported by Kurobane et al.127 as a 
chemically rearranged analogue of 1 by dissolving the latter into polar organic solvents, 
such as pyridine, acetone, and acetonitrile, either at room or higher temperatures for 
hours to days, depending on the solvent used. This suggests that 4 may have occurred as 
an artifact of the purification scheme. The NMR data of compound 4 were given in the 
Supporting Information (Table 21, Figure 54). 
 
 
Figure 38. ECD spectra of penicillixanthone A (4) [0.05 mM] and penicillixanthone B (5) 
[0.06 mM] in CHCl3, cell length 2 cm. 
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Figure 39. Experimental and calculated CD spectra for penicillixanthone A (4) in 
chloroform. 
 
Compound 5 (2.05 mg), which was obtained as a yellow powder, had a chemical 
formula of C32H30O14 as determined by HRESIMS and analysis of 1H NMR, 13C NMR 
and edited-HSQC data (Figure 55), establishing an index of hydrogen deficiency of 18. 
The NMR data suggested an asymmetric secalonic acid analogue with structural 
similarity to 2 (Figure 41, Table 12). However, as was observed in 1 vs. 4, the 2,2'- 
linkage in 2 was supplanted by a 2,4'-linkage in 5, as evidenced by diagnostic HMBC 
cross correlations of H-3 and H-3' with C-4' and C-4, respectively (Figure 41). Two 
proton singlets, corresponding to H-5/H-5' (δH 4.14/3.99) in 5 implied a 
pseudoaxial/pseudoequatorial cis orientation of H-5/H-6 and H-5'/H-6', similar to that in 
2, which were further supported by NOESY correlations between H-5/H-6 and H-5'/H-6' 
(Figure 41). The two monomeric moieties in 5 were assigned the same configuration as 2, 
as evidenced by a negative Cotton effect at 332 nm in the CD spectrum of 5, ∆ε = -18.9, 
and negative values of optical rotation for both compounds (Table 20). The absolute 
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configuration of 5 was established as (5R,6R,10aS,5'R,6'R,10a'S) by comparing 
experimental and calculated ECD spectra predicted by TDDFT (Figure 40).122-125 These 
data suggested the structure of 5, which was ascribed the trivial name penicillixanthone 
B. As noted for 4,119 compound 5 was likely an artifact produced by rearrangement of 2 
in polar organic solvents. 
 
Table 12. NMR Data for 5 (500 MHz for 1H, 125 MHz for 13C; Chemical Shifts 
in δ, Coupling Constants in Hz, CDCl3) 
 
position δC δH mult (J in Hz) Position δC δH mult (J in Hz) 
1 159.39  1ʹ 161.90  
2 119.37  2ʹ 110.79 6.60, d (8.6) 
3 139.57 7.47, d (8.6) 3ʹ 140.09 7.33, d (8.6) 
4 107.90 6.58, d (8.6) 4ʹ 115.87  
4a 157.22  4aʹ 154.51  
5 71.46 4.14, s 5ʹ 70.89 3.99, s 
6 28.56 2.12, m 6ʹ 28.54 2.12, m 
7 32.73 2.38, m 7ʹ 32.58 2.38, m 
  2.49, m   2.49, m 
8 180.23  8ʹ 179.43  
8a 99.94  8ʹa 99.73  
9 187.64  9ʹ 187.89  
9a 107.03  9ʹa 106.88  
10a 84.89  10ʹa 84.40  
11 17.62 1.17, dd (6.9, 0.6) 11ʹ 17.60 1.13, dd (6.9, 0.6) 
12 171.38  12ʹ 170.89  
13 53.69 3.75, s 13ʹ 53.41 3.64, s 
1-OH  11.91 1ʹ-OH  11.56 
5-OH  2.55, brs 5ʹ-OH  2.77, brs 
 
  
 
95 
 
Figure 40. Experimental and calculated CD spectra for penicillixanthone B (5) in 
chloroform. 
 
Compound 6 (0.75 mg) was obtained as a yellow gum. The molecular formula was 
deduced as C16H16O6 by HRESIMS and analysis of 1H NMR, 13C NMR and edited-
HSQC data (Figure 56), indicating an index of hydrogen deficiency of 9. Inspection of 
the HRMS and NMR data suggested 6 as a tetrahydroxanthone derivative with structural 
similarity to the monomeric unit of 1. However, key differences were the replacement of 
the C-2 quaternary carbon in 1 (δC 118.3) by an aromatic methine in 6 (δH/δC 
110.5/6.54), and the replacement of the hydrogen-bonded phenolic proton in 1 (δH 13.78) 
by an olefinic proton in 6 (δH 7.23) (Tables 13 and 19). COSY data identified two spin 
systems as H-5/H-6/H2-7/H-8 and H-2/H-3/H-4 (Figure 41). Further examination of the 
NMR spectra, including HMBC data (Figure 41), yielded the planar structure of 6, which 
was ascribed the trivial name blennolide H. The relative configuration of 6 was found to 
be (5S,6R,10aS), the same as that of the monomeric units of 1, deduced from NOESY 
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correlations, coupling constants, and negative optical rotation values for both compounds 
(Figure 41, Table 20). 
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Figure 41. Key HMBC, COSY, and NOESY correlations of 5-10 and 16. 
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Table 13. NMR data for 6 (500 MHz for 1H, 175 MHz for 13C; 
chemical shifts in δ, coupling constants in Hz, Methnol-d4) 
 
position δC δH mult (J in Hz) 
1 163.0  
2 110.5 6.54, dd (8.6, 0.6) 
3 138.5 7.39, dd (8.6, 8.0) 
4 107.7 6.56, dd (8.0, 0.6) 
4a 159.5  
5 77.5 3.92, dd (11.5, 2.9) 
6 30.0 2.36, m 
7 33.8 2.16, ddd (20.6, 10.3, 2.9) 
  2.72, dt (20.6, 5.2) 
8 141.9 7.23, dd (5.2, 2.9) 
8a 129.9  
9 184.7  
9a 107.7  
10a 85.8  
11 17.7 1.15, d (6.3) 
12 169.1  
13 53.3 3.69, s 
1-OH  12.00, s 
5-OH  2.74, s 
 
 
 
 
 
Figure 42. ECD spectrum of blennolide H (6) [0.43 mM] in MeOH, cell length 2 cm. 
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Diastereoisomers 7 (5.36 mg) and 8 (1.02 mg) were obtained as colorless oils with a 
molecular formula of C16H16O7, as determined by HRESIMS and analysis of 1H NMR, 
13C NMR and edited-HSQC data (Figures 57 and 58), establishing an index of hydrogen 
deficiency of 9. Compounds 7 and 8 showed similar 1H and 13C NMR spectra (Figures 57 
and 58, Table 14) with small differences in four chemical shift values. Interestingly, 
compounds 7 and 8 displayed opposite signs for optical rotation data; while compound 7 
was levorotatory (-26.14°), compound 8 was dextrorotary (+42.05°). Moreover, the CD 
spectra of 7 and 8 were mirror images of each other (Figure 43). Analysis of the HRMS 
and NMR data indicated 7 and 8 as monomers and structurally related to the monomeric 
units of compounds 1-5. In comparison to the chromanone moiety in compounds 1-5, the 
chromanone moiety, rings A and B, were reserved in 7 and 8, as evidenced from 
comparable 13C NMR data and the hydrogen-boned phenolic proton (δH 11.43), except 
for a quaternary aromatic carbon that was replaced by an aromatic methine in 7 and 8. In 
contrast, however, ring C experienced significant changes, as evidenced from 1D and 2D-
NMR data. The 13C NMR spectra displayed signals characteristic of ester functionality 
(δC 175.3 and 175.7 for 7 and 8, respectively; Table 14). Thus, ring C was established as 
a γ-lactone moiety, as evidenced from the 1H-1H COSY spin system of H-9/H-10/(H3-
13)/H-11 and HMBC correlations from H3-13 to C-11 and C-9, H-9 to C-12, and H-11 to 
C-9 (Figure 41). On the other hand, HMBC correlations from H2-3 to C-9 and C-14 and 
from H-9 to C-14 indicated a 2,9-linkage between the chromanone and the γ-lactone 
moieties, establishing the planar structures of 7 and 8 (Figure 41). The relative 
configuration of ring C in compounds 7 and 8 was similar based on NOESY correlations 
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between H3-13 and H-9 and coupling constant values of 4.0 and 3.4 ppm for H-9 in 
compounds 7 and 8, respectively, implying a pseudodiaxial trans orientation of H-9/H-10 
(Figure 41). The spatial arrangement of 7 and 8 were different, as observed via NOESY 
data, particularly between H-10 to H-11α and H-3α, H-9 to H2-3 in 7 and from H-9 to H-
3α in 8 (Figure 41). Putting these data together, and taking into consideration the fact that 
compounds 7 and 8 could not be enantiomers, since they were separated using non-
enantioselective methods, compounds 7 and 8 could either be epimers in C-2 or have the 
same configuration at C-2 but the opposite configuration of ring C. Eventually, the 
absolute configuration of 7 and 8 was established by comparing the experimental ECD 
data with those obtained through molecular modeling calculations. The agreement 
between the observed and calculated ECD (Figure 44) established the absolute 
configuration of 7 as (2S,9S,10S) and for 8 as (2R,9S,10S), supporting epimerization at C-
2. The NMR and optical rotation data of 8 indicated similarity with paecilin B, which was 
isolated from the mangrove endophytic fungus, Paecilomyces sp., and its planar structure 
was published on 2007.128 However, significant differences in the 1H and 13C NMR data 
of compound 8 and paecilin B were observed (See supplementary Table 22 for 
comparison). Recently, paecilin B was reported as a monomer and as a subunit of a dimer 
from the seagrass-derived fungus Bipolaris sp. with the same absolute configuration 
determined for 8.129 Two structurally related compounds, blennolide D and blennolide E, 
where C-11 is hydroxylated, were reported previously from Blennoria sp.114 Hence, the 
trivial name 11-deoxyblennolide D was ascribed to compound 7. The planar structure of 
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compounds 7 and 8 was reported previously by synthesis but without the reporting of 
NMR data.130 
 
 
Figure 43. ECD spectra of 11-deoxyblennolide D (7) [0.16 mM] and paecilin B (8) [0.56 
mM] in chloroform, cell length 2 cm. 
 
 
Figure 44. Experimental and calculated CD spectra for 11-deoxyblennolide D (7) paecilin 
B (8) in chloroform. 
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Table 14. NMR Data for 7 and 8 (500 MHz for 1H, 125 MHz for 13C; 
Chemical Shifts in δ, Coupling Constants in Hz, CDCl3) 
 
position 7 8 δC, type δH mult (J in Hz) δC, type δH mult (J in Hz) 
2 84.3  84.3  
3 39.8 3.04, dd (17.2, 0.6) 40.7 3.07, d (17.2) 
  3.17, d (17.2)  3.48, d (17.2) 
4 194.1  194.9  
4a 107.7  107.5  
5 162.0  161.9  
6 110.7 6.55, dd (8.6, 0.6) 110.6 6.54, dd (8.6, 0.6) 
7 139.2 7.42, t (8.6) 139.0 7.40, t (8.6) 
8 107.7 6.54, dd (8.6, 0.6) 107.5 6.49, dd (8.6, 0.6) 
8a 159.2  159.3  
9 87.6 4.43, dd (4.0, 0.6) 86.5 4.36, dd (3.4, 0.6) 
10 30.1 2.83, m 29.7 2.85, m 
11 36.2 2.21, dd (17.8, 4.6) 36.4 2.21, dd (17.8, 4.6) 
  2.89, dd (17.8, 9.2)  3.01, dd (17.8, 9.2) 
12 175.3  175.7  
13 20.9 1.28, d (6.9) 20.7 1.18, d (6.9) 
14 168.9  169.2  
15 53.8, 3.72, s 53.7 3.74, s 
5-OH  11.43, s  11.45, s 
 
Compound 9 (1.07 mg) was isolated as a yellow gum with a molecular formula of 
C16H16O6 as deduced by HRESIMS, 1H NMR, 13C NMR and edited-HSQC data (Figure 
47), indicating an index of hydrogen deficiency of 18. Analysis of the NMR data, 
including HMBC and NOESY spectra, suggested 9 as a heterodimer, with one 
monomeric moiety similar to the monomeric units of 2 and the other similar to 7 (Table 
15 and Figure 41). A key difference between the monomeric moiety in 9 that was related 
to 7 was replacement of the C-6 aromatic methine (δH/δC 110.7/6.55) in 7 by a 
quaternary carbon in 9 (δC 118.1). A 2,6'-linkage in 9 was evident by diagnostic HMBC 
correlations of H-3 to C-6' and H-7' to C-2, respectively, establishing the planar structure 
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of 9 (Figure 41). The absolute configuration was deduced based on the monomeric 
constituents. The secalonic acid moiety was assigned the same configuration as 2, 
evidenced from similar NOESY correlations and coupling constant values of H-5 and 
preservation of the configuration at C-10a through the series. As well, the moiety similar 
to 7 was assigned the same configuration as 7 based on consistencies in the 1H, 13C, and 
NOESY NMR data (Tables 14 and 15, and Figure 41). Hence the absolute structure of 9 
was assigned as (5R,6R,10aS,2'S,9'S,10'S) and was confirmed by ECD calculations 
(Figure 46). The NMR data of 9 were found to be in agreement with those for blennolide 
G, which was reported previously from Blennoria sp.114 However, compound 9 and 
blennolide G showed opposite CD and optical rotation data, and opposite absolute 
configuration at four chiral centers, indicating 9 as a diastereoisomer of blennolide G 
(Table 20, Figure 45). The trivial name blennolide I was ascribed to 9. 
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Table 15. NMR Data for 9 and 10 (700 MHz for 1H, 175 MHz for 13C; 
Chemical Shifts in δ, Coupling Constants in Hz, CDCl3) 
 
position 9 10 δC δH mult (J in Hz) δC δH mult (J in Hz) 
1 159.4  159.3  
2 118.3  117.8  
3 139.6 7.42, d (8.3) 140.1 7.45, d (8.5) 
4 107.5 6.57, d (8.3) 107.5 6.62, d (8.5) 
4a 157.2  158.4  
5 71.3 4.12, s 78.0 3.93, dd (11.2, 2.7) 
6 28.5 2.11, m 29.2 2.41, m 
7 32.6 2.40, dd (18.9, 6.1) 36.2 2.32, dd (19.4, 10.6) 
  2.52, dd (18.9, 11.2)  2.73, dd (19.4, 6.5) 
8 179.9  177.6  
8a 99.9  101.5  
9 187.5  187.1  
9a 107.0  106.9  
10a 84.8  84.8  
11 17.5 1.17, d, (7.1) 18.0 1.17, d, (6.5) 
12 171.2  170.2  
13 53.5 3.71, s 53.3 3.71, s 
1-OH  11.85  11.72 
5-OH  2.52  2.77, d (2.7) 
8-OH  13.95  13.76 
2ʹ 84.2  84.2  
3ʹ 39.7 3.05, d (17), 3.21, d (17) 39.7 3.05, d (17), 3.21, d (17) 
4ʹ 194.0  194.0  
4ʹa 107.6  107.6  
5ʹ 159.2  159.2  
6ʹ 118.1  118.1  
7ʹ 141.3 7.52, d (8.3) 141.3 7.51, d (8.5) 
8ʹ 107.3 6.61, d (8.3) 107.3 6.62, d (8.5) 
8ʹa 158.6  158.6  
9ʹ 87.5 4.45, d (3.8) 87.5 4.46, d (4.1) 
10ʹ 30 2.84, m 30 2.84, m 
11ʹ 36.0 2.91, dd (18.0, 9.3) 36.0 2.92, dd (17.9, 9.4) 
  2.23, dd (18.0, 4.8)  2.22, dd (17.9, 4.6) 
12ʹ 175.1  175.1  
13ʹ 20.9 1.28, d (7.1) 20.9 1.28, d (6.8) 
14ʹ 168.8  168.8  
15ʹ 53.7 3.76, s 53.7 3.75, s 
5ʹ-OH  11.88  11.89 
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Figure 45. ECD spectra of blennolide I (9) [0.06 mM] and blennolide J (10) [0.17 mM] in 
chloroform, cell length 2 cm. 
 
 
Figure 46. Experimental and calculated CD spectra for blennolide I (9) in chloroform. 
Compound 10 (0.63 mg), which was isolated as a yellow gum, had a molecular 
formula of C16H16O6 as deduced by HRESIMS, 1H NMR, 13C NMR and edited-HSQC 
data (Figure 60), indicating an index of hydrogen deficiency of 18. Analysis of the NMR 
data indicated 10 as an asymmetric heterodimer with structural similarity to 9. Key 
differences between 9 and 10 were chemical shift values and splitting patterns of H-5, H-
6, and H2-7 (Table 15, Figures 59 and 60). A proton singlet in 9 (δH 4.12), corresponding 
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to H-5, was replaced by a doublet (δH 3.93, d, J = 11.2) in 10, suggesting a pseudodiaxial 
trans orientation of H-5/H-6 in 10. These data indicated that the secalonic acid moiety in 
10 was similar to the monomeric units of 1, while the 11-deoxyblennolide D moiety was 
preserved, as in 9. A 2,6'-linkage in 10, also similar to 9, was confirmed by diagnostic 
HMBC correlations of H-3 with C-6' and H-7' with C-2, respectively, establishing the 
planar structure of 10 (Figure 41). As for 9, the absolute configuration of 10 was deduced 
based on the monomeric constituents and ECD calculations as (5S,6R,10aS,2'S,9'S,10'S) 
(Figure 47). The trivial name blennolide J was ascribed to compound 10. 
 
 
Figure 47. Experimental and calculated CD spectra for blennolide J (10) in chloroform. 
Compounds 11-13 were identified as the resorcylic acid lactones, aigialomycin (4.24 
mg),131 hypothemycin (19.58 mg),132 and dihydrohypothemycin (3.68 mg),131 
respectively, while compounds 14 and 15 were pyrenochaetic acid C (2.71 mg)133 and 
nidulalin B (1.68 mg),134 respectively. In all cases, the spectroscopic and spectrometric 
data were in agreement with those reported in the literature. 
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Compound 16 (0.79 mg) was isolated as a colorless oil with a molecular formula of 
C12H14O5 as revealed by HRESIMS, 1H NMR, 13C NMR and edited-HSQC data (Figure 
66), indicating an index of hydrogen deficiency of 6. UV absorption maxima of 301, 270, 
and 233 nm were indicative of an aromatic carbonyl compound.135 Inspection of the 
NMR data showed signals characteristic of six aromatic carbons, two of which were 
oxygenated, and two doublet aromatic protons with coupling constant values of 2.3 Hz, 
and two phenolic protons. These data suggested a 1,2,3,5-tetrasubstituted benzene ring 
with two aromatic protons meta to each other (Figure 66, Table 16). Benzene ring 
substituents were confirmed by HMBC correlations (Figure 41). COSY data identified a 
1,2,3-tetrasubtituted pentane moiety (H2-4/H-3/H-11/H-12/H-13) with C-3 and C-11 
being oxygenated and the terminal methylene attached to the benzene ring (Figure 41). 
HMBC correlations from H2-4 to C-6 and C-10 confirmed C-5 as the attachment point of 
the aliphatic side chain with the aromatic ring. Chemical shift values (δH/δC 4.43/81.1) 
for H-3/C-3 indicated esterification of C-3 to form a six membered ring with the ester 
carbonyl (δC 170.2) that was attached to the benzene ring at C-2. Further examination of 
the NMR data yielded the planar dihydroisocoumarin structure of 16, which was ascribed 
the trivial name pyrenomycin. The absolute configuration of 16 was assigned via a 
modified Mosher’s ester method,68 establishing the configuration as 3R and 11S (Figure 
48). Similar dihydroisocoumarin compounds were isolated previously from marine 
sponges, plants, fungi, and insects, including hiburipyranone,136 3-(2-hydroxypropyl)-8-
hydroxy-3,4-dihydroisocoumarin,137 and (3S,1′R)-3-(1-hydroxyethyl)-6,8-dihydroxy-7-
methyl-3,4-dihydroisocoumarin.138 
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Table 16. NMR Data for 16 (700 MHz for 1H, 175 MHz for 13C; 
Chemical Shifts in δ, Coupling Constants in Hz, Methnol-d4) 
 
position δC δH mult (J in Hz) 
1 170.2  
3 81.1 4.43, dt (12.7, 3.3) 
4 29.0 2.75, dd (16.4, 3.3) 
  3.11, dd (16.4, 12.7) 
5 142.2  
6 107.2 6.21, brd (2.3) 
7 164.2  
8 100.9 6.15, d (2.3) 
9 168.8  
10 99.6  
11 73.1 3.58, dt (8.6, 3.3) 
12 25.1 1.67, m 
13 9.2 1.03, t (7.5) 
9-OH  8.55, s 
11-OH  1.28, brs 
7-OH  4.57, brs 
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Figure 48. ΔδH values [Δδ (in ppm) = δS − δR] obtained for (S)- and (R)-MTPA 
esters (16a and 16b, respectively) of pyrenomycin (16) in pyridine-d5. 
 
Compounds (1-15) were tested for cytotoxicity in the MDA-MB-435 and SW-620 
cancer cell lines. Of the tetrahydroxanthone derivatives, 1 and 4 were the most potent 
with IC50 values less than 0.50 µM in both cell lines (Table 17). Based on the 
cytotoxicity data of related analogues, the configuration of C-5/C-5' became evident 
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(Table 17). Compounds 1 and 4, with 5S,5'S configuration, were the most potent, with a 
2,2'-linkage for 1 and a 2,4'-linkage for 4. A 5S,5'R configuration, as in 3, was 
approximately 20 times less active than 1, while a 5R,5'R configuration rendered 2 
inactive; all of these had a 2,2'-linkage of the monomeric units. For those with a 2,4'-
linkage, compound 5 with 5R,5'R was approximately 30 times less active than 4. 
Heterodimeric 10, which was composed of the monomeric units of 1 and compound 7, 
was approximately 25 times less active than 1. Conversely, compound 9, which was 
composed of the monomeric units of 2 and compound 7 was inactive. On the other hand, 
all three monomeric compounds (6-8) were inactive. Consistent with the cytotoxcity data 
obtained in this study, 1 and its chemically rearranged 2,4'-dimer 4, were reported to have 
equipotent activity against cultured mouse leukemia L1210 cells.110 Moreover, 1 was 
reported to have a protecting effect of the dopaminergic neurons from1-methyl-4-
phenylpyridinium (MPP+)-induced cell death,139 and attenuation of colchicine-induced 
apoptosis of the cortical neurons.140 
In agreement with the literature,115 cytotoxicty data of the structurally related RALs 
(11-13) indicated the importance of the (Z)-enone for activity, as in hypothemycin (IC50 
value of 0.58 µM, MDA-MB-435). Alternatively, dihydrohypothemycin, with an (E)-
enone, and aigialomycin A, with a reduced enone, were both inactive (IC50 value > 10 
µM). RALs containing a (Z)-enone have been reported as potent inhibitors of several 
ATPases and kinases, including TAK1.141,142  
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Table 17. Cytotoxicity of Compounds 1-15 Against Two 
Human Tumor Cell Lines 
 
compounda 
IC50 values in µMb 
MDA-MB-435c SW-620c 
1 0.16 0.41 
2 NA 19.12 
3 3.27 3.67 
4 0.18 0.21 
5 5.20 5.55 
10 4.06 6.14 
12 0.58 2.14 
aCompounds 6-9, 11, and 13-15 were inactive with IC50 >20 µM. 
bIC50 values were determined as the concentration required to 
inhibit growth to 50% of control with 72 h incubation. 
cPositive control was vinblastine tested at concentration of 1 nM in 
MDA-MB-435 cells and 10 nM in SW620 cells, which had 23% 
and 76% viable cells, respectively. 
 
The antimicrobial activity of the isolated compounds (1-15) was evaluated against a 
panel of bacteria and fungi (Table 18 and 23). Compounds 3 and 5 showed promising 
activity against the Gram-positive bacterium Micrococcus luteus with MIC values of 5 
and 15 µg/mL, respectively. Secalonic acid A (1) was reported to have activity against 
Bacillus subtilis and Piriculaia oryzae107 and a phlogistic activity,143 while 
penicillixanthone A (4) was reported to have medium antibacterial activity against M. 
luteus, Pseudoalteromonas nigrifaciens, and B. subtilis.144 
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Table 18. Antimicrobial Activities of Compounds 1-15 
 
compounda 
Antimicrobial activity MIC  (µg/mL) 
M. luteus S. aureus 
1  38 75 
2  36 NA[b] 
3  5 39 
4 46 93 
5 15 59 
10 43 43 
Ampicillinb 4  
Vancomycinb -- 0.25 
aSee table 23 for compounds 6-9, 11, and 12-15. 
bPositive control. 
cNA: not active with MIC > 145 µg/mL. 
 
In summary, a total of 18 polyketides (1-16), of which six were new, were isolated 
from a fungal co-culture of A. versicolor and S. terrestris (MSX45109). Cytotoxicity 
assays suggested compounds 1, 4, and 12 as the most potent. When evaluated for 
antimicrobial activity, compounds 3 and 5 showed promising M. luteus activity. In 
addition of updating the literature with spectroscopic and spectrometric data for some the 
known isolated compounds, this study also updated the literature with bioassay and SAR 
data of structurally related analogues.  
Methods 
General. UV and CD spectra were obtained using a Varian Cary 100 Bio UV-Vis 
spectrophotometer (Varian Inc., Walnut Creek, CA, USA) and an Olis DSM 17 CD 
spectrophotometer (Olis, Inc. Bogart, GA, USA), respectively. NMR data were collected 
using either a JEOL ECA-500 NMR spectrometer operating at 500 MHz for 1H and 125 
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MHz for 13C, or a JEOL ECS-400 NMR spectrometer equipped with a high sensitivity 
JEOL Royal probe operating at 400 MHz for 1H and 100 MHz for 13C (both from JEOL 
Ltd., Tokyo, Japan), or an Agilent 700 MHz NMR spectrometer (Agilent Technologies, 
Inc., Santa Clara, CA, USA), equipped with a cryoprope, operating at 700 MHz for 1H 
and 175 MHz for 13C. Residual solvent signals were utilized for referencing. High 
resolution mass spectra (HRMS) were obtained using a Thermo LTQ Orbitrap XL mass 
spectrometer equipped with an electrospray ionization source (Thermo Fisher Scientific, 
San Jose, CA, USA). A Waters Acquity UPLC system (Waters Corp., Milford, MA, 
USA) utilizing a Waters BEH C18 column (1.7 µm; 50 × 2.1 mm) was used to check the 
purity of the isolated compounds with data collected and analyzed using Empower 
software. Phenomenex Gemini-NX C18 analytical (5 µm; 250 × 4.6 mm), preparative (5 
µm; 250 × 21.2 mm), and semipreparative (5 µm; 250 × 10.0 mm) columns (all from 
Phenomenex, Torrance, CA, USA) were used on a Varian Prostar HPLC system 
equipped with ProStar 210 pumps and a Prostar 335 photodiode array detector (PDA), 
with data collected and analyzed using Galaxie Chromatography Workstation software 
(version 1.9.3.2, Varian Inc.). Flash chromatography was performed on a Teledyne ISCO 
CombiFlash Rf 200 using Silica Gold columns (both from Teledyne Isco, Lincoln, NE, 
USA) and monitored by UV and evaporative light-scattering detectors. 
Fungal Strain Isolation and Identification. Mycosynthetix fungal strain 
MSX45109 was isolated from plant material collected in a mangrove habitat in 1989. 
Morphological examination of cultures suggested that MSX45109 was not a pure culture, 
but a mixture of two morphologically different strains. Molecular techniques were used 
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to identify these strains by sequencing the internal transcribed spacer regions 1 & 2 and 
5.8S nrDNA (ITS).45 DNA extraction, PCR amplification, sequencing, and phylogenetic 
analyses were performed as described previously.63,81,97-99  BLAST search in GenBank 
and (http://www.boldsystems.org/index.php/IDS_OpenIdEngine) database, the curated 
BOLD systems, using ITS rDNA sequences suggested that one strain belonged to the 
Aspergillus versicolor (Eurotiales, Ascomycota), while the other strain belonged to 
Setophoma terrestris (Pleosporales, Ascomycota). Morphological examinations of the 
culture characteristics corroborated the ITS data. The ITS sequences of the two strains 
will bw deposited in the GenBank (accession no XXX). A voucher culture of two strains 
of MSX45109 is maintained in the Mycosynthetix Inc., Hillsborough, NC, USA.  
Fermentation, Extraction and Isolation. Storage conditions, fermentation, and 
extraction procedure of the fungal strain MSX45109 were as described previously.19,62,63 
In brief, a seed culture of strain MSX45109 grown in YESD medium was used to 
inoculate a 2.8-L Fernbach flask (Corning, Inc., Corning, NY, USA) containing 150 g 
rice and 300 mL H2O. The solid culture was incubated at room temperature for 14 days 
and then extracted by addition of a 500 mL mixture of 1:1 MeOH-CHCl3. The culture 
was chopped into small pieces and left to shake at ~125 rpm at room temperature. 
followed by vacuum filtration. The solid phase was washed with 100 mL of 1:1 MeOH-
CHCl3. To the filtrate, 900 mL CHCl3 and 1500 mL H2O were added so that the final 
ratio of CHCl3-MeOH-H2O was 4:1:5. The mixture was mixed by stirring for ½ h and 
then transferred into a separatory funnel. The organic bottom layer was drawn off and 
evaporated to dryness and then re-constituted in 100 mL of 1:1 MeOH-CH3CN and 100 
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mL of hexanes. The biphasic solution was stirred for 15 min and then transferred to a 
separatory funnel. The MeOH-CH3CN layer was drawn off and evaporated to dryness 
under vacuum. The defatted material (~1.5 g) was dissolved in a mixture of CHCl3-
MeOH, adsorbed onto Celite 545, and fractionated via flash chromatography using a 
gradient solvent system of hexane-CHCl3-MeOH at a 40 mL/min flow rate and 53.3 
column volumes over 63.9 min to afford five fractions. Fraction 3 (~627 mg) was 
subjected to preparative reversed phase HPLC over a Phenomenex Gemini-NX C18 
preparative column using a gradient system of 40:60 to 60:40 over 30 min of CH3CN-
H2O (acidified with 0.1% formic acid) at a flow rate of 21.24 mL/min to yield thirteenth 
sub-fractions. Sub-fractions 4, 5, 10, and 12 yielded compounds 11 (4.24 mg), 12 (19.58 
mg), 1 (35.10), and 2 (48.40 mg), which eluted at 7.8, 8.7, 25.1, and 29.0 min, 
respectively. The other sub-fractions were subjected to further purifications as follows: 
sub-fraction 1 (2.34 mg) was subjected to semi-preparative HPLC purification over a 
Phenomenex Gemini-NX C18 column using a gradient system of 50:50 to 70:30 of 
MeOH-H2O (acidified with 0.1% formic acid) over 15 min at a flow rate of 4.72 mL/min 
to yield compound 16 (0.79 mg), which eluted at ~13.1 min. Sub-fraction 6 (8.54 mg) 
was subjected to preparative HPLC purification using a Phenomenex Gemini-NX C18 
and a gradient system of 50:50 to 70:30 of MeOH-H2O (acidified with 0.1% formic acid) 
over 15 min at a flow rate of 21.24 mL/min to yield compounds 15 (1.68 mg) and 13 
(3.68 mg), which eluted at ~8.0 and ~18.9 min, respectively. Sub-fraction 7 (1.49 mg) 
was subjected to semipreparative HPLC purification using a Phenomenex Gemini-NX 
C18 column and a gradient system of 50:50 to 70:30 of MeOH-H2O (acidified with 0.1% 
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formic acid) over 15 min at a flow rate of 4.72 mL/min to yield compound 6 (0.75 mg), 
which eluted at ~17.5 min. Sub-fraction 9 (18.23 mg) was subjected to preparative HPLC 
purification using a Phenomenex Gemini-NX C18 and a gradient system of 50:50 to 
70:30 of MeOH-H2O (acidified with 0.1% formic acid) over 15 min at a flow rate of 
21.24 mL/min to yield compounds 7 (5.36 mg), 8 (1.02), and 14 (2.71 mg), which eluted 
at ~11.6, ~13.5 and ~19.5 min, respectively. An aliquot of sub-fraction 10 (~20 mg) was 
further purified using preparative HPLC over a Phenomenex Gemini-NX C18 utilizing a 
gradient solvent system of 70:30 to 90:10 of MeOH-H2O (acidified with 0.1% formic 
acid) over 15 min at a flow rate of 21.24 mL/min to yield compounds 10 (0.63 mg) and 1 
(3.11 mg), which eluted at ~9.5 and ~14.8 min, respectively. An aliquot of sub-fraction 
11 (~20 mg) was subjected to semi-preparative HPLC purification over a Phenomenex 
Gemini-NX C18 column using a gradient system of 70:30 to 90:10 of MeOH-H2O 
(acidified with 0.1% formic acid) over 15 min at a flow rate of 4.72 mL/min to yield 
compound 3 (9.49 mg), which eluted at ~12.3 min and compound 9 (1.07 mg) that was 
obtained by further purification of sub-fraction 1. Sub-fraction 13 (21.49 mg) was 
subjected to preparative HPLC purification using a Phenomenex Gemini-NX C18 and a 
gradient system of 70:30 to 90:10 of MeOH-H2O (acidified with 0.1% formic acid) over 
15 min at a flow rate of 21.24 mL/min to yield compounds 2 (2.85 mg) and 4 (5.39 mg), 
which eluted at ~10.5 and ~19.9 min, respectively, and compound 5 (2.05 mg), which 
obtained by further purification of sub-fraction 2. 
Penicillixanthone B (5): Yellow powder; [𝛼]D20 = −112° (𝑐 = 0.03 in acetone); 
UV (MeOH) λmax (log ε) 349 (3.64), 336 (3.63), 250 (3.58) nm; CD (c 6.26 × 10-5 M, 
 
116 
CHCl3) λ (∆ε) 225 (-55.3) nm, 243 (+48.4) nm, 332 (-18.9) nm; 347 (+2.6) nm, 376 (-
8.8) nm; 1H NMR (CDCl3, 500 MHz) and 13C NMR (CDCl3, 125 MHz), see Table 12 
and Supplementary Figure 55; HRESIMS m/z  639.1691  [M + H]+ (calcd for C32H31O14 
639.1708). 
Blennolide H (6): Yellow gum; [𝛼]D20 = −25.3° (𝑐 = 0.01 in chloroform); UV 
(MeOH) λmax (log ε) 283 (3.48), 193 (3.68) nm; CD (c 4.27 × 10-4 M, CHCl3) λ (∆ε) 231 
(+11.9) nm, 269 (-20.9) nm, 298 (-19.8) nm; 1H NMR (CDCl3, 500 MHz) and 13C NMR 
(CDCl3, 175 MHz), see Table 13 and Supplementary Figure 56; HRESIMS m/z  
305.1012  [M + H]+ (calcd for C16H17O6 305.1020). 
11-Deoxyblennolide D (7): Colorless oil; [𝛼]D20 = −26.14° (c = 0.03 in 
chloroform); UV (MeOH) λmax (log ε) 349 (3.21), 270 (3.45), 224 (3.37) nm; CD (c 1.56 
× 10-4 M, CHCl3) λ (∆ε) 235 (+6.2) nm, 267 (-53.8) nm, 307 (-16.4) nm; 346 (+0.5) nm; 
1H NMR (CDCl3, 500 MHz) and 13C NMR (CDCl3, 125 MHz), see Table 14 and 
Supplementary Figure 57; HRESIMS m/z  321.0963  [M + H]+ (calcd for C16H17O7 
321.0969). 
Paecilin B (8): Colorless oil; [𝛼]D20 = +42.05° (𝑐 = 0.09 in chloroform); UV 
(MeOH) λmax (log ε) 346 (3.20), 271 (3.49), 193 (3.70) nm; CD (c 5.62 × 10-4 M, CHCl3) 
λ (∆ε) 235 (-44.7) nm, 267 (+35.2) nm, 307 (+17.0) nm; 346 (-8.7) nm; 1H NMR (CDCl3, 
500 MHz) and 13C NMR (CDCl3, 125 MHz), see Table 14 and Supplementary Figure 58; 
HRESIMS m/z  321.0961  [M + H]+ (calcd for C16H17O7 321.0969). 
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Blennolide I (9): Yellow powder; [𝛼]D20 = −102.30° (𝑐 = 0.09 in chloroform); 
UV (MeOH) λmax (log ε) 349 (2.81), 258 (3.69), 224 (3.69) nm; CD (c 6.26 × 10-5 M, 
CHCl3) λ (∆ε) 241 (+13.9), 275 (-6.3) nm, 334 (-8.7) nm; 1H NMR (CDCl3, 700 MHz) 
and 13C NMR (CDCl3, 175 MHz), see Table 15 and Supplementary Figure 59; 
HRESIMS m/z  639.1682  [M + H]+ (calcd for C32H31O14 639.1708). 
Blennolide J (10): Yellow powder; [𝛼]D20 = −93.5° (𝑐 = 0.08 in chloroform); UV 
(MeOH) λmax (log ε) 349 (3.37), 336 (3.37), 237 (3.4) nm; CD (c 1.72 × 10-4 M, CHCl3) 
λ (∆ε) 245 (38.9), 262 (-14.9) nm, 337 (-13.9) nm, 377 (-16.7) nm; 1H NMR (CDCl3, 700 
MHz) and 13C NMR (CDCl3, 175 MHz), see Table 15 and Supplementary Figure 60; 
HRESIMS m/z  639.1683  [M + H]+ (calcd for C32H31O14 639.1708). 
Pyrenomycin (16): Coloreless oil; [𝛼]D20 = −5.7° (𝑐 = 0.05 in chloroform); UV 
(MeOH) λmax (log ε) 301 (3.09), 270 (3.12), 233 (3.07) nm; 1H NMR (Methnol-d4, 700 
MHz) and 13C NMR (CDCl3, 175 MHz), see Table 16 and Supplementary Figure 66; 
HRESIMS m/z  239.0909  [M + H]+ (calcd for C12H16O5 239.0914). 
Preparation of the (R)- and (S)-MTPA ester derivatives of Pyrenomycin (16): 
To 0.10 mg of compound 16 was added 400 µL of pyridine-d5 and transferred into an 
NMR tube. To initiate the reaction, 20 μL of S-(+)-α-methoxy-α-
(trifluoromethyl)phenylacetyl (MTPA) chloride was added into the NMR tube with 
careful shaking and then monitored immediately by 1H NMR at the following time 
points: 0, 5, 10, 15, 30, 60, and 120 min. The reaction was found to be complete in 2 h, 
yielding the mono (R)-MTPA ester derivative (16b) of 16. 1H NMR data of 16b (500 
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MHz, pyridine-d5): δH 1.85 (3H, d, J = 7.5, H3-13), 1.81 (1H, m, H-12a), 1.90 (1H, m, 
H-12b), 4.81 (1H, m, H-11), 5.61 (1H, m, H-3). In an analogous manner, 0.10 mg of 
compound 16 dissolved in 400 µL pyridine-d5 was reacted in a second NMR tube with 
20 µL (R)-(-)-α-MTPA chloride for 1 h, to afford the mono (S)-MTPA ester (6a). 1H 
NMR data of 16a (500 MHz, pyridine-d5): δH 1.75 (3H, d, J = 6.9, H3-13), 1.70 (1H, m, 
H-12a), 1.80 (1H, m, H-12b), 4.85 (1H, m, H-11), 5.65 (1H, m, H-3). 
Cytotoxicity Assay. The cytotoxicity of compounds (1-15) were tested against the 
MDA-MB-435100 human melanoma (HTB-129, ATCC) and the SW-620101 human 
colorectal adenocarcinoma (CCL-227, ATCC) cell lines as described previously.19 
Antimicrobial Assay. Minimal inhibitory concentrations (MICs) of compounds (1-
15) were measured against a panel of bacteria and fungi as described previously.18,102,103 
All measurements were made in duplicate. 
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Supporting Infromation 
 
 
 
 
Figure 49. UPLC chromatograms of compounds 1-16 (ELSD detection), demonstrating 
>90% purity. All data were acquired via an Acquity UPLC system with a BEH C18 (1.7 
μm 2.1 × 50 mm) column and a CH3CN-H2O gradient that increased linearly from 20 to 
100% CH3CN over 4.5 min. 
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Figure 49 (continued). UPLC chromatograms of compounds 1-16 (ELSD detection), 
demonstrating >90% purity. All data were acquired via an Acquity UPLC system with a 
BEH C18 (1.7 μm 2.1 × 50 mm) column and a CH3CN-H2O gradient that increased 
linearly from 20 to 100% CH3CN over 4.5 min. 
  
(9) (10) 
(11) (12) 
(13) (14) 
(15) (16) 
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Table 19. 1H NMR Data for 1-3 (500 MHz; Chemical Shifts in δ, Coupling 
Constants in Hz, CDCl3) 
 
position 
δH mult (J in Hz) 
1 2 3 
3 7.45, d (8.6) 7.42, d (8.6) 7.42, d (8.6) 
4 6.63, d (8.6) 6.57, d (8.6) 6.57, d (8.6) 
5 3.92, dd (11.2, 0.5) 4.11, d (1.2) 4.11, s 
6 2.41, m 2.10, m 2.10, m 
7 2.31, dd (19.2, 10.7) 2.40, dd (18.9, 6.3) 2.40, dd (18.9, 6.3) 
 2.73, dd (19.2, 6.4) 2.52, dd (18.9, 11.4) 2.52, dd (18.9, 11.5) 
11 1.17, d, (6.4) 1.17, d, (6.9) 1.17, d, (6.9) 
13 3.72, s 3.72, s 3.72, s 
1-OH 11.76 11.87 11.88 
5-OH 2.81, d (2.7) 2.60, brs 2.57, s 
8-OH 13.78   
3' 7.45, d (8.6) 7.42, d (8.6) 7.45, d (8.6) 
4' 6.63, d (8.6) 6.57, d (8.6) 6.62, d (8.6) 
5' 3.92, dd (11.2, 0.5) 4.11, d (1.2) 3.92, dd (11.5, 0.5) 
6' 2.41, m 2.10, m 2.41, m 
7' 2.31, dd (19.2, 10.7) 2.40, dd (18.9, 6.3) 2.31, dd (18.9, 10.9) 
 2.73, dd (19.2, 6.4) 2.52, dd (18.9, 11.4) 2.73, dd (18.9, 6.3) 
11' 1.17, d, (6.4) 1.17, d, (6.9) 1.17, d, (6.3) 
13' 3.72, s 3.72, s 3.72, s 
1'-OH 11.76 11.87 11.74 
5'-OH 2.81, d (2.7) 2.60, brs 2.84, s 
8'-OH 13.78 --- --- 
 
 
 
122 
Table 20. CD and Optical Rotation Data, Experimental vs. Literature, of Compounds 1-4, 8-9, and Blennolide G 
compound 
CD: Conc. Solvent;  λmax (Δε) nm Optical rotation 
Experimental Literature Experimental Literature 
Secalonic acid A (1) 0.03 × 10
-3 M, CHCl3 
332 (-38.8) 
CHCl3 
334 (~ -8)145 
[𝛼]𝐷25 = −61°  
(c = 0.38, Chloroform) 
[𝛼]𝐷20 = −76° (chloroform).
146 
[𝛼]𝐷20 = −177° (pyridine).
146 
Secalonic acid E (2) 0.03 × 10
-3 M, CHCl3 
332 (-24.6) ---- 
[𝛼]𝐷25 = −108°  
(c = 0.04, Chloroform)  
[𝛼]𝐷22 = −212° 
(c = 0.41, pyridine).120 
Secalonic acid G (3) 0.03 × 10
-3 M, CHCl3 
332 (-31.2) ---- 
[𝛼]𝐷25 = −73° 
(c = 0.6, Chloroform) 
[𝛼]𝐷25 = −106.9° 
(c = 1.055, Chloroform).121 
[𝛼]𝐷0 = −201.6° 
(c = 1.105, pyridine).130 
Penicillixanthone A (4) 0.05 × 10
-3 M, CHCl3 
331 (-24.7), 322 (-24.9) 
dioxane 
330 (~ -15)127 
[𝛼]𝐷26 = −16° 
(c = 0.4, Acetone) 
[𝛼]𝐷25 = −2.201° 
(c = 0.25, Acetone).126 
[𝛼]𝐷20 = −110.9° 
(c = 0.289, pyridine).127 
Paecilin B (8) 
0.56 × 10-4 M, CHCl3 
235 (-44.7), 267 
(+35.2), 307 (+17.0); 
346 (-8.7) 
---- [𝛼]𝐷
20 = +42° 
(c = 0.09, Chloroform) 
[𝛼]𝐷25 = +40.6° 
(c = 0.1, chloroform).128 
Blennolide I (9) 
6.26 × 10-5 M 
334 (-8.7), 275 (-6.3) 
241 (+13.9) 
--- [𝛼]𝐷
20 = −102° 
(c = 0.09, Chloroform) ---- 
Blennolide G ---- 
6.2 × 10-3 M 
379 (+2.4), 361 (+3.4), 
333 (+4.4), 279 (+2.3), 
274 (+2.3), 224 (-19.4)114 
---- [𝛼]𝐷
25 = +81.1° 
(c = 0.29, Chloroform).114 
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Table 21. NMR Data for 4 (500 MHz for 1H, 125 MHz for 13C; Chemical Shifts 
in δ, Coupling Constants in Hz, CDCl3) 
 
position δC δH mult (J in Hz) position δC δH mult (J in Hz) 
1 159.5  1ʹ 161.9  
2 118.2  2ʹ 110.6 6.60, d (8.6) 
3 140.7 7.80, d (8.6) 3ʹ 140.9 7.48, d (8.6) 
4 107.6 6.61, d (8.6) 4ʹ 115.6  
4a 158.5  4aʹ 155.5  
5 77.1 3.93, dd (11.5, 0.6) 5ʹ 76.8 3.82, d (11.5, 0.6) 
6 29.5 2.40, m 6ʹ 29.3 2.40, m 
7 36.4 2.29, m 7ʹ 36.4 2.29, m 
  2.72, m   2.72, m 
8 177.5  8ʹ 177.9  
8a 101.9  8ʹa 101.7  
9 187.3  9ʹ 187.4  
9a 107.3  9ʹa 107.2  
10a 85.2  10ʹa 85.1  
11 18.3 1.17, d (6.3) 11ʹ 18.2 1.10, d (6.3) 
12 170.5  12ʹ 170.3  
13 53.5 3.72, s 13ʹ 53.4 3.68, s 
1-OH  11.64, s 1ʹ-OH  11.39, s 
5-OH  2.85, brs 5ʹ-OH  2.61, brs 
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Figure 50. Key HMBC, COSY, and NOESY correlations of 4. 
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Table 22. NMR Data for 8 and Paecilin B (500 MHz for 1H, 125 MHz for 
13C; Chemical Shifts in δ, Coupling Constants in Hz, CDCl3) 
 
Position 8 paecilin B
a 
δC, type δH mult (J in Hz) δC, type δH mult (J in Hz) 
2 84.3  84.87  
3 40.7 3.07, d (17.2) 39.98 3.53, d (17.4) 
  3.48, d (17.2)  3.16, d (17.4) 
4 194.9  195.00  
4a 107.5  130.42  
5 161.9  161.89  
6 110.6 6.54, dd (8.6, 0.6) 109.77 6.61, d (8.1) 
7 139.0 7.40, t (8.6) 138.97 7.46, t (8.4, 8.3) 
8 107.5 6.49, dd (8.6, 0.6) 107.80 6.51, d (7.8) 
8a 159.3  155.38  
9 86.5 4.36, dd (3.4, 0.6) 82.63 4.97, d (6.6) 
10 29.7 2.85, m 33.58 2.87, m 
11 36.4 2.21, dd (17.8, 4.6) 36.8 2.73, dd (17, 7) 
  3.01, dd (17.8, 9.2)  2.41, dd (17, 7) 
12 175.7  174.66  
13 20.7 1.18, d (6.9) 14.63 1.34, d (6.9) 
14 169.2  169.30  
15 53.7 3.74, s 53.10 3.72, s 
5-OH  11.45, s  11.49, br s 
aZ. Y. Guo, Z. G. She, C. L. Shao, L. Wen, F. Liu, Z. H. Zheng and Y. C. Lin, Magn. 
Reson. Chem. 2007, 45, 777-780. 
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Figure 51. 1H and 13C NMR spectra of compound 1 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 52. 1H and 13C NMR spectra of compound 2 [500 MHz for 1H and 125 MHz for 13C, pyridine-d5]. 
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Figure 53. 1H and 13C NMR spectra of compound 3 [500 MHz for 1H and 100 MHz for 13C, CDCl3]. 
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Figure 54. 1H and 13C NMR spectra of compound 4 [500 MHz for 1H and 100 MHz for 13C, CDCl3]. 
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Figure 55. 1H and 13C NMR spectra of compound 5 [500 MHz for 1H and 100 MHz for 13C, CDCl3]. 
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Figure 56. 1H and 13C NMR spectra of compound 6 [500 MHz for 1H and 175 MHz for 13C, CDCl3]. 
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Figure 57. 1H and 13C NMR spectra of compound 7 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 58. 1H and 13C NMR spectra of compound 8 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 59. 1H and 13C NMR spectra of compound 9 [700 MHz for 1H and 175 MHz for 13C, CDCl3]. 
Blennolide I (9) 
OO
OMe
O
O
O OH
O
OOH
OH
MeO O
OH
H
 
 
134 
 
Figure 60. 1H and 13C NMR spectra of compound 10 [700 MHz for 1H and 175 MHz for 13C, CDCl3]. 
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Figure 61. 1H and 13C NMR spectra of compound 11 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 62. 1H and 13C NMR spectra of compound 12 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 63. 1H and 13C NMR spectra of compound 13 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 64. 1H NMR spectrum of compound 14 [500 MHz, CDCl3]. 
OMe O
O
HO
Pyrenochaetic acid C (14) 
 
 
139 
 
Figure 65. 1H and 13C NMR spectra of compound 15 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 66. 1H and 13C NMR spectra of cmpound 16 [700 MHz for 1H and 175 MHz for 13C, Methnaol-d4]. 
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Table 23. Antimicrobial Activities of Compounds 1-15 
 
compound 
Antimicrobial Activity MIC  (µg/mL) 
M. 
luteus 
S. 
aureus 
E. 
coli 
M. 
smegmatis 
S. 
cerevisiae 
C. 
albicans 
C. 
neoformans 
A. 
niger 
1  38 75 75 >75 75 75 75 75 
2  36 >145 >145 >145 >145 >145 >145 >145 
3  5 39 >78 >78 >78 >78 >78 >78 
4 46 93 >93 >93 >93 >93 >93 >93 
5 15 59 >118 >118 >118 >118 >118 >118 
6 >43 >43 >43 >43 >43 >43 >43 >43 
7 >58 >58 >58 >58 >58 >58 >58 >58 
8 >40 >40 >40 >40 >40 >40 >40 >40 
9  >70 >70 >70 >70 >70 >70 >70 >70 
10 43 43 >85 >85 >85 >85 >85 >85 
11 >88 >88 >88 >88 >88 >88 >88 >88 
12 >133 >133 >133 >133 >133 >133 >133 >133 
13  >120 >120 >120 >120 >120 >120 >120 >120 
14  >70 >70 >70 >70 >70 >70 >70 >70 
15 >83 >83 >83 >83 >83 >83 >83 >83 
Vancomycina -- 0.25 -- -- -- -- -- -- 
Ampicillina 4 -- 8 -- -- -- -- -- 
Ciprofloxacina -- -- -- 2 -- -- -- -- 
Amphotericin Ba -- -- -- -- 3.9 25 25 100 
aPositive controls         
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CHAPTER VI 
 
ISOCHROMENONES, ISOBENZOFURANONE, AND 
TETRAHYDRONAPHTHALENES PRODUCED BY PARAPHOMA RADICINA, A 
FUNGUS ISOLATED FROM A FRESHWATER HABITAT 
 
Tamam El-Elimat, Huzefa A. Raja, Mario Figueroa, Joseph O. Falkinham III, 
Nicholas H. Oberlies. This chapter has been submitted to Phytochemistry (2014). 
 
Six isochromenones (1-6), of which two were new [clearanols F (5) and G (6)], one 
isobenzofuranone (7), and two tetrahydronaphthalene derivatives (8 and 9), the latter of 
which was new [radinaphthalenone (9)], were isolated and identified from a culture of the 
fungus Paraphoma radicina, which was isolated from submerged wood in a freshwater 
lake. The structures were elucidated using a set of spectroscopic and spectrometric 
techniques; the absolute configurations of compounds 5 and 6 were determined by 
comparison of their experimental ECD measurements with values predicted by TDDFT 
calculations. Compounds 1-9 were evaluated for antimicrobial activity against an array of 
bacteria and fungi. The inhibitory activity of compound 4 against Staphylococcus aureus 
biofilm formation was evaluated.  
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Introduction 
In search of structurally diverse scaffolds from ecologically unique fungi, our group 
has initiated investigations of freshwater fungi,98,99 specifically ascomycetes that inhabit 
submerged woody and herbaceous organic matter in lakes and streams.147 Freshwater 
fungi represent an ecologically important though poorly studied class of fungi in terms of 
chemistry148,149 and mycology.147 Only fragmentary knowledge, at best, exists regarding 
habitat and substrate distribution patterns, species identities, and role(s) that these fungi 
play in freshwater ecosystems. Of the 1.5 M to 5.1 M estimated fungi in the world,8,23 
only about 3,000 species have been characterized from freshwater habitats. This is 
somewhat surprising given that less than 2% of the planet is covered by freshwater.147,150 
Similarly, of the 14,000 secondary metabolites that have been isolated from fungi,151 only 
about 125 compounds, i.e. less than 1%, have been from freshwater fungi.148,149 
A fungus, which was accessioned as G104, was isolated from submerged wood in a 
freshwater lake and was identified as Paraphoma radicina. This fungus produced six 
isochromenones (1-6), of which two were new [clearanol F (5), and clearanol G (6)], and 
four were known [(R)-3,4-dihydro-4,6,8-trihydroxy-4,5-dimethyl-3-
methyleneisochromen-1-one (1), (R)-3,4-dihydro-4,8-dihydroxy-6-methoxy-4,5-
dimethyl-3-methyleneisochromen-1-one (2), 3,8-dihydroxy-3-hydroxymethyl-6-
methoxy-4,5-dimethyl-isochroman-1-one (3), and clearanol C (4)]. Also isolated were 
one known isobenzofuranone (R)-7-hydroxy-3-((S)-1-hydroxyethyl)-5-methoxy-3,4-
dimethylisobenzofuran-1(3H)-one (7) and two tetrahydronaphthalene derivatives 
[isosclerone (8) and radinaphthalenone (9)], the latter having not been reported 
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previously. Herein, details of the isolation, structural elucidation, and determination of 
the absolute configuration of these compounds are presented. Structurally related 
compounds have been reported to have various degrees of antifungal activity152-154 and 
mild antimycobacterial activity.155 As such, compounds 1-9 were evaluated against a 
panel of microorganisms; the most promising (4) was also tested in a Staphylococcus 
aureus biofilm assay. 
Results and Discussion 
Two large-scale solid-phase cultures (LS1 and LS2) of the fungus (G104) were 
extracted with 1:1 CHCl3-MeOH and partitioned with organic solvents. The organic 
extracts were purified using flash chromatography to yield 3 and 4 fractions, respectively, 
which were then subjected to further purifications using preparative and semipreparative 
HPLC to yield nine compounds (1-9). The purity of the isolated compounds was 
evaluated via UPLC (Figure 72). Compounds 1-6 and 7 belong to isochromenone and 
isobenzofuranone classes of natural products, respectively, while compounds 8 and 9 
were tetrahydronaphthalene derivatives. 
Compounds 1 (5.53 mg), 2 (34.16 mg), and 4 (9.19 mg) had molecular formulas of 
C12H12O5, C13H14O5, and C13H14O4, respectively, as determined by HRESIMS. The 
NMR and HRMS data of these were similar, indicative of analogous structures, with key 
differences being a methoxy moiety in 2 relative to 1 and an OH moiety in 2 relative to 4. 
The NMR, HRMS, CD and optical rotation data identified 1, 2, and 4 as the known 
compounds, (R)-3,4-dihydro-4,6,8-trihydroxy-4,5-dimethyl-3-methyleneisochromen-1-
one, (R)-3,4-dihydro-4,8-dihydroxy-6-methoxy-4,5-dimethyl-3-methyleneisochromen-1-
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one, and (S)-8-hydroxy-6-methoxy-4,5-dimethyl-3-methyleneisochromen-1-one 
(clearanol C), respectively (Figure 67 and Table 26). Compound 2 was first isolated in 
2002 from the EtOAc extract of a broth of the marine fungus Halorosellinia oceanica,155 
and compounds 1, 2 and 4 were isolated in 2011 from the culture broth of Leptosphaeria 
sp., which was collected from woody debris.152,154 Compound 4 was re-isolated in 2012 
from a complex microbial mat that occupied an iron-rich freshwater spring and was 
ascribed the trivial name clearanol C.153 
Compound 3 (7.5 mg) was obtained as a colorless oil with a molecular formula of 
C13H16O6 as determined by HRESIMS. The NMR data revealed the presence of an 
inseparable pair of compounds existing in 7:1 ratio, with the major one identified as the 
known compound 3,8-dihydroxy-3-hydroxymethyl-6-methoxy-4,5-dimethyl-isochroman-
1-one (See Table 26 for CD and optical rotation data).154 Tayone et al. suggested the 
minor compound as a stereogenic tautomer of the major compound around the hemiacetal 
moiety at C3 (Figure 67).154 These were first isolated in 2011 from an Allantophomopsis 
sp. 156 and later in the same year from a Leptosphaeria sp.154 
Compound 7 (3.5 mg), which was obtained as a colorless oil, had a molecular 
formula of C13H16O5 as determined by HRESIMS. The NMR, HRMS, and optical 
rotation data identified 7 as the known compound (R)-7-hydroxy-3-((S)-1-hydroxyethyl)-
5-methoxy-3,4-dimethylisobenzofuran-1(3H)-one (Figure 67 and Table 26),152 which was 
first isolated in 2011 from the culture broth of Leptosphaeria sp.152 
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Figure 67. Structures of compounds 1-9. 
Compound 5 (0.85 mg) was also obtained as a colorless oil. The molecular formula 
was determined as C13H16O6 via HRESIMS, establishing an index of hydrogen 
deficiency of 6. The NMR data suggested structural similarity with 3a, both having the 
same molecular formula. Key differences were noticed in the chemical shift and splitting 
of the C-10 methyl group. It changed from a doublet that resonated at 1.14 ppm in 3a into 
a singlet resonating at 1.53 ppm in 5. Moreover, C-3 changed from a quaternary carbon 
(δC 103.3) in 3a into a methine (δH/δC 4.36/82.4) in 5. Additionally, C-4 changed from a 
methine in 3a (δH/δC 3.27/36.1) into an oxygenated quaternary carbon (δC 72.4) in 5. 
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These data suggested a switch in the hydroxyl group position from C-3 in 3a to C-4 in 5 
(Table 24 and Figures 73 and 74 for the 1H and 13C NMR data). An HMBC correlation 
was observed from 12-OCH3 to C-6, indicating the connectivity of the methoxy group. 
HMBC correlations from H-11 to C-6 and C-4a, from H-7 to C-5 and C-8a, from 8-OH to 
C-7 and C-8, from 10-CH3 to C-4a and C-3, from 4-OH to 10-CH3, from H-3 to C-4a, 
and from 9-CH2 to C-4 were observed (Figure 68). These data suggested the planar 
structure of 5 (Figure 67), which was ascribed the trivial name clearanol F. The absolute 
configuration of 5 was determined by comparing experimental and calculated ECD 
spectra predicted by the time-dependent density functional theory (TDDFT) method.122-
125 Similar studies have used calculated ECD values for determination of the absolute 
configuration of a series of chromone derivatives from Penicillium species 157 and 
isochromenones from Leptosphaeria species.152,154 Theoretical ECD spectra calculated 
for the four possible diastereomers 5a−5d were compared with the experimental spectra 
(Figure 79). A detailed conformational search was performed for each diastereomer using 
molecular mechanics followed by geometry optimization with DFT at the 
B3LYP/DGDZVP2 level for the most stable conformers.125,158 The relative free energies 
and the Boltzmann distribution for the most relevant conformers of each diastereomer (4, 
7, 4, and 5 conformers for 5a-5d, respectively), each with a ΔG0 range of between 0.0 
and 3.0 kcal mol−1, were taken into account to obtain population-weighted averaged 
calculated ECD spectra (Figures 69 and 79, and Table 27). The results for 5c (3S,4R) 
were in excellent agreement with the experimental ECD spectrum where two negative 
low amplitude Cotton effects were observed at approximately 225 and 255 nm, along 
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with two positive effects at approximately 235 and 275 nm (Figure 70), confirming the S 
and R configurations at C-3 and C-4, respectively. 
 
Table 24. NMR Data for 5 and 6 [700 MHz for 1H, 175 MHz for 13C; Chemical 
Shifts in δ, Coupling Constants in Hz, CDCl3] 
 
position 
5 6 
δC, type δH, mult, J in Hz δC, type δH, mult, J in Hz 
1 169.5, C --- 166.5, C --- 
3 82.4, CH 4.36, dd, 6.3, 5.7 159.6, C --- 
4 72.4, C --- 72.3, C --- 
4a 144.6, C --- 146.1, C --- 
5 116.2, C --- 117.6, C --- 
6 165.8, C --- 165.4, C --- 
7 98.8, CH 6.42, s 99.2, CH 6.46, s 
8 163.7, C --- 164.8, C --- 
8a 98.9, C --- 99.2, C --- 
9 61.2, CH2 4.06, dd, 11.5, 6.3 95.9, CH2 4.94, d, 1.7 
  4.12, dd, 11.5, 5.7  5.12, d, 1.7 
10 21.1, CH3 1.53, s 31.3, CH3 1.72, s 
11 12.2, CH3 2.33, s 55.3, CH2 4.98, d, 9.2 
12 56.2, CH3 3.85, s 56.4, CH3 3.88, s 
4-OH --- 2.51, s --- --- 
8-OH --- 11.45, s --- 11.40, s 
9-OH --- 2.17, br s --- 2.28, br 
 
O
O
OH O
OH
OH
1
4
4a 36
8 8a
9
1011
12
 
O
O
OH O
OH
1
4
4a 36
8 8a
9
1011
12
HO
 
O
O
OH
OH
1
2
3
4 4a 5
6
788a
9
 
5 6 9 
Figure 68. Key HMBC correlations of compounds 5, 6, and 9. 
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Figure 69. DFT B3LYP/DGDZVP2 geometry optimized conformers of 5c [(3S,4R)-
5)] at 298 K and 1 atm, accounting for ca. 99% of the conformational population. 
 
 
Figure 70. Experimental and calculated CD spectra for 5 in CH3CN. 
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Compound 6 (0.65 mg) was obtained as a colorless oil. The molecular formula was 
determined as C13H14O6 via HRESIMS. The NMR data suggested an isochromenone 
with structural similarity to 2. However, compound 6 had an extra oxygen atom as 
evidenced by a 16 amu difference in the HRMS between 2 and 6. Examination of the 1- 
and 2-D NMR data indicated that the C-11 methyl group in 2 (δH/δC 2.36/29.0) was 
hydroxylated in 6 (δH/δC 4.98/55.3). Key HMBC correlations were observed from H2-11 
to C-6 and C-4a, confirming the connectivity of the methylene hydroxyl group to C-4 and 
establishing the structure of 6 (Figures 67, 68, 75, and 76). The trivial name, clearanol G, 
was ascribed to this compound. The absolute configuration at C-4 was established by 
comparing the ECD data with those obtained through molecular modeling calculations 
following the same protocol described for compound 5 (Table 28). The agreement 
between the observed and calculated ECD (Figure 71) confirmed the R configuration at 
C-4. 
 
 
Figure 71. Experimental and calculated CD spectra for 6 in CH3CN. 
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In addition to compounds 1-7, two tetrahydronaphthalene derivatives, one known (8) 
and one new (9), were isolated and identified as well. The known compound 8 was 
identified as isosclerone by means of NMR, HRMS, and optical rotation data, which all 
compared favorably to the literature.91 Compound 9 (0.81 mg) was isolated as an off-
white powder. The molecular formula was determined as C11H10O4 by HRESIMS, 
indicative of an index of hydrogen deficiency of 7. The 1H NMR data revealed the 
presence of one aromatic proton (δH 6.57, s), two methylenes (δH 2.98, m, and 3.02 m), 
one methyl (δH 2.38, s), and two hydroxyl protons (δH 11.36, s, and 5.91, broad peak, for 
5-OH and 7-OH, respectively) (Table 25 and Figure 77). The 13C NMR data revealed 11 
carbons, consistent with the HRMS data and indicative of two carbonyls (δC 198.8 and 
201.5 for C-1 and C-4, respectively), six aromatic carbons (δC 113.4, 162.1, 107.3, 163.0, 
118.5, and 135.7 for C-4a, C-5, C-6, C-7, C-8, and C-8a, respectively), suggesting a penta 
substituted benzene ring, two methylenes (δC 40.0 and 37.2 for C-2 and C-3, 
respectively), and one methyl (δC 11.9 for C-9) (Table 25 and Figure 78). The benzene 
ring and the two carbonyl groups accounted for six degrees of unsaturation, leaving the 
remaining one accommodated by a ring. HMBC correlations were observed from CH3-9 
to C-7 and C-8a from H-6 to C-8 and C-4a, from CH2-2 to C-8a, and C-4, and from CH2-
3 to C-1 (Figure 68). These spectroscopic and spectrometric data suggested the structure 
of 9 (Figure 67), which was ascribed the trivial name radinaphthalenone. 
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Table 25. NMR Data for 9 (500 MHz for 1H, 100 MHz for 13C; 
Chemical Shifts in δ, Coupling Constants in Hz, CDCl3) 
 
position δC, type δH, mult 
1 198.8, C --- 
2 40.0, CH2 2.98, m 
3 37.2, CH2 3.02, m 
4 201.5, C --- 
4a 113.4, C --- 
5 162.1, C --- 
6 107.3, CH 6.57, s 
7 163.0, C --- 
8 118.5, C --- 
8a 135.7, C --- 
9 11.9, CH3 2.38, s 
5-OH --- 11.36, s 
7-OH --- 5.91, broad 
 
Compounds 1-9 were tested for antimicrobial activity against an array of bacteria 
and fungi (Table 29). Compound 4 showed promising activity against S. aureus with an 
MIC value of 33 µg/mL. Compound 4 was reported by Gerea et al.153 to have weak 
inhibitory activity against Candida albicans biofilm formation and modest inhibition 
against polyene-resistant C. albicans. As such, 4 was evaluated for inhibitory activity 
against S. aureus biofilm formation and was found inactive. Compound 7 was reported to 
have strong antifungal activity against Cochliobolus miyabeanus at 0.5 μg/mL.152 When 
tested against A. niger, compound 7 was inactive (Table 29). 
Conclusions 
From a fungus that was isolated from a freshwater niche, nine compounds (1-9) 
belonging to three structural classes, isochromenones, isobenzofuranones, and 
tetrahydronaphthalenes, were isolated and identified. The absolute configuration of the 
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new isochromenones, 5 and 6, was elucidated by means of TDDFT ECD spectra 
calculations. While most of the compounds were inactive, compound 4 had activity 
against S. aureus. Coupled with literature data on 4 and 7 regarding activity against 
biofilm formation in C. albicans and antifungal activity against C. miyabeanus, these 
compounds may confer a competitive advantage for this fungus, which was collected 
from a freshwater habitat. The current study demonstrated how structurally diverse 
compounds can be revealed from ecologically unique environments such as freshwater 
habitat, a highly underexplored source of bioactive natural products. 
Paraphoma radicina is a plurivorous species, and it was originally reported from 
young cysts of nematodes from root surfaces of soybean in different counties in North 
Carolina, USA.159 It was interesting to isolate the same species of fungus from the same 
state but a different environment. Its occurrence in both terrestrial and freshwater habitats 
suggested that it may be an immigrant species sensu Park.160 
Experimental 
General Experimental Procedures. UV and CD spectra were acquired on a Varian 
Cary 100 Bio UV-Vis spectrophotometer and an Olis DSM 17 CD spectrophotometer 
(Olis), respectively. NMR experiments were conducted using either a JEOL ECA-500 
NMR spectrometer operating at 500 MHz for 1H and 125 MHz for 13C, or a JEOL ECS-
400 NMR spectrometer equipped with a high sensitivity JEOL Royal probe operating at 
400 MHz for 1H and 100 MHz for 13C, or an Agilent 700 MHz NMR spectrometer, 
equipped with a cryoprope, operating at 700 MHz for 1H and 175 MHz for 13C. Residual 
solvent signals were utilized for referencing. HRESIMS was performed on a Thermo 
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LTQ Orbitrap XL mass spectrometer equipped with an electrospray ionization source. 
UPLC was carried out on a Waters Acquity system with data collected and analyzed 
using Empower 3 software. HPLC was carried out using a Varian Prostar HPLC system 
equipped with ProStar 210 pumps and a Prostar 335 photodiode array detector (PDA), 
with data collected and analyzed using Galaxie Chromatography Workstation software 
(version 1.9.3.2). For preparative HPLC, a Phenomenex Gemini-NX C18 (5 µm; 250 × 
21.2 mm) column was used at a 21 mL/min flow rate. For UPLC, a Waters BEH C18 
column (1.7 µm; 50 × 2.1 mm) was used with a 0.6 mL/min flow rate. Flash 
chromatography was performed on a Teledyne ISCO CombiFlash Rf 200 using a 4 g 
Silica Gold column and monitored by UV and evaporative light-scattering detectors. All 
other reagents and solvents were obtained from Fisher Scientific and were used without 
further purification. The HTP MBEC Assay Biofilm Incubator (Innovotech Inc., 
Edmonton, Alberta, Canada) was used for the S. aurous biofilm assay. 
Fungal Strain Isolation and Identification. The fungal strain, G104, was isolated 
from submerged wood sampled in October of 2011 from a freshwater lake in Greensboro, 
North Carolina, USA (Lake Brandt; 36˚10' 1''N, 79˚50' 18''W). Collection methods and 
culturing conditions were based on earlier work by Shearer et al.161,162 Strain G104 was 
identified using molecular techniques by sequencing the internal transcribed spacer 
regions 1 & 2 and 5.8S nrDNA (ITS)45 along with the D1 and D2 regions of the 28S 
nuclear ribosomal large subunit rRNA gene (LSU).95 Methodology for DNA extraction, 
PCR amplification, sequencing, and phylogenetic analyses were performed as described 
previously.63,81,97-99 BLAST search in GenBank using ITS rDNA sequences and 
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phylogenetic analysis using partial LSU sequence data suggested that strain G104 had 
phylogenetic affinities to Paraphoma radicina (McAlpine) Morgan-Jones & J.F. White 
belonging to the section Phoma (Figure 80).159,163 Therefore, strain G104 was identified 
as Paraphoma radicina (Ascomycota). The combined ITS and LSU sequence was 
deposited in the GenBank (accession no. KF938577). A voucher culture of strain G104 is 
maintained in the Department of Chemistry and Biochemistry culture collection at the 
University of North Carolina at Greensboro. 
Fermentation and Isolation. The culture of strain G104 was stored on a malt 
extract slant and was transferred periodically. A fresh culture was prepared in a similar 
slant and subsequently grown on 2% MEA, potato dextrose agar (PDA, Difco), and 
YESD media. After 14–21 d, agar plugs of the fungus were used to inoculate 30 mL of 
autoclaved rice medium, prepared using 10 g of rice and twice the volume of rice with 
H2O in a 250 mL Erlenmeyer flask. Large scale cultures were prepared by the parallel 
processing of four such cultures in quadruplicates, which were incubated at 22 °C until 
showing good growth (approximately 14 d). 
To a large scale culture, 500 mL of 1:1 MeOH-CHCl3 were added. The culture was 
chopped with a spatula and shaken overnight (~16 h) at ∼100 rpm at rt. The sample was 
filtered with vacuum, and the remaining residues were washed with 100 mL of 1:1 
MeOH-CHCl3. To the filtrate, 900 mL CHCl3 and 1500 mL H2O were added; the 
mixture was stirred for 30 min and then transferred into a separatory funnel. The bottom 
layer was drawn off and evaporated to dryness. The dried organic extract was re-
constituted in 100 mL of 1:1 MeOH-CH3CN and 100 mL of hexanes. The biphasic 
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solution was shaken vigorously and then transferred to a separatory funnel. The MeOH-
CH3CN layer was drawn off and evaporated to dryness under vacuum. The defatted 
material (231 mg) was dissolved in a mixture of CHCl3-MeOH, adsorbed onto Celite 
545, and fractionated via flash chromatography using a gradient solvent system of 
hexane-CHCl3-MeOH at a 18 mL/min flow rate and 68.1 column volumes over 18.2 min 
to afford three fractions. Fraction 1 (78.87 mg) was subjected to preparative HPLC using 
a gradient system of 20:80 to 80:20 of CH3CN-H2O (acidified with 0.1% formic acid) 
over 20 min at a flow rate of 21 mL/min to yield six sub-fractions. Sub-fractions 1, 3, 4, 
and 6 yielded compounds 8 (0.71 mg), 7 (1.61 mg), 2 (16.05 mg), and 4 (9.19 mg), which 
eluted at ~11.3, 12.0, 17.6, and 21.2 min, respectively. Fraction 2 (26.11 mg) was 
subjected to preparative HPLC using a gradient system of 30:70 to 40:60 of CH3CN-H2O 
(acidified with 0.1% formic acid) over 20 min at a flow rate of 21 mL/min to yield four 
sub-fractions. Sub-fractions 1 and 2 yielded compounds 6 (0.65 mg) and 3 (5.64 mg), 
which eluted at 10.7 and 12.6 min, respectively. Fraction 3 (~84.99 mg) was subjected to 
preparative HPLC using a gradient system of 20:80 to 40:60 of CH3CN-H2O (acidified 
with 0.1% formic acid) over 20 min at a flow rate of 21 mL/min to yield four sub-
fractions. Sub-fractions 3 and 4 yielded compounds 5 (0.85 mg) and 3 (1.88 mg), which 
eluted at ~17.1 and 19.6 min, respectively. 
To generate more material for biological evaluation, another large scale culture of 
strain G104 was extracted and fractionated as described above. The MeOH-CH3CN 
fraction (242 mg) was subjected to fractionation using flash chromatography using a 
gradient solvent system of hexane-CHCl3-MeOH at a 30 mL/min flow rate and 61.0 
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column volumes over 34.1 min to afford four fractions. Fraction 2 (145.95 mg) was 
subjected to preparative HPLC using a gradient system of 40:60 to 80:20 of CH3CN-H2O 
(acidified with 0.1% formic acid) over 15 min at a flow rate of 21 mL/min to yield six 
sub-fractions. Sub-fractions 1, 2, and 3 yielded compounds 7 (1.89 mg), 8 (0.82 mg), and 
2 (18.11 mg), which eluted at 4.5, 7.6, and 13.1 min, respectively. Fraction 3 (35.69 mg) 
was subjected to preparative HPLC using a gradient system of 20:80 to 60:40 of CH3CN-
H2O (acidified with 0.1% formic acid) over 15 min at a flow rate of 21 mL/min to yield 
four sub-fractions. Sub-fraction 3 yielded compound 1 (5.53 mg), which eluted at ~16.0 
min. 
Clearanol F (5): Colorless oil; [𝛼]𝐷25 = +18° (c = 0.05, Chloroform); UV (MeOH) 
λmax (log ε) 313 (3.20), 269 (3.36), 228 (3.36), 217 (3.75) nm; CD (c 7.46 × 10-5 M, 
CH3CN) λ (∆ε) 209 (+29.4) nm, 228 (-11.3) nm, 242 (+9.8) nm; 261 (-1.0) nm, 273 
(+2.6) nm; 1H NMR (CDCl3, 700 MHz) and 13C NMR (CDCl3, 175 MHz), see Table 24; 
HRESIMS m/z  269.1013  [M + H]+ (calcd for C13H17O6 269.1020). 
Clearanol G (6): Colorless oil; [𝛼]𝐷25 = +43° (c = 0.03, Chloroform);UV (MeOH) 
λmax (log ε) 308 (3.18), 268 (3.36), 228 (3.41) nm; CD (c 7.51 × 10-5 M, CH3CN) λ (∆ε) 
221 (-18.9) nm, 242 (+21.7) nm, 266 (+19.3) nm, 316 (-4.0) nm; 1H NMR (CDCl3, 700 
MHz) and 13C NMR (CDCl3, 175 MHz), see Table 24; HRESIMS m/z  267.0861  [M + 
H]+ (calcd for C13H15O6 267.0863). 
Radinaphthalenone (9): Off-white powder; UV (MeOH) λmax (log ε) 352 (3.28), 
293 (3.24), 244 (3.35), 211 (3.18) nm; 1H NMR (CDCl3, 500 MHz) and 13C NMR 
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(CDCl3, 100 MHz), see Table 25; HRESIMS m/z  207.0647  [M + H]+ (calcd for 
C11H11O4 207.0652). 
Computational Methods. Theoretical calculations of ECD spectra for compounds 5 
and 6 were performed with the Gaussian 09 (Gaussian Inc., Pittsburgh, PA, USA) 
program package.164 Geometry optimizations for both compounds were carried out using 
the PM3 semi-empirical force field calculations as implemented in the Spartan 08 
program (Wavefunction Inc. Irvine, CA, USA).165 A Monte Carlo search protocol166 was 
carried out considering an energy cutoff of 5 kcal/mol. In each case, the minimum energy 
structures were filtered and checked for duplicity. Each conformer was geometrically 
optimized using hybrid DFT method B3LYP and basis set DGDZVP2 
(B3LYP/DGDZVP2), and thermochemical parameters and the frequencies at 298 K and 1 
atm. The self-consistent reaction field method (SCRF) with conductor-like continuum 
solvent model (COSMO) was employed to perform the ECD calculation of major 
conformers of compounds 5 and 6 in CH3CN solution with the same basis set. The 
calculated excitation energy (in nm) and rotatory strength R, in dipole velocity (Rvel) and 
dipole length (R len) forms, were simulated into an ECD curve by using the following 
Gaussian function: 
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where σ  is the width of the band at 1/e height, and Ei and Ri are the excitation energies 
and rotatory strengths for transition i, respectively. σ  = 0.40 eV and Rvel were used. All 
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quantum calculations were carried out on a Linux operating system in the KanBalam 
cluster from a Hewlett-Packard HP CP 4000, which includes 1368 AMD Opteron 
processors at 2.6 GHz and a RAM memory of 3 terabytes (KanBalam, Dirección General 
de Cómputo y de Tecnologías de Información y Comunicación, UNAM). 
Antimicrobial Assay. Minimal inhibitory concentrations (MICs) of compounds 1-9 
were measured as described previously.18,102,103 All measurements were made in 
duplicate. The positive controls were ampicillin, rifamycin, and amphotericin B. 
Biofilm-Grown Cells Inhibition by a 96-Well Plate Assay. The inhibition of 
biofilm-grown cells of S. aureus strain ATCC 6358 was measured as described by Nett et 
al.167 with the only change being the growth of the S. aureus strain in Mueller-Hinton 
broth at 37° C. The MIC was defined as the lowest concentration that resulted in 50% 
(IC50) and 90% (IC90) reduction in reduced XTT absorbance. Vancomycin was used as a 
positive control and showed an IC90 of 0.5 µg/mL. 
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Supplementary Data 
 
 
Table 26. CD and Optical Rotation Data, Experimental vs. Literature, of Compounds 1-4 and 7 
 
compound 
CD: Conc. solvent;  λmax (Δε) nm Optical rotation 
Experimental Literature Experimental Literature 
1 1.7 × 10
-5 M, CH3CN 
226 (-9.4); 207 (+17.5)  
2.5 × 10-4 M, CH3CNa 
226 (-2.2); 207 (+5.2)  
[𝛼]𝐷25 = +300°  
(c = 0.02, Chloroform) 
[𝛼]𝐷25 = +161°  
(c = 0.19, Chloroform).a 
2 1.7 × 10
-5 M, CH3CN 
225 (-8.3); 205 (+20.2)  
5.2 × 10-5 M, CH3CNa 
225 (-7.4); 207 (+12.3)  
[𝛼]𝐷25 = +229°  
(c = 0.09, Chloroform) 
[𝛼]𝐷25 = +96°  
(c = 0.11, Chloroform).a 
3a 7.4 × 10
-5 M, CH3CN 
267 (+21.4); 218 (-2.5)  
4.1 × 10-5 M, CH3CNb 
260 (+2.1); 215 (-4.8)  
[𝛼]𝐷25 = +55°  
(c = 0.07, Chloroform) 
[𝛼]𝐷25 = +61°  
(c = 0.68, Chloroform).b 
4 
1.7 × 10-5 M, CH3CN 
267 (+23.0); 237 
(+23.8); 212 (-21.2)  
6.4 × 10-5 M, CH3CNb 
266 (+12.6); 213 (-10.0); 
235 (+15.2)  
[𝛼]𝐷25 = +215°  
(c = 0.02, Chloroform) 
[𝛼]𝐷25 = +143°  
(c = 0.15, Chloroform).b 
7 1.2 × 10
-4, CH3CN 
254 (+6.2); 215 (-46.8)  
3.0 × 10-5, CH3CNa 
258 (+2.7); 215 (-7.7) 
[𝛼]𝐷25 = −26°  
(c = 0.09, Chloroform) 
[𝛼]𝐷25 = −27°  
c = 0.20, Chloroform).a 
aTayone, W. C.; Honma, M.; Kanamaru, S.; Noguchi, S.; Tanaka, K.; Nehira, T.; Hashimoto, M. J. Nat. Prod. 
2011, 74, 425-429. 
bTayone, W. C.; Kanamaru, S.; Honma, M.; Tanaka, K.; Nehira, T.; Hashimoto, M. Biosci. Biotech. Bioch. 2011, 
75, 2390-2393. 
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Table 27. Relative Free Energies (∆Grel)a and Equilibrium Population 
(p)b Values of the Conformers of 5a-5d 
 
conformer 5a conformer 5b 
∆Grel p (%) ∆Grel p (%) 
5a-1 0.0000 41.90 5b-1 0.0000 53.61 
5a-2 0.1902 30.39 5b-2 0.6363 18.31 
5a-3 0.2931 25.55 5b-3 0.9835 10.19 
5a-4 1.7571 2.16 5b-4 1.1175 8.13 
   5b-5 1.3668 5.34 
   5b-6 1.7411 2.84 
   5b-7 2.0879 1.58 
conformer 5c conformer 5d 
∆Grel p (%) ∆Grel p (%) 
5c-1 0.0000 90.30 5d-1 0.0000 49.95 
5c-2 1.7079 5.05 5d-2 0.5309 20.39 
5c-3 1.9940 3.12 5d-3 0.7430 14.25 
5c-4 2.4188 1.52 5d-4 0.9891 9.41 
   5d-5 1.2559 6.00 
aB3LYP B3LYP/DGDZVP2, in kcal/mol 
bPopulation percentages based on ∆Grel, assuming Boltzmann statistics at 
T=298.15 K and 1 atm 
 
Table 28. Relative Free Energies (∆Grel)a and Equilibrium Population 
(p)b Values of the (R) and (S) Conformers of Compound 6 
 
conformer (R)-6 conformer (S)-6 
∆Grel p (%) ∆Grel p (%) 
(R)-1 0.0000 52.75 (S)-1 0.0000 43.25 
(R)-2 0.3242 30.52 (S)-2 0.4689 19.60 
(R)-3 0.7324 15.32 (S)-3 0.4689 19.60 
(R)-4 2.1486 0.14 (S)-4 0.7931 11.34 
   (S)-5 1.2013 0.57 
   (S)-6 2.6176 0.05 
aB3LYP B3LYP/DGDZVP2, in kcal/mol 
bPopulation percentages based on ∆Grel, assuming Boltzmann statistics at 
T=298.15 K and 1 atm 
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Table 29. Antimicrobial Activities of Compounds 1-9 
 
compound 
Minimal inhibitory concentration (µg/mL) 
S. aureus E. coli M. smegmatis S. cerevisiae A. niger 
1 >108 108 108 >108 >108 
2 >138 >138 >138 >138 >138 
3 >190 >190 >190 >190 >190 
4 33 >130 130 >138 >138 
5 >108 >108 >108 >108 >108 
6 >88 >88 >88 >88 >88 
7 >153 >153 >153 >153 >153 
8 >63 >63 >63 >63 >63 
9 60 >60 >60 >60 >60 
Ampicillina 0.2 >250 >250 >250 >250 
Rifamycina 0.2 31 4 >250 >250 
Amphotericin Ba 0.2 >250 250 3.9 31 
aPositive controls. 
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Figure 72. UPLC chromatograms of compounds 2-9 (λ 254 nm) and 1 (ELSD detection), 
demonstarting >95% purity for compounds 1-8 and >93% for compound 9. All data were 
acquired via an Acquity UPLC system with a BEH C18 (1.7 μm 2.1 × 50 mm) column 
and a CH3CN/H2O gradient that incresaed linrealy from 20 to 100% CH3CN over 4.5 
min. 
(1) (2) 
(3) (4) 
(5) (6) 
(7) (8) 
(9) 
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Figure 73. 1H NMR spectrum of clearanol F (5) [700 MHz, CDCl3]. 
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Figure 74. 13C NMR specrum of clearanol F (5) [175 MHz, CDCl3]. 
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Figure 75. 1H NMR spectrum of clearanol G (6) [700 MHz, CDCl3]. 
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Figure 76. 13C NMR spectrum of clearanol G (6) [175 MHz, CDCl3]. 
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Figure 77. 1H NMR spectrum of radinaphthalenone (9) [500 MHz, CDCl3]. 
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Figure 78. 13C NMR Spctrum of radinaphthalenone (9) [100 MHz, CDCl3].
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Figure 79. Experimental CD spectrum for 5 in CH3CN compared with calculated CD 
spectra for compounds 5a-5d at the B3LYP/DGDZVP2 Level. 
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Figure 80. Phylogram of the most likely tree (-lnL = -7198.77) from a RAxML analysis 
of 81 taxa (alignment downloaded from TreeBase (www.treebase.org) by Gruyter et al. 
Mycologia 2010, 102, 1066-1081). Partial LSU sequence (D1/D2 domains) of strain 
G104 was included in the ML analysis. Numbers above branches refer to RAxML 
bootstrap support values based on 1000 replicates. Strain G104 is highlighted and shows 
phylogenetic affinities with P. radicina. 
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CHAPTER VII 
 
RESORCYLIC ACID LACTONES FROM A FRESHWATER HALENOSPORA SP. 
 
Tamam El-Elimat, Huzefa A. Raja, Joseph O. Falkinham III, Cynthia S. Day, and 
Nicholas H. Oberlies. This chapter is intended for submission to Journal of Natural 
Products (2014). 
 
Fourteen new resorcylic acid lactone analogues [greensporones A‒N (1-14)], were 
isolated from an organic extract of a culture of a freshwater aquatic fungus Halenospora 
sp. The structures were elucidated using a set of spectroscopic and spectrometric 
techniques. The absolute configuration of one representative member of the compounds 
(7) was assigned using X-ray crystallography of an analogue that incorporated a heavy 
atom, while for compounds 8-11, a modified Mosher’s ester method was utilized. The 
relative configurations of compounds (12-14) were determined on the basis of NOE data. 
Compounds 12-14 were proposed as artifacts produced by intramolecular 
cycloetherification of ε-hydroxy-α,β-unsaturated ketone moieties of parent compounds 
during the extraction and purification processes. Compounds (1-14) were evaluated as 
TAK1-TAB1 inhibitors, and as antimicrobials against a panel of bacteria and fungi. 
 
Fungi are one the highly diverse organisms that exist on earth, though they are not 
well investigated.168 For example, of the 1.5 M to 5.1 M estimated species of fungi in the 
planet,8,23,169 less than 100,000 have been described in the literature.170,171 Interestingly, 
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fungi from freshwater habitats, specifically ascomycetes that inhabit and decompose 
submerged woody and herbaceous organic matter in lotic and lentic habitats, represent an 
even less well-studied area of mycology, resulting in slightly more than 3,000 described 
species to date.147 Freshwater fungi also represent an understudied source of bioactive 
secondary metabolites. Only a few studies have explored the natural products of 
freshwater fungi, resulting in the identification of about 125 compounds or less than 1% 
of the 14,000 compounds that have been characterized from fungi.148,149 Hence, our group 
has launched investigations of freshwater fungi98,99,172 as potential sources of new 
scaffolds for drug design and development. 
A freshwater fungus that was accessioned as G87 was sampled from submerged 
wood substrate in a stream on the campus of the University of North Carolina at 
Greensboro and was identified putatively as Halenospora sp., Helotiales, Leotiomycetes, 
Ascomycota. The organic extract exhibited promising toxicity in the brine shrimp test, 
and as a talented chemist, a series of fourteen new structurally related resorcylic acid 
lactones (RALs) were characterized [greensporones A‒N (1-14)]. There has been 
growing interest in macrocycles in drug discovery due to their interesting biological 
activities and unique properties, including cell permeability and oral bioavailability.173 
Herein, we report the isolation, structure elucidation, and stereochemical assignment of 
compounds 1-14. They were also evaluated as antimicrobials against a panel of bacteria 
and fungi. Moreover, as these polyketide derived metabolites were reported to be potent 
inhibitors of ATPases and kinases, including TAK1,141,142 they were examined as TAK1-
TAB1 inhibitors, but found inactive.  
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Results and Discussion 
An organic extract [CHCl3-MeOH (1:1)] of the G87 culture that was grown on rice 
was partitioned with 1:1 CH3CN-MeOH and hexane. The resulting extract displayed 
promising toxicity in the brine shrimp test,49,174,175 23% survival at 10 µg/mL, and hence 
was chosen for further investigations to explore its profile of secondary metabolites. The 
organic extract was fractionated using flash chromatography to afford five fractions. Of 
these, fractions 3 and 4 showed interesting HPLC profiles with PDA data indicating a 
series of structurally related compounds. Thus, these fractions were subjected to further 
purifications using preparative and semipreparative HPLC to yield fourteen compounds 
(1-14). The purity of the isolated compounds was measured by UPLC (Figure 86, 
Supporting Information). 
Compound 1 (33.93 mg) was obtained as a colorless solid. The molecular formula 
was determined as C19H21O6Cl by HRESIMS. The NMR, HRMS, and optical rotation 
data were similar to those for a recently reported RAL analogue, cryptosporiopsin A, 
described by Talontsi et al.176 in 2012 from the culture of Cryptosporiopsis sp., an 
endophytic fungus from leaves and branches of Zanthoxylum leprieurii (Rutaceae). 
Although the planar structure between 1 and cryptosporiopsin A were identical, we have 
proposed a new name for 1 for two reasons. First, and as explained in more detail below, 
we have strong evidence that the absolute configuration for 1 at position 2 was S. In 
contrast, cryptosporiopsin A was drawn as 2R; however, those authors did not discuss 
their reasoning for this conclusion, although it could be due to similarities they observed 
to ponchonin D.176 Moreover, the trivial name proposed by those authors176 was utilized 
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in 1969 for a structurally unrelated compound.20,21 As such, compound 1 was ascribed the 
new trivial name greensporone A.  
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Figure 81. Structures of compounds 1-14. 
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In addition to 1, a series of structurally related RALs (2-14) that differ in the 
geometry and substitution pattern of the 14-membered macrocyclic lactone ring were 
isolated and structurally characterized by analyses of their HRMS and NMR data. 
Compound 2 (1.04 mg) was isolated as a colorless solid. The molecular formula was 
determined as C19H21O6Cl, via HRESIMS along with 1H, 13C, and edited-HSQC data 
(Tables 30 and 32;  Figure 88, Supporting Information), establishing an index of 
hydrogen deficiency of 9. Analyses of the HRMS and NMR data suggested 2 as a RAL 
with structural similarity with 1. For example, compound 2 showed two ketone 
carbonyls, δC 210.4 and 196.8 ppm for C-5 and C-10, respectively. The upfield shift of C-
10 relative to C-5 indicated the conjugation of the C-10 ketone carbonyl with a double 
bond, resulting from an α,β-unsaturated ketone. Additional similarities included NMR 
signals characteristic of 6 aromatic carbons and one singlet aromatic proton, suggesting a 
pentasubstituted benzene ring, with two downfield shifted carbons (δC 153.3 and 156.6) 
indicating oxygenation as observed in 1. Other substituents included a methoxy group, a 
methyl doublet (JH3-1/H-2 = 6.3 Hz), deshielded methylene protons (JH-11a/H-11b = 18.3 Hz), 
and an ester group. 1H-1H COSY data identified two spin systems (H3-1/H-2/H2-3/H2-4) 
and H2-6/H2-7/H-8/H-9) that were connected by the ketone carbonyl C-5, as supported 
by HMBC correlations (Figure 82). A key difference between compounds 1 and 2 was 
the geometry of C-8/C-9 double bond, being Z in 2 versus E in 1, as evidenced by the 
coupling constants of the olefinic protons (JH-8/H-9 = 11.5 in 2 versus 16.0 Hz in 1). All of 
the benzene ring and the macrocyclic lactone ring substituents were confirmed by HMBC 
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correlations (Figure 82). These data established the structure of 2, being the cis analogue 
of 1, and the trivial name greensporone B was ascribed. 
 
Table 30. 1H NMR Data (500 MHz) for 1-4 in CDCl3 (Chemical Shifts in δ, 
Coupling Constants in Hz) 
 
position 1 2 3 4 
1 1.33, d (6.3) 1.30, d (6.3) 1.33, d (6.3) 1.36, d (6.3) 
2 5.16, m 5.12, m 5.23, m 5.18, m 
3 1.73, m 1.7, m 1.61, m 1.76, m 
 1.97, m 1.89, m 2.14, m 2.01, m 
4 2.42, dt 
(19.5, 6.3) 
2.32, m 2.30, m 2.43, m 
 2.57, m 2.56, m 2.62, m 2.67, m 
6 2.47, m 2.36, m 2.25, m 2.47, m 
 2.54, m 2.62, m 2.50, m 2.53, m 
7 2.48, m 2.51, m 1.71, m 2.47, m 
 2.54, m 3.85, m  2.56, m 
8 6.88, ddd 
(16.0, 6.3, 2.9) 
6.06, ddd 
(16.6, 11.5, 5.2) 
1.51, m 6.79, m 
   1.76, m  
9 6.06, d (16.0) 6.29, dd 
(11.5, 1.7) 
2.41, ddd 
(16.0, 8.6, 2.9) 
6.04, d (16.0) 
   2.61, m  
11 3.84, d (16.0) 4.01, d (18.3) 3.90, d (18.3) 3.33, d (14.3) 
 4.19, d (16.0) 4.11, d (18.3) 4.02, d (18.3) 4.31, d (14.3) 
13    6.44, d (2.3) 
15 6.58, s 6.58, s 6.56, s 6.31, d (2.3) 
19 3.78, s 3.77, s 3.77, s 3.74, s 
14-OH 6.02, br s 5.77, s 5.73, s 6.33, br s 
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Figure 82. Key HMBC and COSY correlations of 2-14. 
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Compound 3 (1.15 mg), which was obtained as a colorless  solid, had a molecular 
formula of    C19H23O6Cl as evidenced by HRESIMS and analysis of 1H NMR, 13C NMR 
and edited-HSQC data (Tables 30 and 32; Figure 89, Supporting Information). The 
HRMS and NMR data indicated 3 as a dihydro analogue of 1 as evidenced via a 2 amu 
difference in the HRMS data and by replacement of the H-8 and H-9 olefinic protons in 1 
by four aliphatic protons (δH 1.51/1.76 and 2.41/2.61 for H2-8 and H2-9, respectively). 
Lack of conjugation of the C-8/C-9 double bond with the ketone carbonyl in 3 resulted in 
a downfield shift of C-10 in 3 (δC 206.3) relative to 1 (δC 194.4). Further analyses of 
NMR data, including 1H-1H COSY and HMBC experiments (Figure 82) yielded the 
structure of 3, which was ascribed the trivial name greensporone C. 
Compound 4 (2.06 mg) was obtained as a colorless solid with a molecular formula 
of    C19H22O6 as evidenced by HRESIMS and analysis of 1H NMR, 13C NMR and 
edited-HSQC data (Tables 30 and 32; Figure 90, Supporting Information). The HRMS 
and NMR data indicated 4 as a dechlorinated analogue of 1, as evidenced by both the 
absence of the characteristic isotopic pattern of the chlorine in the HRMS data of 4, and 
the appearance of an extra aromatic proton (δH 6.44) in the 1H NMR spectrum of 4 that 
based on coupling constant (JH-13/H-15 = 2.3 Hz) was meta coupled to H-15 (δH 6.31). 
Analyses of NMR spectra, including 1H-1H COSY and HMBC data (Figure 82), yielded 
the structure of 4, which was ascribed the trivial name greensporone D. 
Compound 5 (22.66 mg) was also obtained as a colorless solid. The molecular 
formula was determined as C19H24O5 via HRESIMS, establishing an index of hydrogen 
deficiency of 8. The NMR data suggested structural similarity with 4. However, a key 
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difference was replacement of the C-5 ketone carbonyl in 4  (δC 209.9) by a methylene 
moiety (δC/δH/δH 25.6/1.31/1.39), which resulted in an extended 1H-1H COSY spin 
system in 5 that spanned from H3-1 to H-9. Further analyses of the NMR spectra, 
including HMBC data (Tables 31 and 32, Figure 82; Figure 91, Supporting Information) 
suggested the structure of 5, which was given the trivial name greensporone E. 
Compound 6 (1.81 mg), which was also obtained as a colorless solid, had a 
molecular formula of C18H22O5 as determined by HRESIMS. The NMR data suggested 
structural similarity with 5 (Tables 31 and 32; Figure 92, Supporting Information). 
However, a key difference was replacement of the CH3-19 (δC/δH 56.0/3.74) in 5 by a 
chelated phenolic proton (δH 11.76) in 6, as supported by a 14 amu difference in the 
HRMS data. Analyses of the NMR spectra, including 1H-1H COSY and HMBC data 
(Figure 82), established the structure of 6, which was given the trivial name greensporone 
F. 
Compound 7 (21.81 mg), which was isolated as a white solid, was identified as a 
dihydro derivative of 5, as suggested by a 2 amu difference in the HRMS data. NMR data 
indicated replacement of the H-8 and H-9 olefinic protons in 5 by four aliphatic protons 
(δH 1.54/1.64 and 2.32/2.56 for H2-8 and H2-9, respectively) (Tables 31 and 32; Figure 
93, Supporting Information). A downfield shift of C-10 in 7 (δC 211.1), relative to that of 
5 (δC 199.5), was indicative of the lack of an α,β-unsaturated ketone carbonyl in 7. These 
data, along with other NMR spectra, including 1H-1H COSY and HMBC data (Figure 
82), identified the structure of 7, which was ascribed the trivial name greensporone G. 
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Table 31. 1H NMR Data (500 MHz) for 5-8 in CDCl3 (Chemical Shifts in δ, 
Coupling Constants in Hz) 
 
position 5 6 7 8 
1 1.32, d (6.3) 1.28, d (6.3) 1.30, d (6.3) 1.34, d (6.3) 
2 5.15, m 5.13, m 5.23, m 5.08, m 
3 1.58, m 1.50, m 1.60, m 1.74, m 
 1.68, m 1.66, m  1.82, m 
4 1.24, m 1.38, m 1.33a, m 1.25, m 
 1.51, m 1.50, m  1.75, m 
5 1.31, m 1.45, m 1.21, m 3.55, m 
 1.39, m  1.36, m  
6 1.56, m 1.68, m 1.34a, m 1.61, m 
    1.83, m 
7 2.23, m 2.25, m 1.25, m 2.25, m 
  2.35, m   
8 6.85, dt 
(16.0, 7.5) 
7.06, dt 
(16.0, 7.5) 
1.54, m 
1.64, m 
6.78, ddd 
(15.5, 9.2, 6.9) 
9 6.10, d (16.0) 6.17, d (16.0) 2.32, m 6.08, d (15.5) 
   2.56, m  
11 3.44, d (14.9) 3.92, d (17.2) 3.48, d (17.8) 3.85, d (17.2) 
 4.34, d (14.9) 4.39, d (17.2) 4.29, d (17.8) 4.21, d (17.2) 
13 6.47, d (2.3) 6.15, d (2.3) 6.17, d (2.3)  
15 6.31, d (2.3) 6.32, d (2.3) 6.19, d (2.3) 6.59, s 
19 3.74, s  3.71, s 3.80, s 
14-OH 7.89, br s 6.16, s 7.25, br s 5.86, s 
16-OH  11.76, s   
aSignals may be interchanged 
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Table 32. 13C NMR Data (125 MHz) for 1-7 in CDCl3 (Chemical Shifts in 
δ) 
 
position 1 2 3 4 5 6 7 
1 20.3 19.8 20.3 20.5 20.6 20.3 20.5 
2 71.8 71.6 71.4 71.2 71.3 73.9 70.9 
3 28.5 28.5 28.7 28.5 34.9 34.6 34.9 
4 39.8 34.1 35.6 39.4 23.3 23.8 26.3b 
5 210.0 210.4 211.3 209.9 25.6 28.3 22.4 
6 40.8 43.0 42.8 40.5 25.8 25.8 25.5a 
7 29.0 24.8 22.9 28.6 30.9 33.1 25.4 
8 146.4 147.2 23.2 147.1 150.5 150.3 23.3 
9 129.9 127.1 41.3 130.7 129.9 129.7 41.8 
10 194.7 196.8 206.3 198.0 199.6 198.1 211.1 
11 42.7 45.9 44.7 43.7 44.1 47.2 46.3 
12 132.1 131.6 131.8 135.0 135.0 139.0 133.8 
13 113.6 113.0 112.8 109.6 109.5 113.3 110.3 
14 153.7 153.3 153.2 158.4 159.1 160.8 158.6 
15 99.1 99.1 98.9 98.5 98.7 103.1 98.6 
16 157.0 156.6 156.7 159.5 159.6 165.6 159.0 
17 117.9 118.4 118.8 116.1 115.8 106.1 116.1 
18 167.2 167.0 167.4 168.1 168.5 170.8 168.7 
19 56.2 56.2 56.2 56.0 56.0 --- 55.7 
aSignals may be interchanged 
 
Compound 8 (2.40 mg) was obtained as a colorless solid with a molecular formula 
of C19H23O6Cl as determined via HRESIMS and analysis of 1H NMR, 13C NMR and 
edited-HSQC data (Tables 31 and 35; Figure 94, Supporting Information). The NMR data 
suggested structural similarity with 1. However, a key difference was replacement of the 
C-5 ketone carbonyl (δC 210.0) in 1 by a carbinol carbon in 8 as evidenced from the 
NMR chemical shift values (δH/δC 69.1/3.55) and a 2 amu difference in the HRMS data. 
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Further analyses of NMR spectra, including the extended 1H-1H COSY spin system from 
H3-1 to H-9 and HMBC data (Figure 82), established the structure of 8, to which the 
trivial name greensporone H was ascribed. 
 
Table 33. 1H NMR Data (500 MHz) for 9-11 (Chemical Shifts in δ, 
Coupling Constants in Hz) 
 
position 9a 10b 11a 
1 1.30, d (6.3) 1.21, d (5.7) 1.33, d (6.3) 
2 5.13, m 4.91, m 5.24, m 
3 1.75, m 1.51, m 1.69, m 
  1.76, m  
4 1.11, m 1.06, m 1.24, m 
 1.66, m 1.52, m 1.61, m 
5 3.48, m 3.35, m 3.70, m 
6 1.61, m 1.41, m 1.47, m 
 1.77, m 1.68, m 1.56, m 
7 2.12, m 2.15, m 1.37, m 
 3.48, m   
8 6.08, ddd 
(16.0, 11.5, 4.6) 
6.64, ddd 
(16.0, 8.0, 7.5) 
1.53, m 
1.75, m 
9 6.30, dd 
(11.5, 1.7) 
5.95, d (16.0) 2.29, ddd 
(13.8, 9.7, 3.4) 
   2.66, ddd 
(13.8, 8.6, 2.9) 
11 4.03, d (18.3) 3.36, d (16.0) 3.88, d (18.3) 
 4.16, d (18.3) 4.03, d (16.0) 4.25, d (18.3) 
13  6.25, d (2.3)  
15 6.58, s 6.35, d (2.3) 6.56, s 
19 3.77, s 3.68, s 3.77, s 
5-OH 1.2 br. s 4.48, br. s 3.76 
14-OH 5.80, s 9.99, br. s 5.87, s 
aIn CDCl3 
bIn DMSO 
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Compound 9 (1.16 mg) was also isolated as a colorless solid. The molecular formula 
was determined as C19H23O6Cl via HRESIMS, same as that of greensporone H (8). 
Analyses of the HRMS and NMR data suggested 9 as a geometric isomer of 8, in 
reference to the C-8/C-9 double bond, having a Z-configuration in 9 versus an E-
configuration in 8, supported by the coupling constants of the olefinic protons (JH-8/H-9 = 
11.5 Hz in 9 vs. 15.5 Hz in 8) (Tables 33 and 35; Figure 95, Supporting Information). All 
other substituents, including the benzene ring and the macrocyclic lactone ring 
substituents, were confirmed by analyses of the 1H-1H COSY and HMBC data (Figure 
82), establishing the structure of 9, to which the trivial name greensporone I was 
ascribed. 
Compound 10 (13.21 mg) was obtained as a white solid. HRESIMS and analysis of 
1H NMR, 13C NMR and edited-HSQC data suggested a molecular formula of C19H24O6 
(Tables 33 and 35; Figure 96, Supporting Information). The HRMS and NMR data 
designated 10 as a dechlorinated analogue of 8, as evidenced by a 34 amu difference in 
the HRMS data and absence of the characteristic isotopic pattern of the chlorine. 1H 
NMR data of 10 relative to 8 indicated an extra aromatic proton (δH 6.25, J = 2.3 Hz), 
which was meta coupled to H-15 (δH 6.35, J = 2.3 Hz). Further analyses of the NMR 
spectra including 1H-1H COSY and HMBC data (Figure 82), suggested the structure of 
10, which was ascribed the trivial name greensporone J. 
Compound 11 (4.0 mg), which was isolated as a white solid, was identified as a 
dihydro derivative of 8 as evidenced by a 2 amu difference in the HRMS data. NMR data 
indicated replacement of the H-8 and H-9 olefinic protons in 8 by four aliphatic protons 
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(δH 1.53/1.75 and 2.29/2.66 for H2-8 and H2-9, respectively). A downfield shift of C-10 
in 11 (δC 205.9) relative to that of 8 (δC 195.1) was indicative of the lack of conjugation 
of the C-8/C-9 double bond with the ketone carbonyl. These data along with other NMR 
data including 1H-1H COSY and HMBC experiments (Figure 82) identified the structure 
of 11, which was ascribed the trivial name greensporone K. 
Compound 8 underwent chemical changes in CDCl3 solution resulted in the 
formation of   compound 12, which was obtained as a colorless solid. The molecular 
formula was determined as C19H23O6Cl via HRESIMS along with 1H, 13C, and edited-
HSQC data (Tables 34 and 35; Figure 98, Supporting Information), establishing an index 
of hydrogen deficiency of 9. Analyses of the HRMS and NMR data suggested 2 as a 
RAL with structural similarity with 8, sharing the same molecular formula. Key 
differences were the lack of the α,β-conjugated double bond in 12, as evidenced by a 
downfield shift of the ketone carbonyl (δC 203.9) relative to 8 (δC 195.1), and the 
replacement of the C-8 and C-9 olefinic protons in 8 by three aliphatic protons in 12 
(δC/δH 76.3/4.32 and 46.6/2.53/2.81 for CH-8 and CH2-9, respectively), suggesting 
oxygenation of C-8 in 12. Another key difference was the downfield shift of C-5/H-5 in 
12 (δC/δH 79.3/3.79) relative to 8 (δC/δH 69.1/3.55). Key HMBC correlations included 
H2-6 to C-4 and C-8; H2-7 to C-5, H2-9 to C-7 and C-10; and H-8 to C-5 and C-10 
(Figure 82). 1H-1H COSY identified one extended spin system H3-1/H-2/H2-3/H2-4/H-
5/H2-6/H2-7/H-8/H2-9 (Figure 82). These data suggested a C-5 to C-8 tetrahydrofuran 
ring in 12 relative to 8. The observed NOESY correlations between H-5/H-8 and H-2/H-5 
indicated a cis-THF ring, thereby establishing the relative configuration at C-5 and C-8 
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(Figure 83). These data established the structure of 12, to which the trivial name 
greensporone L was ascribed. We believe that 12 was produced by intramolecular 
cycloetherification of the ε-hydroxy-α,β-unsaturated ketone moiety in 8 (Figure 103, 
Supporting Information). 
 
Table 34. 1H NMR Data (500 MHz) for 12-14 (Chemical Shifts 
in δ, Coupling Constants in Hz) 
 
position 12 13 14 
1 1.32, d (6.2) 1.32, d (6.3) 1.32, d (6.9) 
2 5.21, m 5.26, m 5.41, m 
3 1.72, m 1.83, m 1.62, m 
 1.90, m  2.33, m 
4 1.38, m 1.51, m 1.48, m 
 1.79, m 1.96, m 1.92, m 
5 3.79, m 3.81, m 3.99, tdd 
(10.3, 4.6, 2.3) 
6 1.55, m 1.50, m 1.30, m 
 2.02, m  1.89, m 
7 1.75, m 1.65, m 1.57, m 
 1.91, m 1.94, m 2.10, m 
8 4.33, m 4.14, m 4.27, qd 
(8.6, 2.9) 
9 2.53, dd 
(13.5, 6.9) 
2.55, dd 
(13.2, 8.0) 
2.27, m 
 2.81, dd 
(13.5, 4.6) 
2.62, dd 
(13.2, 3.4) 
2.49, dd 
(12.0, 8.6) 
11 3.99, d (18.5) 3.90, d (17.2) 3.55, d (16.0) 
 4.13, d (18.5) 3.99, d (17.2) 4.21, d (16.0) 
13  6.25, d (2.3) 6.10, d (2.3) 
15 6.59, s 6.34, d (2.3) 6.34, d (2.3) 
19 3.77, s 3.77, s 3.78, s 
14-OH 5.70, s 5.62, br. s 6.07, br. s 
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Figure 83. Key NOESY correlations of 12-14. 
Compound 13 (1.42 mg) was obtained as a white solid. HRESIMS and analysis of 
1H NMR, 13C NMR and edited-HSQC data suggested a molecular formula of C19H24O6 
(Tables 34 and 35; Figure 99, Supporting Information). The HRMS and NMR data 
suggested 13 as a dechlorinated analogue of 12, as evidenced by a 34 amu difference in 
the HRMS data of 13 and absence of the characteristic isotopic pattern of the chlorine 
atom. 1H NMR data of 13 relative to 12 indicated an extra aromatic proton (δH 6.25) that 
was meta coupled to H-15 (δH 6.34) (JH-13/H-15 = 2.3 Hz). Further analyses of NMR data, 
including 1H-1H COSY and HMBC data (Figure 82), suggested the structure of 13, which 
was ascribed the trivial name greensporone M. Similar to 12, NOESY correlations 
between H-5 and H-8 supported a cis-THF ring (Figure 83). As for 12, compound 13 was 
likely an artifact produced by intramolecular cycloetherification of the ε-hydroxy-α,β-
unsaturated ketone moiety in 10 during the extraction and purification processes. To test 
this hypothesis, an aliquot of 10 was suspended (not soluble) in CDCl3 and a proton 
NMR spectrum was collected, a poor signal was obtained due to the insolubility issue. 
The NMR tube was left to stand at room temperature for few days, then another proton 
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NMR spectrum was collected. The NMR spectrum showed signals of good intensity that 
matched those of 13 (Figure 100, Supporting Information). 
 
Table 35. 13C NMR Data ( 175 MHz)  for 12 and (125 MHz) for 8-11 and 
13-14 in CDCl3 (Chemical Shifts in δ) 
 
position 8 9 10a 11 12 13 14 
1 20.1 19.9 20.1 20.3 21.5 20.9 18.3 
2 71.3 71.0 69.3 70.8 73.4 72.7 72.3 
3 31.0 31.0 30.2 30.7 33.8 33.0 30.1 
4 29.4 29.1 29.2 29.8 34.7 31.3 30.0 
5 69.1 69.0 66.1 68.7 79.3 79.5 77.2 
6 35.0 36.7 34.6 36.1 31.6 33.5 33.5 
7 28.8 24.3 28.2 23.2 29.8 30.5 32.2 
8 147.7 148.3 148.2 23.7 76.3 76.1 76.5 
9 128.1 127.1 128.4 41.7 46.6 47.9 47.2 
10 195.1 196.7 195.9 205.9 203.9 207.7 210.1 
11 44.2 45.7 44.6 44.3 48.6 49.0 48.6 
12 132.6 131.7 135.6 131.8 132.1 134.2 134.3 
13 113.4 112.9 109.7 113.4 113.1 109.2 108.1 
14 153.7 153.2 159.8 153.4 153.3 157.7 158.0 
15 99.2 100.0 98.5 99.0 99.1 98.3 98.3 
16 157.6 156.6 159.2 157.0 157.0 159.0 158.8 
17 118.2 118.5 114.1 118.2 119.2 117.3 118.0 
18 167.1 167.6 167.3 167.7 166.9 167.7 167.8 
19 56.3 56.1 55.9 56.1 56.4 56.0 56.0 
aIn DMSO 
 
Compound 14 (1.80 mg) was obtained as a white solid. HRESIMS and analysis of 
1H NMR, 13C NMR and edited-HSQC data suggested a molecular formula of C19H24O6 
(Tables 34 and 35; Figure 101, Supporting Information). The HRMS and NMR data 
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suggested structural similarity to 13, both sharing the same molecular formula and the 
same planar structure, as evidenced from analyses of the 2D NMR data of 14, including 
1H-1H COSY and HMBC spectra (Figure 82). However, a key difference was the absence 
of the H-5 to H-8 NOESY correlations in 14 relative to 13. This observation was 
supported by NOESY correlations observed from H-8 to H-7b, H-7b to H-6a, and H-5 to 
H-6b, indicating that H-8, H-7b, and H-6a were on the same phase of the tetrahydrofuran 
ring (Figure 83). Hence, 14 and 13 differed in the spacial arrangement of the 
tetrahydrofuran ring, being cis in 13 versus trans in 14. The trivial name greensporone N 
was ascribed to compound 14. 
The absolute configuration of the stereogenic center in 7 was established as 2S by 
single-crystal X-ray diffraction analysis of the bromobenzoyl derivative (compound 15, 
Figure 84, Figure 102, Supporting Information). The configuration of the C-2 asymmetric 
carbon in compounds 1-6 and 8-14 was proposed to be analogous to that of 7; as 
described below, this supposition was supported by Mosher’s esters in compounds 8-11. 
The known greensporone A (1) [cryptosporiopsin A] was reported to have a 2R 
configuration176 by analogy to ponchonin D;177 however, no direct measurements were 
made to confirm this. The RAL analogues identified in this study were structurally 
related to the well-known RAL monorden (synonym radicicol)178,179 and its analogues 
pochonins A-F177 and K-P.180 For monorden, single crystal X-ray diffraction via analysis 
of the anomalous scattering established the configuration of the CH3 (C-2) as R.179 
However, optical rotation data comparison with monorden177 and 1H–1H coupling 
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constants and NOESY data analysis was used to assign the relative stereochemistry of 
pochonins.180 
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Figure 84. X-ray crystallographic structure of 14-(4-bromobenzoyl)greensporone G 
(15). 
 
For compounds 8-11, NOESY correlations were observed from H-2 to H-5, 
indicating that those pair of protons was on the same face of the macrocycle ring. The 
absolute configurations of 8-11 were assigned via a modified Mosher’s ester method,68 
establishing the configurations as 2S and 5S (Figure 85). It is worth pointing out that due 
to the instability of compound 8 in solution, i.e. tendency to undergoe intramolecular 
cycloetherification of the ε-hydroxy-α,β-unsaturated ketone moiety, the 1H-NMR peaks 
corresponding to the (S)- and (R)-MTPA esters of 8 were of low intensity and we were 
unable to recognize the chemical shifts of other than H-2 and H-9. 
Compounds (1-14) were evaluated as TAK1-TAB1 inhibitors using 5Z-7-
oxozeaenol19 as a positive control and as antimicrobials against a panel of bacteria and 
fungi and were found inactive. Although inactive as TAK1-TAB1 inhibitors, the data 
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obtained extended our understanding of the structure activity relationship of the RAL 
family of compounds. 
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Figure 85. ΔδH values [Δδ (in ppm) = δS − δR] obtained for (S)- and (R)-MTPA esters A) 
8a and 8b, respectively of greensporone H (8),  B)  9a and 9b, respectively of 
greensporone I (9), C)  10a and 10b, respectively of greensporone J (10), and D)  11a and 
11b, respectively of greensporone K (11) in pyridine-d5. 
 
In conclusion, fourteen new RALs (1-14) were isolated and characterized from the 
freshwater fungus Halenospora sp. The absolute configuration of compound 7 was 
assigned using X-ray crystallography of an analogue that incorporated a heavy atom. 
NOE data were used to assign the relative configuration of compounds (12-14). While for 
compounds 8-11, a modified Mosher’s ester method was used. The current study proved 
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the importance of the freshwater fungi, a highly underexplored natural resource, as a rich 
source of new scaffolds for drug design and development.  
Experimental Section 
General Experimental Procedures. UV data were obtained using a Varian Cary 
100 Bio UV-Vis spectrophotometer (Varian Inc., Walnut Creek, CA, USA). NMR data 
were collected using either a JEOL ECA-500 NMR spectrometer operating at 500 MHz 
for 1H and 125 MHz for 13C, (JEOL Ltd., Tokyo, Japan), or an Agilent 700 MHz NMR 
spectrometer (Agilent Technologies, Inc., Santa Clara, CA, USA), equipped with a 
cryoprobe, operating at 700 MHz for 1H and 175 MHz for 13C. Residual solvent signals 
were utilized for referencing. High resolution mass spectra (HRMS) were measured using 
a Thermo LTQ Orbitrap XL mass spectrometer equipped with an electrospray ionization 
source (Thermo Fisher Scientific, San Jose, CA, USA). A Waters Acquity UPLC system 
(Waters Corp., Milford, MA, USA) utilizing a Phenomenex Kinetex C18 column (1.3 µm; 
50 × 2.1 mm) was used to evaluate the purity of the isolated compounds with data 
collected and analyzed using Empower 3 software. Phenomenex Gemini-NX C18 
analytical (5 µm; 250 × 4.6 mm), preparative (5 µm; 250 × 21.2 mm), and 
semipreparative (5 µm; 250 × 10.0 mm) columns (all from Phenomenex, Torrance, CA, 
USA) were used on a Varian Prostar HPLC system equipped with ProStar 210 pumps and 
a Prostar 335 photodiode array detector (PDA), with data collected and analyzed using 
Galaxie Chromatography Workstation software (version 1.9.3.2, Varian Inc.). Flash 
chromatography was performed on a Teledyne ISCO CombiFlash Rf 200 using Silica 
Gold columns (both from Teledyne Isco, Lincoln, NE, USA) and monitored by UV and 
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evaporative light-scattering detectors. X-ray crystallography data were acquired using a 
Bruker APEX CCD diffractometer (MoKα radiation, graphite monochromator). All other 
reagents and solvents were obtained from Fisher Scientific and were used without further 
purification.  
Fungal Strain Isolation and Identification. The fungal strain, G87, was isolated 
from a sample of submerged wood collected in July of 2011 from a freshwater stream at 
the campus of the University of North Carolina in Greensboro, North Carolina, USA 
(36˚4' 16''N, 79˚48' 28''W). A culture of strain G87 is preserved in the Department of 
Chemistry and Biochemistry culture collection at the University of North Carolina at 
Greensboro. The culture is stored on a potato dextrose agar slant with periodic transfer. 
Previously outlined collection methods and culturing conditions were followed.161,162 
Molecular identification of strain G87 was carried out by sequencing the internal 
transcribed spacer regions 1 & 2 and 5.8S nrDNA (ITS)45 along with the D1 and D2 
regions of the 28S nuclear ribosomal large subunit rRNA gene (LSU).95,181 DNA 
extraction, PCR amplification, and sequencing were performed according to previously 
published procedures.63,81,97-99 A BLAST search in GenBank using the complete ITS 
rDNA sequence showed 98% sequence similarity of the strain G87 with several members 
of the Leotiomycetes, Ascomycota. In particular, strain G87 showed sequence homology 
with a number of sequences belonging to Halenospora varia (Anastasiou) E.B.G. 
Jones182 (GenBank KF156329; Identities = 474/483 (98%); Gaps = 0/483 (0%), 
Halenospora varia; GenBank AJ608987; Identities = 524/534 (98%); Gaps = 1/534 
(0%), Zalerion varium (=Halenospora varia). Zalerion varium was originally placed in 
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the genus Zalerion (Lulworthiales, Ascomycota). However, based on ITS data, Bills and 
colleagues183 found that Z. varium had phylogenetic affinities to the Leotiaceae, while the 
type species Z. maritima belonged to the Lulworthiales. Jones and colleagues182 
subsequently transferred Z. varium to a new genus Halenospora varia, Leotiomycetes, 
Ascomycota. Fungal strain G87 also showed 97-98% sequence similarity in ITS data to 
several other genera of aquatic fungi such as Spirosphaera, Tricladium, Lambertella, 
Mycofalcella. To better understand the phylogenetic affinities of G87 to these taxa in the 
Leotiomycetes, a phylogenetic analysis using Maximum Likelihood was employed using 
combined ITS-LSU data for strain G87, along with sequences downloaded from top hits 
in the BLAST search using RAxML v. 7.0.4184 run on the CIPRES Portal v. 2.0185 with 
the default rapid hill-climbing algorithm and GTR model employing 1000 fast bootstrap 
searches. Clades with bootstrap values ≥ 70% were considered significant and strongly 
supported.186 Results of both BLAST and phylogenetic analysis suggested strain G87 to 
show affinities with H. varia, which resides in Clade 7 sensu Baschien and coworkers.187 
However, there was no significant support for G87 clustering with isolates of H. varia 
(Figure 104, Supporting Information). Based on these data, G87 is identified putatively as 
Halenospora aff. varia, Helotiales, Leotiomycetes, Ascomycota. The combined ITS and 
LSU sequence will be deposited in the GenBank (accession no XXX). 
Fermentation, Extraction and Isolation. A fresh culture of strain G87 was 
prepared in a slant and was inoculated into a 50 mL culture tube containing a seed liquid 
culture consisting of 2% MEA, potato dextrose agar (PDA, Difco), and YESD media. 
The culture tube was shaken at room temperature using a rotary shaker at 125 rpm until 
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the fungal strain showed good growth typically within 14 to 21 days. Afterwards, the seed 
culture was used to inoculate a 250 mL Erlenmeyer flask containing 30 mL of autoclaved 
rice medium, prepared using 10 g of rice and twice the volume of rice with H2O. 
Fermentation was carried out by incubating the flask at 22 °C until showing good growth 
(approximately 14 days). Large scale cultures were prepared by the parallel processing of 
four such cultures in quadruplicates.  
To each of the four small-scale solid fermentation cultures that constitute a large-
scale culture of G87, 60 mL of 1:1 MeOH-CHCl3 were added. The cultures were broken 
down into small pieces with a spatula and shaken using a rotary shaker overnight (~16 h) 
at ∼125 rpm at room temperature. The samples were filtered with vacuum, and the 
remaining residues were washed with small volumes of 1:1 MeOH-CHCl3. To the 
combined filtrates, 360 mL CHCl3 and 360 mL H2O were added; the mixture was stirred 
for 30 min and then transferred into a separatory funnel. The organic layer was 
evaporated to dryness under reduced pressure. The obtained organic extract was 
partitioned between 100 mL of 1:1 MeOH-CH3CN and 100 mL of hexanes. The MeOH-
CH3CN layer was evaporated to dryness in vacuum. The defatted extract (~439 mg) was 
dissolved in a mixture of CHCl3-MeOH, adsorbed onto Celite 545, and fractionated via 
flash chromatography using a gradient solvent system of hexane-CHCl3-MeOH at a 30 
mL/min flow rate and 61.0 column volumes over 34.1 min to afford five fractions. 
Fraction 3 (153.25 mg) was subjected to preparative HPLC using a gradient system of 
40:60 to 60:40 of CH3CN-H2O (acidified with 0.1% formic acid) over 30 min at a flow 
rate of 21.24 mL/min to yield fifteen sub-fractions. Sub-fractions 4, 5, 7, 10, 12, and 13 
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yielded compounds 1 (19.65 mg), 2 (1.95 mg), 3 (1.28 mg), 5 (27.73 mg), 6 (2.95 mg), 
and 7 (30.24 mg), which eluted at ~9.8, 11.5, 13.5, 20.5, 22.7, and 23.5 min, respectively. 
Fraction 4 (99.72 mg) was subjected to preparative HPLC using a gradient system of 
20:80 to 40:60 of CH3CN-H2O (acidified with 0.1% formic acid) over 40 min to 60:40 
over 10 min at a flow rate of 21.24 mL/min to yield nineteen sub-fractions. Sub-fractions 
3, 9, 11, 12 and 16 yielded compounds 10 (18.74 mg), 8 (5.17 mg), 11 (6.35 mg), 13 
(1.42 mg) and 14 (1.80 mg), which eluted at 19.0, 25.0, 57.5, 28.5 and 37.3 min, 
respectively. Subfraction 10 (6.65 mg), which eluted at 26.0 min was subjected to further 
preparative HPLC purification using a gradient system of 50:50 to 60:40 of MeOH-H2O 
(acidified with 0.1% formic acid) over 15 min at a flow rate of 21.24 mL/min to yield 
compounds 4 (2.06 mg) and 9 (1.16 mg), which eluted at ~8.3 and 9.7 min, respectively. 
The isolated compounds, except for compounds 4, 9, and 12, were further purified 
by preparative and semipreparative HPLC to generate material of high purity for 
biological evaluation using a mobile phase of MeOH-H2O (acidified with 0.1% formic 
acid) at different gradient systems to yield compounds 1 (13.93 mg), 2 (1.04 mg), 3 (1.15 
mg), 5 (22.66 mg), 6 (1.81 mg), 7 (21.81 mg), 8 (2.40 mg), 10 (13.21 mg), 11 (4.0 mg), 
13 (2.55 mg), and 14 (2.78 mg). 
Greensporone A (1): colorless solid; [𝛼]D20 = +5.0° (𝑐 = 0.20, MeOH); [𝛼]D20 =
−24.6° (𝑐 = 0.26, Chloroform); UV (MeOH) λmax (log ε) 293 (3.32), 233 (3.70) nm; 1H 
NMR (CDCl3, 500 MHz) and 13C NMR (CDCl3, 125 MHz), see Tables 79 and 81; 
HRESIMS m/z 381.1090 [M + H]+ (calcd for C19H22O635Cl 381.1099) and 383.1061 [M 
+ H]+ (calcd for C19H22O637Cl 383.1070). 
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Greensporone B (2): colorless solid; [𝛼]D20 = −37.5° (𝑐 = 0.10, MeOH); UV 
(MeOH) λmax (log ε) 292 (3.12), 225 (3.64) nm; 1H NMR (CDCl3, 500 MHz) and 13C 
NMR (CDCl3, 125 MHz), see Tables 30 and 32; HRESIMS m/z 381.1110 [M + H]+ 
(calcd for C19H22O635Cl 381.1099) and 383.1059 [M + H]+ (calcd for C19H22O637Cl 
383.1070). 
Greensporone C (3): colorless solid; [𝛼]D20 = +30.4° (𝑐 = 0.12, MeOH); UV 
(MeOH) λmax (log ε) 292 (3.25), 221 (3.62) nm; 1H NMR (CDCl3, 500 MHz) and 13C 
NMR (CDCl3, 125 MHz), see Tables 30 and 32; HRESIMS m/z 383.1267 [M + H]+ 
(calcd for C19H24O635Cl 383.1256) and 385.12170 [M + H]+ (calcd for C19H24O637Cl 
385.1226). 
Greensporone D (4): colorless solid; [𝛼]D20 = +55.7° (𝑐 = 0.10, MeOH); UV 
(MeOH) λmax (log ε) 287 (3.28), 234 (3.64) nm; 1H NMR (CDCl3, 500 MHz) and 13C 
NMR (CDCl3, 125 MHz), see Tables 30 and 32; HRESIMS m/z 347.1481 [M + H]+ 
(calcd for C19H23O6 347.1489). 
Greensporone E (5): colorless solid; [𝛼]D20 = +112.3° (𝑐 = 0.33, MeOH); UV 
(MeOH) λmax (log ε) 288 (3.32), 238 (3.65)  nm; 1H NMR (CDCl3, 500 MHz) and 13C 
NMR (CDCl3, 125 MHz), see Tables 31 and 32; HRESIMS m/z 333.1711 [M + H]+ 
(calcd for C19H25O5 333.1697). 
Greensporone F (6): colorless solid; [𝛼]D20 = +29.8° (𝑐 = 0.09, MeOH); UV 
(MeOH) λmax (log ε) 302 (3.52), 263 (3.63), 237 (3.63) nm; 1H NMR (CDCl3, 500 MHz) 
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and 13C NMR (CDCl3, 125 MHz), see Tables 31 and 32; HRESIMS m/z 319.1553 [M + 
H]+ (calcd for C18H23O5 319.1540). 
Greensporone G (7): white solid; [𝛼]D20 = +79.5° (𝑐 = 0.29, MeOH); UV (MeOH) 
λmax (log ε) 286 (3.34), 252 (3.48), 224 (3.60) nm; 1H NMR (CDCl3, 500 MHz) and 13C 
NMR (CDCl3, 125 MHz), see Tables 31 and 32; HRESIMS m/z 335.1868 [M + H]+ 
(calcd for C19H27O5 335.1853). 
Greensporone H (8): colorless solid; [𝛼]D20 = −18.3° (𝑐 = 0.12, MeOH); UV 
(MeOH) λmax (log ε) 292 (3.34), 227 (3.61) nm; 1H NMR (CDCl3, 500 MHz) and 13C 
NMR (CDCl3, 125 MHz), see Tables 31 and 35; HRESIMS m/z 383.1273 [M + H]+ 
(calcd for C19H24O635Cl 383.1256) and 385.12195 [M + H]+ (calcd for C19H24O637Cl 
383.1256). 
Greensporone I (9): colorless solid; [𝛼]D20 = −31.9° (𝑐 = 0.12, MeOH); UV 
(MeOH) λmax (log ε) 292 (3.24), 230 (3.67) nm; 1H NMR (CDCl3, 500 MHz) and 13C 
NMR (CDCl3, 125 MHz), see Tables 33 and 35; HRESIMS m/z 383.1245 [M + H]+ 
(calcd for C19H24O635Cl 383.1256) and 385.1220 [M + H]+ (calcd for C19H24O637Cl 
385.1226). 
Greensporone J (10): white solid; [𝛼]D20 = +116.5° (𝑐 = 0.27, MeOH); UV 
(MeOH) λmax (log ε) 288 (3.33), 236 (3.64) nm; 1H NMR (DMSO, 500 MHz) and 13C 
NMR (DMSO, 125 MHz), see Tables 33 and 35; HRESIMS m/z 349.1657 [M + H]+ 
(calcd for C19H25O6 349.1646). 
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Greensporone K (11): white solid; [𝛼]D20 = +26.0° (𝑐 = 0.20, MeOH); UV 
(MeOH) λmax (log ε) 292 (3.43), 226 (3.67) nm; 1H NMR (CDCl3, 500 MHz) and 13C 
NMR (CDCl3, 125 MHz), see Tables 33 and 35; HRESIMS m/z 385.1427 [M + H]+ 
(calcd for C19H26O635Cl 385.1412) and 387.1374 [M + H]+ (calcd for C19H26O637Cl 
387.1383). 
Greensporone L (12): colorless solid; [𝛼]D20 = +30.0° (𝑐 = 0.05, MeOH); UV 
(MeOH) λmax (log ε) 291 (3.34), 226 (3.60)nm; 1H NMR (CDCl3, 700 MHz) and 13C 
NMR (CDCl3, 175 MHz), see Tables 34 and 35; HRESIMS m/z 383.1268 [M + H]+ 
(calcd for C19H24O635Cl 383.1256) and 385.1239 [M + H]+ (calcd for C19H24O637Cl 
385.1226). 
Greensporone M (13): white solid; [𝛼]D20 = −30.7° (𝑐 = 0.11, MeOH); UV 
(MeOH) λmax (log ε) 286 (3.20), 248 (3.35), 224 (3.54) nm; 1H NMR (CDCl3, 500 MHz) 
and 13C NMR (CDCl3, 125 MHz), see Tables 34 and 35; HRESIMS m/z 349.1661 [M + 
H]+ (calcd for C19H25O6 349.1646). 
Greensporone N (14): white solid; [𝛼]D20 = +154.4° (𝑐 = 0.07, MeOH); UV 
(MeOH) λmax (log ε) 285 (3.17), 223 (3.55) nm; 1H NMR (CDCl3, 500 MHz) and 13C 
NMR (CDCl3, 125 MHz), see Tables 34 and 35; HRESIMS m/z 349.1661 [M + H]+ 
(calcd for C19H25O6 349.1646). 
14-(4-Bromobenzoyl)greensporone G (15): to a sample of compound 7 (7.7 mg, 1 
eq.) dissolved in 1 mL anhydrous THF, 4-bromobenzoyl chloride (6.1 mg, 1.2 eq.) and 
DMAP (2.8 mg, 1 eq.) were added and the mixture was stirred at room temperature under 
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nitrogen. To enhance the solubility of the reagents, 0.3 mL anhydrous CH2Cl2 was 
added. The mixture was left stirring overnight and monitored for completion using TLC. 
The reaction mixture (16.8 mg) was purified via a reversed phase preparative HPLC 
using a Phenomenex Gemini-NX C18 (5 µm; 250 × 21.2 mm) column and a gradient 
system of 70:30 to 90:10 of CH3CN-H2O (acidified with 0.1% formic acid) over 15 min 
at a flow rate of 21.24 mL/min to yield compound 15 (8.84 mg), which eluted at 17.3 
min. 1H NMR (CDCl3, 500 MHz) δ 8.02 (2H, d, J = 8.6), 7.65 (2H, d, J = 8.6), 6.74 (1H, 
d, J = 2.3), 6.67 (1H, d, J = 2.3), 5.27 (1H, m), 4.18 (1H, d, J = 17.8), 3.81 (3H, s), 3.61 
(1H, d, J = 17.8), 2.55 (1H, ddd, J = 13.2, 8.6, 4.6), 2.33 (1H, ddd, J = 13.2, 8.6, 4.6), 
1.71-1.51 (5H, m), 1.43-1.19 (7H, m), 1.34 (3H, d, J = 6.3) (Figure 102, Supporting 
Information). HRESIMS m/z 517.1205 [M + H]+ (calcd for C26H3079BrO6 517.1220) and 
519.1185 [M + H]+ (calcd for C26H3081BrO6 519.1200). 
Preparation of the (R)- and (S)-MTPA ester derivatives of greensporones H (8), 
I (9), J (10), and K (11): To 0.31, 0.20, 0.31, and 0.45 mg of compounds 8-11 were 
added 400 µL of pyridine-d5 and transferred into an NMR tubes. To initiate the reactions, 
20 μL of S-(+)-α-methoxy-α-(trifluoromethyl)phenylacetyl (MTPA) chloride were added 
into each NMR tube with careful shaking and then monitored immediately by 1H NMR at 
the following time points 5, 10, and 15 min. The reactions completed within 5 min, 
yielding the mono (R)-MTPA ester derivatives (8b) of 8, (9b) of 9, (10b) of 10, and 
(11b) of 11. 1H NMR data (500 MHz, pyridine-d5) of 8b: δH 6.13 (1H, m, H-2), 6.39 
(1H, d, J = 17.8 , H-9); of 9b: 1.24 (3H, d, J = 6.3, H3-1), 5.13 (1H, m, H-2), 5.27 (1H, 
m, H-5), 6.13 (1H, td, J = 12.0, 5.7, H-8), and 6.42 (1H, d, J = 12.0, H-9); 10b:  1.30 (3H, 
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d, J = 6.3, H3-1), 5.22 (1H, m, H-2), 5.30 (1H, m, H-5), 6.97 (1H, dd, J = 15.5, 7.5, H-8), 
and 6.33 (1H, d, J = 15.5, H-9); 11b: 1.28 (3H, d, J = 6.3, H3-1), 5.36 (1H, m, H-2), 5.41 
(1H, m, H-5), 2.37 (1H, m, H-9a), 2.79 (1H, m, H-9b), 4.19 (1H, d, J = 18.9, H-11a), and 
4.39 (1H, J = 18.9, H-11b). In an analogues manner, 0.31, 0.20, 0.31, and 0.45 mg of 
compounds 8-11 dissolved in 400 µL pyridine-d5 were reacted in NMR tubes with 20 µL 
(R)-(-)-a-MTPA chloride for 15 min, to afford the mono (S)-MTPA esters (8a, 9a, 10a, 
and 11a). 1H NMR data (500 MHz, pyridine-d5) of 8a: δH 6.17 (1H, m, H-2), 6.38 (1H, d, 
J = 17.8 , H-9); of 9a:  1.32 (3H, d, J = 6.3, H3-1), 5.15 (1H, m, H-2), 5.41 (1H, m, H-5), 
6.12 (1H, dd, J = 12.0, 4.0, H-8), and 6.41 (1H, d, J = 12.0, H-9); 10a: 1.36 (3H, d, J = 
6.3, H3-1), 5.25 (1H, m, H-2), 5.44 (1H, m, H-5), 6.96 (1H, dd, J = 15.5, 7.5, H-8), and 
6.29 (1H, d, J = 15.5, H-9); 11a: 1.33 (3H, d, J = 6.3, H3-1), 5.37 (1H, m, H-2), 5.52 (1H, 
m, H-5), 2.39 (1H, m, H-9a), 2.76 (1H, m, H-9b), 4.20 (1H, d, J = 18.9, H-11a), and 4.35 
(1H, J = 18.9, H-11b). 
X-ray Crystallography. Crystallographic data for compound 15 will be deposited 
with the Cambridge Crystallographic Data Centre, deposition number XXX. Compound’s 
15 crystals were grown in a mixture of ethyl acetate and hexane at room temperature. 
A clear colorless rectangular-parallelepiped-like specimen of C26H29BrO6, approximate 
dimensions 0.120 mm × 0.190 mm × 0.520 mm, was used for the X-ray crystallographic 
analysis. The X-ray intensity data were measured on a Bruker APEX CCD system 
equipped with a graphite monochromator and a Mo Kα sealed X-ray tube (λ = 0.71073 
Å). The total exposure time was 18.57 h. The frames were integrated with the Bruker 
SAINT software package using a narrow-frame algorithm. The integration of the data 
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using a monoclinic unit cell yielded a total of 23715 reflections to a maximum θ angle 
of 30.20° (0.71 Å resolution), of which 7231 were independent (average redundancy 
3.270, completeness = 99.4%, Rint = 3.10%) and 6524 (90.22%) were greater than 2σ(F2). 
The final cell constants of a = 22.9481(11) Å, b = 5.2631(3) Å, c = 21.5301(11) Å, β = 
108.6660(10)°, volume = 2463.6(2) Å3, are based upon the refinement of the XYZ-
centroids of 9887 reflections above 20 σ(I) with 7.114 < 2θ < 61.72°. Data were corrected 
for absorption effects using the multi-scan method (SADABS). The ratio of minimum to 
maximum apparent transmission was 0.774. The calculated minimum and maximum 
transmission coefficients (based on crystal size) are 0.4710 and 0.8210. The structure was 
solved and refined using the Bruker SHELXTL Software Package, using the space 
group C 1 2 1, with Z = 4 for the formula unit, C26H29BrO6. The final anisotropic full-
matrix least-squares refinement on F2 with 300 variables converged at R1 = 3.69%, for 
the observed data and wR2 = 9.56% for all data. The goodness-of-fit was 1.033. The 
largest peak in the final difference electron density synthesis was 1.225 e-/Å3 and the 
largest hole was -0.811e-/Å3 with an RMS deviation of 0.057 e-/Å3. On the basis of the 
final model, the calculated density was 1.395 g/cm3 and F(000), 1072 e-. For absolute 
structure determination, Flack x determined using 2675 quotients [(I+)-(I-)]/[(I+)+(I-)],188 
with absolute structure parameter of -0.011 (3). Crystal data, data collection and structure 
refinement details were summarized in Table 36, Supporting Information. 
Antimicrobial Assay. Minimal inhibitory concentrations (MICs) of compounds (1-
11 and 13-14) were measured against a panel of bacteria and fungi using methods that 
were described previously.18,102,103 All measurements were run in duplicate. 
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Tak1-TAB1 (Transforming growth factor-β activated kinase-1/TAK-1 binding 
protein 1) Inhibitor Assays. The assay was performed at BPS Bioscience Inc. 5Z-7-
oxozeaenol19 was used as a positive control. Detailed experimental procedures are 
provided in the Supporting Information. 
 
Supporting Information 
Tak1-TAB1 (Transforming growth factor-β activated kinase-1/TAK-1 binding 
protein 1) Inhibitor Assays. The assay was performed using Kinase-Glo Plus 
luminescence kinase assay kit (Promega). It measures kinase activity by quantitating the 
amount of ATP remaining in solution following a kinase reaction. The luminescent signal 
from the assay is correlated with the amount of ATP present and is inversely correlated 
with the amount of kinase activity. Compounds (1-14) were diluted in 10% DMSO and 5 
µL of the dilution was added to a 50 µL reaction so that the final concentration of DMSO 
is 1% in all of reactions. The compounds were preincubated with the enzyme in a 
reaction mixture for 10 min at room temperature. The enzymatic reactions were initiated 
by adding ATP (20 µM at final) and conducted for 40 minutes at 30 oC. The 50 µL 
reaction mixture contained 40 mM Tris, pH 7.4, 10 mM MgCl2, 0.1 mg/mL BSA, 1 mM 
DTT, 0.2 mg/mL MBP substrate, 20 µM ATP and Tak1-TAB1. After the enzymatic 
reaction, 50 µL of Kinase-Glo Plus Luminescence kinase assay solution (Promega) was 
added to each reaction and the plate was incubated for 20 minutes at room temperature. 
Luminescence signal was measured using a BioTek Synergy 2 microplate reader. Tak1-
TAB1 activity assays were performed in duplicate at each concentration. The 
 
204 
luminescence data were analyzed using the computer software, Graphpad Prism. The 
difference between luminescence intensities in the absence of Tak1-TAB1 (Lut) and in 
the presence of Tak1-TAB1 (Luc) was defined as 100% activity (Lut – Luc). Using 
luminescence signal (Lu) in the presence of the compound, % activity was calculated as: 
% activity = [(Lut - Lu)/(Lut - Luc)]×100%, where Lu= the luminescence intensity in the 
presence of the compound. The values of % activity versus a series of compound 
concentrations were then plotted using non-linear regression analysis of Sigmoidal dose-
response curve generated with the equation Y=B+(T-B)/1+10((LogEC50-X)×Hill Slope), where Y 
= percent activity, B = minimum percent activity, T = maximum percent activity, X = 
logarithm of compound and Hill Slope = slope factor or Hill coefficient. The IC50 value 
was determined by the concentration causing a half-maximal percent activity. 
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Figure 86. UPLC chromatograms of compounds 1-11 and 13-14 (λ 254 nm), 
demonstrating >96% purity for compounds 2-11 and 13-14 and >94% for compound 1. 
All data were acquired via an Acquity UPLC system with a Phenomenex Kinetex C18 
(1.3 µm; 50 × 2.1 mm) column and a CH3CN/H2O gradient that increased linearly from 
20 to 100% CH3CN over 1.2 min. 
(1) (2) 
(3) (4) 
(5) (6) 
(7) (8) 
(9) (10) 
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Figure 86 (continued). UPLC chromatograms of compounds 1-11 and 13-14 (λ 254 nm), 
demonstrating >96% purity for compounds 2-11 and 13-14 and >94% for compound 1. 
All data were acquired via an Acquity UPLC system with a Phenomenex Kinetex C18 
(1.3 µm; 50 × 2.1 mm) column and a CH3CN/H2O gradient that increased linearly from 
20 to 100% CH3CN over 1.2 min. 
(11) (13) 
(14) 
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Figure 87. 1H and 13C NMR spectra of compound 1 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 88. 1H and 13C NMR spectra of compound 2 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 89. 1H and 13C NMR spectra of compound 3 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 90. 1H and 13C NMR spectra of compound 4 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 91. 1H and 13C NMR spectra of compound 5 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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 Figure 92. 1H and 13C NMR spectra of compound 6 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 93. 1H and 13C NMR spectra of compound 7 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 94. 1H and 13C NMR spectra of compound 8 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 95. 1H and 13C NMR spectra of compound 9 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 96. 1H and 13C NMR spectra of compound 10 [500 MHz for 1H and 125 MHz for 13C, DMSO]. 
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Figure 97. 1H and 13C NMR spectra of compound 11 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 98. 1H and 13C NMR spectra of compound 12 [700 MHz for 1H and 175 MHz for 13C, CDCl3]. 
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Figure 99. 1H and 13C NMR spectra of compound 13 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 100. Stack plot of the 1H NMR spectra of compound 10 (upper), compound 13 (lower) and the rearranged product of 
compound 10 (middle) [500 MHz, CDCl3]. 
greensporone J (10)  
greensporone M (13) 
greensporone M (13) resulted from in an NMR tube 
cycloetherification of greensporone J (10)  
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Figure 101. 1H and 13C NMR spectra of compound 14 [500 MHz for 1H and 125 MHz for 13C, CDCl3]. 
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Figure 102. 1H NMR spectrum of compound 15 [500 MHz, CDCl3]. 
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Figure 103. Proposed mechanism for the intramolecular cycloetherification of ε-hydroxy-
α,β-unsaturated ketones. 
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Figure 104. Phylogram of the most likely tree (-lnL = 10610.60) from a RAxML analysis 
of 116 taxa based on combined ITS and D1/D2 regions of LSU nrDNA sequence data 
(1052 bp). Numbers refer to RAxML bootstrap support values ≥ 70% based on 1000 
replicates. Strain G87 is putatively identified as having phylogenetic affinities to 
Halenospora varia (Clade 7 sensu Baschien et al. 2013 highlighted). Bar indicates 
nucleotide substitution per site. A 3-week-old colony of G87 on PDA media is also 
shown.  
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Table 36. Crystal data, data collection, and refinement details of 15 
 
Crystal data 
C26H29BrO6 F(000) = 1072 
Mr = 517.40 Dx = 1.395 Mg m-3 
Monoclinic, C2 Mo Kα radiation, λ = 0.71073 Å 
a = 22.9481 (11) Å Cell parameters from 9887 reflections 
b = 5.2631 (3) Å θ = 3.6–30.9° 
c = 21.5301 (11) Å µ = 1.71 mm-1 
β = 108.6665 (6)° T = 193 K 
V = 2463.6 (2)  Å3 Rectangular-parallepiped, colourless 
Z = 4 0.52 × 0.19 × 0.12 mm 
Data collection 
Bruker APEX CCD diffractometer 7231 independent reflections 
Radiation source: sealed tube 6524 reflections with I > 2σ(I) 
Graphite monochromator Rint = 0.031 
φ and ω scans θmax = 30.2°, θmin = 3.6° 
Absorption correction: multi-scan; Data 
were corrected for scaling and absorption 
effects using the multi-scan technique 
(SADABS). The ratio of minimum to 
maximum apparent transmission was 0.774. 
The calculated minimum and maximum 
transmission coefficients (based on crystal 
size) are 0.471 and 0.821. 
h = -32→32 
Tmin = 0.577, Tmax = 0.746 k = -7→7 
23715 measured reflections l = -30→30 
Refinement 
Refinement on F2 Secondary atom site location: structure-
invariant direct methods 
Least-squares matrix: full Hydrogen site location: inferred from 
neighbouring sites 
R[F2 > 2σ(F2)] = 0.037 H-atom parameters constrained 
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Table 36 (Continued). Crystal data, data collection, and refinement details of 15 
wR(F2) = 0.096 w = 1/[σ2(Fo2) + (0.0457P)2 + 2.0649P] 
where P = (Fo2 + 2Fc2)/3 
S = 1.03 (∆/σ)max = 0.001 
7231 reflections ∆〉max = 1.23 e Å-3 
300 parameters ∆〉min = -0.81 e Å-3 
1 restraint Absolute structure: Flack x determined 
using 2675 quotients [(I+)-(I-)]/[(I+)+(I-)] 
(Parsons and Flack (2004), Acta Cryst. 
A60, s61). 
Primary atom site location: structure-
invariant direct methods 
Absolute structure parameter: -0.011 (3) 
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CHAPTER VIII 
 
FLAVONOLIGNANS FROM ASPERGILLUS IIZUKAE, A FUNGAL ENDOPHYTE 
OF MILK THISTLE (SILYBUM MARIANUM) 
 
Tamam El-Elimat, Huzefa A. Raja, Tyler N. Graf, Stanley H. Faeth, Nadja B. Cech, 
and Nicholas H. Oberlies. Journal of Natural Products 2014, 77, 193-199. 
 
Silybin A (1), silybin B (2), and isosilybin A (3), three of the seven flavonolignans 
that constitute silymarin, an extract of the fruits of milk thistle (Silybum marianum), were 
detected for the first time from a fungal endophyte, Aspergillus iizukae, isolated from the 
surface-sterilized leaves of S. marianum. The flavonolignans were identified using a 
UPLC-PDA-HRMS-MS/MS method by matching retention times, HRMS, and MS/MS 
data with authentic reference compounds. Attenuation of flavonolignan production was 
observed following successive sub-culturing of the original flavonolignan-producing 
culture, as is often the case with endophytes that produce plant-based secondary 
metabolites. However, production of 1 and 2 resumed when attenuated spores were 
harvested from cultures grown on a medium to which autoclaved leaves of S. marianum 
were added. The cycle of attenuation followed by resumed biosynthesis of these 
flavonolignans was replicated in triplicate.  
 
Silybum marianum (L.) Gaertn. (Asteraceae), known commonly as milk thistle, has 
been used for centuries for treatment of liver disorders, including cirrhosis and chronic 
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hepatitis.189-195 Silymarin, the crude extract of the fruits (achenes), represents a mixture of 
at least seven flavonolignans [silybin A (1), silybin B (2), isosilybin A (3), isosilybin B 
(4), silychristin, isosilychristin, and silydianin] and the flavonoid taxifolin.196 Silymarin 
has been the subject of intensive studies for its profound biological activities, particularly 
in the areas of cancer chemoprevention and hepatoprotection,197-202 and our group has 
been studying the chemistry of flavonolignans for more than ten years.203-207 Recently, 
studies were initiated on the chemical mycology of endophytic fungi in milk thistle by 
examining the chemical profiles of fungal endophytes and how these are influenced by 
the native substrate. 
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Figure 105. Structures of compounds 1-4. 
Fungal endophytes are a diverse group of primarily ascomycetous fungi, which are 
defined functionally by their asymptomatic occurrence within plants.208,209 They occur in 
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all major lineages of plants and in natural and anthropogenic communities ranging from 
the arctic region to the tropics.210-212 The ecological roles and chemical interactions of 
endophytic fungi are currently under intense investigation, particularly in relation to their 
host plants. 
The capability of certain endophytic fungi to produce compounds associated with 
plant secondary metabolites has gained prominence since the report of the anticancer 
agent taxol from Taxomyces andreanae, a fungal endophyte that was isolated from the 
inner bark of Taxus brevifolia.213 Subsequently, several research groups have explored 
endophytic fungi for the production of associated plant secondary metabolites, and 
examples include the cytotoxic agents podophyllotoxin214,215 and 
deoxypodophyllotoxin,216 camptothecin and related analogues,217-222 and vinblastine,223 
the herbal antidepressant hypericin and its precursor emodin,224,225 and the insecticides 
azadirachtin A and B.226 Unfortunately, sustainable production of these and other 
compounds by fungal endophytes has proven difficult. Almost without exception, 
attenuation of production of the target compounds following sub-culturing of the 
endophytes occurs.227 The reasons for this attenuation could be attributed to factors that 
stem from loss of interactions with the host plant, coexisting endophytes (of fungal and/or 
bacterial origin), insects, and/or herbivores,228,229 resulting in the silencing of genes in 
axenic monocultures.230 Herein, reported for the first time is the production of two 
flavonolignans, silybin A (1) and silybin B (2), from an endophytic fungus that was 
isolated from the leaves of milk thistle. The fungus was identified as Aspergillus iizukae 
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Sugiyama (Eurotiomycetes, Ascomycota) using molecular and morphological 
characterization techniques. 
 
 
 
 
Figure 106. A) (-)-ESI SIC of reference standards compared to that of an extract of the 
fungus A. iizukae (m/z: 481); (-)-ESI high-resolution mass spectra (left) and MS/MS CID 
fragmentation data (right) of B) silybin A (1), C) silybin B (2), and D) isosilybin A (3).  
A) 
B) 
C) 
D) 
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Following isolation of 21 unique fungal endophytes from leaves, stems, seeds, and 
roots of milk thistle, organic extracts of cultures grown on a solid medium were prepared 
and dereplicated against an in-house database of bioactive fungal secondary metabolites 
containing more than 180 compounds using a UPLC-PDA-HRMS-MS/MS method.80 As 
a standard protocol, all cultures isolated in our laboratory were dereplicated before 
engaging in the scale-up or purification processes, so as to avoid the re-isolation of 
known compounds, particularly mycotoxins.80,231 Subsequently, the 21 fungal endophytes 
were examined for the production of flavonolignans. To do so, a database of authentic 
reference standards of the major silymarin constituents was constructed using the same 
dereplication strategy80 by recording HRMS, MS/MS data, UV absorption maxima, and 
retention times utilizing the negative-ionization mode (Table 37, Supporting 
Information). The MS files of the extracts, which were acquired previously for 
dereplicating mycotoxins, were re-analyzed for the production of flavonolignans. Among 
the fungal endophyte isolates, only two cultures, coded G77 and G82, had detectable ions 
that matched, tentatively, with four flavonolignan standards (1-4) in terms of HRMS, 
MS/MS fragments and retention times. Interestingly, G77 was harvested from the leaves 
while G82 was harvested from the stems; however, they both were identified later as A. 
iizukae. The former culture produced a higher level of signals that matched that of the 
flavonolignans, and as such, was pursued further. Due to the close retention times, 
identical molecular ion peaks, and similar fragmentation patterns, the method80 was 
unable to differentiate between either silybin A/silybin B or isosilybin A/isosilybin B. To 
discern between these pairs of diastereoisomers, a chromatographic method was 
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optimized to target flavonolignans, and this was utilized when re-acquiring the UPLC-
PDA-HRMS-MS/MS data. Using this refined dereplication system (Table 37, Supporting 
Information), the compounds were identified as silybin A (1), silybin B (2), and 
isosilybin A (3) (Figure 106). 
Upon successive sub-culturing of the original axenic flavonolignans-producing 
culture (A. iizukae), attenuation of the production of flavonolignans was observed. In an 
attempt to stimulate the fungus to biosynthesize these compounds, an experiment was 
designed by growing A. iizukae on potato dextrose agar (Difco) to which autoclaved milk 
thistle leaves were added (Figure 107). Following growth for one month, spores (asexual 
conidia) were transferred aseptically from the plate and were used either to inoculate the 
rice medium directly or to inoculate a liquid culture containing 2% soy peptone, 2% 
dextrose, and 1% yeast extract (YESD medium). After seven days, this liquid culture was 
used to inoculate the rice medium. In addition, an agar plug from a culture of A. iizukae 
that was grown on PDA medium without autoclaved milk thistle leaves was used to 
inoculate the rice medium directly. All three cultures were grown on rice for 21 days and 
then extracted and analyzed by UPLC-PDA-HRMS using the system optimized for 
flavonolignans. The flavonolignans, silybin A (1) and silybin B (2), were detected only in 
the solid medium that was inoculated directly by spores from A. iizukae grown on 
medium that included autoclaved milk thistle leaves. Upon sub-culturing of this 
flavonolignan-producing culture, the production of flavonolignans was attenuated again. 
However, flavonolignan production was re-stimulated by growing the attenuated culture 
on PDA medium with autoclaved milk thistle leaves and harvesting spores for inoculation 
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on rice medium (Figure 108). Importantly, the conidiophores were up to 1.5 mm long 
(Figure 109, Supporting Information).232 Hence, it was easy to harvest a small amount of 
spores using the tip of a sterile bent sewing needle, which was attached to a 20 cm long 
needle holder, without touching the surface of the agar. Moreover, the flavonolignans 
were not detected in organic extracts of the milk thistle leaves used in this study. 
 
 
Figure 107. Experimental design for the fungus, A. iizukae, grown in potato dextrose agar 
culture with and without autoclaved milk thistle (Silybum marianum) leaves. Production 
of flavonolignans by the fungus, A. iizukae, was observed only in experiment A. G77 
refers to the in-house code of the fungus A. iizukae, MT stands for milk thistle, and PDA 
for potato dextrose agar. 
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Figure 108. Flavonolignans production by A. iizukae upon sub-culturing. Abbreviations; 
G77: A. iizukae, MT: milk thistle, PDA: potato dextrose agar, 1: silybin A, 2: silybin B, 
and 3: isosilybin A. 
 
The flavonolignan content of the various A. iizukae cultures was quantified using a 
calibration curve for an authentic sample of silybin B (2) (Figure 110, Supporting 
Information). The first A. iizukae isolate showed 0.22, 0.15, and 0.13 µg/g extract of 1-3, 
respectively. The third A. iizukae culture showed 0.26 and 0.07 µg/g extract of 1 and 2, 
respectively. The fifth A. iizukae culture showed 0.03 µg/g extract for 1, while 2 was too 
low to be quantified. The limit of detection was estimated as 0.01 µg/g. Isosilybin A (3) 
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was detected only in the first A. iizukae culture, while none of the flavonolignans were 
detected in cultures 2 and 4 (Figure 108). 
Neither artificial reconstitution of the interaction between a camptothecin attenuated 
fungal endophyte and its host plant,233 nor supplementing the fungal growth medium with 
host tissue extracts227 were successful in restoring the biosynthesis of camptothecin. 
However, in this flavonolignan example, the ability to stimulate biosynthesis of 
flavonolignan secondary metabolites by adding plant material to the axenic cultures may 
indicate stimulation of gene clusters ascribed to biosynthesis.  
Obvious questions could be raised as to where the flavonolignans originated. The 
leaves that were amended to the cultures were ruled out for three reasons: there were no 
leaves in the medium when the flavonolignans were observed originally, compounds 1-4 
were not detected in the leaves, and most importantly, the spores were removed from the 
Petri dishes without touching the agar medium before being transferred to the rice 
medium for growth. Also, contamination of both glassware and instrumentation were 
dismissed for at least three reasons: solvent blanks were injected between runs on the 
UPLC-PDA-HRMS-MS/MS system, the column on the UPLC was used exclusively for 
fungal samples, and the experiments between amended cultures (i.e. experiments 2 and 4 
in Figure 108) did not show the production of flavonolignans. Further to this point, when 
the flavonolignans were observed originally, via a random screening of more than a score 
of fungal extracts, they were observed only in two samples. Later, it was determined that 
these isolates were identical via morphological and molecular methods. Finally, a 
misidentification of the flavonolignans was excluded, as the reference standards were 
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characterized thoroughly.203,205,234 Having eliminated all of those possibilities, we 
concluded that the leaves in the medium stimulated the biosynthesis of flavonolignans, 
such that these compounds could be observed upon growth of the fungus from spores on 
solid medium. 
Discovery of endophytic fungi that can produce the same compounds of their 
associated host plants could be important from chemical and evolutionary perspectives. 
These may serve as a sustainable and alternative source for biologically active secondary 
metabolites that are produced by endangered or difficult-to-collect plant species. This has 
been attempted with a variety of metabolites.213,215,225 To date, the relative production 
levels in endophytic cultures have not been large enough to be considered viable. Future 
studies that explore adding substrates to culture media may improve this. From an 
evolutionary viewpoint, a horizontal transfer of genes encoding for secondary metabolites 
could have occurred between the host plant and its associated endophytic fungi.230 If so, 
then understanding how plant defenses against herbivores and pathogens evolved may 
need to also consider the impact of endophytic symbiants. Genomic studies of secondary 
metabolite gene clusters may provide additional information on how endophytic fungi are 
capable of producing plant-associated bioactive compounds and if there are cryptic gene 
clusters in fungal endophytes that are capable of yielding plant metabolic products. Such 
studies could yield fungal cultures that are amenable to genetic manipulation for the 
production of non-natural analogues of plant-based secondary metabolites. 
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Experimental Section 
General Experimental Procedures. HRESIMS was performed on a Thermo LTQ 
Orbitrap XL mass spectrometer (ThermoFisher, San Jose, CA, USA) equipped with an 
electrospray ionization source in the negative ionization mode. Source conditions in the 
negative ionization mode were: 275 °C for capillary temperature, 3.5 kV for the source 
voltage, 42 V for capillary voltage, and 110 V for tube lens. Nitrogen was utilized for the 
sheath and auxiliary gases and set to 20 and 10 arb, respectively. Two scan events were 
carried out, full scan (100-2000) and ion trap MS/MS of the most intense ion from the 
parent mass list utilizing CID with normalized collision energy of 30. Thermo Scientific 
Xcalibur 2.1 software was used for instrument control and data analysis. UPLC was 
carried out on a Waters Acquity system [using a HSS T3 (2.1 × 100 mm, 1.8 µm) column 
(Waters Corp., Milford, MA, USA) equilibrated at 50 °C]. A mobile phase consisting of 
MeOH-H2O (acidified with 0.1% formic acid) was used, starting with 30:70 then 
increasing linearly to 55% MeOH within 5 min, then returning to the starting conditions 
within 0.1 min, and holding for 0.9 min, for a total run time of 6 min and a flow rate of 
0.6 mL/min. An Acquity UPLC photodiode array detector was used to acquire PDA 
spectra, which were collected from 201-499 nm with 3.6 nm resolution. Quantification of 
flavonolignans was performed using the same UPLC-MS method based on a linear 
calibration curve (r2 = 1.00) of five concentrations (5, 10, 20, 40, and 80 µg/mL) of an 
authentic standard of silybin B (2) (Figure 109, Supporting Information).205   
Isolation and Fermentation of Fungal Endophyte. A healthy, asymptomatic plant 
of Silybum marianum (milk thistle) was obtained from Horizon Herbs (lot # 6510), a 
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private farming company located in Williams, OR, USA, in August 2011. A voucher 
specimen of the plant material was deposited in the Herbarium of the University of North 
Carolina at Chapel Hill (NUC602014). The stems, leaves, roots, and seeds of the plant 
were cut into small pieces (approximately 2–5 mm in length) and washed in tap water. 
Subsequently, the segments were surface-sterilized by sequential immersion in 95% 
EtOH for 10 sec, NaClO (10–15% available chlorine, Sigma) for 2 min, and 70% EtOH 
for 2 min. The plant segments were transferred under aseptic conditions onto 2% malt 
extract agar (MEA, Difco; 20 g MEA, 1000 mL sterile distilled water with the antibiotics, 
streptomycin sulfate 250 mg/L and penicillin G 250 mg/L). To test the efficacy of the 
surface-sterilization procedure, and to confirm that emergent fungi were endophytic and 
not of epiphytic origin, individual surface-sterilized leaf, stem, root, and seed segments 
were spread and then removed on separate MEA plates with antibiotics; the absence of 
fungal growth on the nutrient medium confirmed the effectiveness of the sterilization 
procedure.235 Plates were sealed with Parafilm and incubated at room temperature until 
emergent fungal colonies were observed. 
One of the endophytes from milk thistle leaves was accessioned as G77. The cultures 
of G77 were subsequently grown on 2% MEA, potato dextrose agar (PDA, Difco), and 
YESD media. After 14–21 days, spores of the fungus were used to inoculate 50 mL of a 
rice medium, prepared using 25 g of rice and twice the volume of rice with H2O in a 250 
mL Erlenmeyer flask. This inoculated medium was incubated at 22 °C until the culture 
showed good growth (approximately 14 days). A voucher culture of the G77 strain is 
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maintained in the Department of Chemistry and Biochemistry culture collection at the 
University of North Carolina at Greensboro. 
Identification of the Fungal Strain. For molecular identification, DNA was 
extracted from fresh cultures of G77 grown on PDA amended with antibiotics 
(streptomycin sulfate 250 mg/L, penicillin G 250 mg/L, distilled water 1 L; antibiotics 
were added to the molten agar immediately after autoclaving). The nuclear internal 
transcribed spacers and intervening 5.8S gene, which together have been proposed as a 
barcoding marker for fungi,45 along with the D1/D2 regions of the adjacent nuclear 
ribosomal large subunit,236 were amplified and sequenced following protocols published 
previously.63 The consensus sequence of the ITS region was submitted for a BLAST 
search using the NCBI GenBank database to obtain species level information. The ITS 
sequence was then utilized in combination with the D1/D2 regions of the LSU for 
subsequent phylogenetic analysis. The top BLAST matches for G77 indicated similarities 
to sequences of A. iizukae (EF669597; Identities = 558/562 (99%), Gaps = 3/562 (0%)) 
and A. iizukae (EF669596; Identities = 558/ 562 (99%), Gaps = 3/562 (0%)). GenBank 
sequence EF669597 belongs to NRRL 3750, which is the type isolate of A. iizukae.237 
The ITS sequence of G77 was also searched against the Fungal Barcoding database 
(http://www.fungalbarcoding.org/) using the pairwise sequence alignment. Results also 
suggested a 99% sequence similarity with an isolate of A. iizukae (DTO 065-G6). After 
the initial BLAST searches, top BLAST hits from the GenBank were downloaded and 
incorporated into a multiple sequence alignment of combined ITS and D1/D2 regions of 
LSU data using MUSCLE238 with default parameters in operation. MUSCLE was 
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implemented using the program Seaview v. 4.1.239 Maximum likelihood (ML) analyses 
were then performed using a RAxML v. 7.0.4240,241 run on the CIPRES Portal v. 2.0185 
with the default rapid hill-climbing algorithm and GTR model employing 1000 fast 
bootstrap searches. In addition, Bayesian analysis was also performed to assess support 
for tree topology using MrBayes.242 The strain G77 was nested in a cluster with 
sequences of A. iizukae including the type isolate (NRRL 3750; EF669597) with 
moderate bootstrap support within the section Flavipedes (Figure 111, Supporting 
Information). Based on the results of the BLAST search and ML analysis, strain G77 was 
identified as A. iizukae. The combined ITS and partial LSU sequence for A. iizukae was 
deposited in GenBank (accession No. AB859956). A. iizukae Sugiyama was reported 
originally in soil from stratigraphic drilling core, Gymna Prefecture, Fujioka, Japan.232 
The endophytic strain isolated from milk thistle leaves was morphologically identical to 
the protologue.232 The same analysis was conducted on G82, an isolate that was harvested 
from the stems of milk thistle; the taxonomy and phylogeny of G77 and G82 were 
identical.  
Extraction. To each solid fermentation culture of A. iizukae, 60 mL of 1:1 MeOH-
CHCl3 were added. The culture was chopped with a spatula and shaken overnight (~16 h) 
at ∼100 rpm at room temperature. The sample was filtered with vacuum, and the 
remaining residues were washed with 10 mL of 1:1 MeOH-CHCl3. To the filtrate, 90 mL 
CHCl3 and 150 mL H2O were added; the mixture was stirred for 30 min and then 
transferred into a separatory funnel. The bottom layer was drawn off and evaporated to 
dryness. The dried organic extract was dissolved in 100 mL of 1:1 MeOH-CH3CN and 
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100 mL of hexanes. The biphasic solution was transferred to a separatory funnel and 
shaken vigorously. The MeOH-CH3CN layer was drawn off and evaporated to dryness 
under vacuum to yield 47.3, 301.7, and 575.9 mg of extract for the first, third, and fifth 
cultures, respectively. For UPLC-PDA-HRMS-MS/MS analysis, a sub-milligram aliquot 
of each extract was dissolved in equal volumes of MeOH and dioxane to obtain a final 
concentration of 2 mg/mL in a total volume of 150 µL. To insure that flavonolignans 
were not carried over between successive injections, consecutive blanks of solvents were 
injected between samples during analysis on the UPLC-PDA-HRMS-MS/MS system. 
Using the same protocols and solvent systems that were used for the fungal cultures, 
approximately 0.5 g of dry, finely ground milk thistle leaves were extracted and 
fractionated; this was repeated on three separate samples of leaves. An aliquot of each of 
the dried MeOH-CH3CN extracts was analyzed for flavonolignans using the UPLC-
PDA-HRMS-MS/MS method.  
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Supporting Information 
 
 
Table 37. Chemical Formulas, Retention Times, UV Absorption Maxima, (-)-ESI HRMS, and (-)-ESI CID 
MS/MS of Silymarin constituents 
 
compound Chemical formula 
Rt (min) 
UV (nm) 
ESI- 
Method 
Ia 
Method 
IIb [M-H]
- MS/MS 
       
Silybin A (1) C25H22O10 3.42 4.04 230, 287 
481.1128 
(-2.5) 
301.03, 453.12, 463.16, 257.07, 
282.98, 454.15, 435.24, 437.34, 
464.19, 451.25 
Silybin B (2) C25H22O10 3.46 4.24 230, 287 
481.1127 
(-2.7) 
301.11, 463.19, 453.08, 257.05, 
283.02, 433.11, 355.09, 435.28, 
454.15, 464.26 
Isosilybin A (3) C25H22O10 3.58 4.74 230, 287 
481.1130 
(-2.2) 
453.13, 257.01, 463.21, 454.19, 
283.08, 437.14, 435.34, 300.90, 
284.02, 229.01 
Isosilybin B (4) C25H22O10 3.60 4.89 232, 287 
481.1125 
(-3.2) 
453.11, 257.05, 463.18, 283.02, 
454.18, 301.01, 437.04, 435.20, 
213.05, 215.14 
Silydianin C25H22O10 2.92 2.93 224, 289 
481.1123 
(-3.5) 
453.16, 463.20, 454.26, 150.92, 
168.84, 391.18, 178.97, 409.20, 
437.18, 301.14 
Silychristin C25H22O10 2.85 2.54 230, 289 
481.1130 
(-2.2) 
355.15, 463.11, 451.21, 337.08, 
433.14, 325.16, 419.25, 453.17, 
445.27, 435.13 
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Table 37 (Continued). Chemical Formulas, Retention Times, UV Absorption Maxima, (-)-ESI HRMS, 
and (-)-ESI CID MS/MS of Silymarin constituents 
 
compound Chemical formula 
Rt (min) 
UV (nm) 
ESI- 
Method 
Ia 
Method 
IIb [M-H]
- MS/MS 
Isosilychristin C25H22O10 2.85 2.30 230, 289 
481.1126 
(-2.9) 
463.18, 445.19, 453.19, 437.11, 
435.21, 178.94, 464.12, 311.10, 
419.14, 433.24 
Taxifolin C15H12O7 2.09 1.59 228, 289 
303.0501 
(-3.0) 
284.96, 176.98, 124.91, 275.14, 
258.99, 178.99, 217.07, 241.03, 
215.70, 174.98 
aUPLC was carried out using a BEH C18 (2.1 × 50 mm, 1.7 µm) column equilibrated at 40 °C. A mobile phase 
consisting of CH3CN-H2O (acidified with 0.1% formic acid) was used, starting with 15:85 then increasing 
linearly to 100% CH3CN within 8 min, holding for 1.5 min and then returning to the starting conditions within 
0.5 min, for a total run time of 10 min and a flow rate of 0.3 mL/min.  
bUPLC was carried out using a HSS T3 (2.1 × 100 mm, 1.8 µm) column equilibrated at 50 °C. A mobile phase 
consisting of MeOH-H2O (acidified with 0.1% formic acid) was used, starting with 30:70 then increasing 
linearly to 55% MeOH within 5 min, then returning to the starting conditions within 0.1 min, and holding for 
0.9 min, for a total run time of 6 min and a flow rate of 0.6 mL/min. 
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Figure 109. Stereomicrographs of A. iizukae culture on PDA media acquired using an 
Olympus SZX16 microscope equipped with an Olympus DP25 camera. In B, note the 
close up of columnar conidial heads (circled) and conidiophores (arrows). Bars: A = 500 
µm. B = 200 µm. The conidial heads are where the conidia (i.e. spores) reside. In this 
fungus, the spores are formed well above (up to 1.5 mm) the surface of the agar in mature 
cultures. Hence, we were able to remove the spores with a bent sewing needle without 
touching the surface of the agar. 
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Figure 110. External calibration curve for silybin B measured by UPLC-ESIMS at 
five concentration levels (0.005, 0.01, 0.02, 0.04, and 0.08 µg/mL), each run in 
triplicate. 
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Figure 111. Phylogram of the most likely tree (-lnL = 4550.35) from a RAxML analysis 
of 60 taxa based on complete ITS and partial region of the 28S large subunit nrDNA 
(1112 bp). Numbers refer to RAxML bootstrap support values based on 1000 replicates. 
Thickened branches indicate Bayesian probabilities ≥ 95%. G77 (highlighted in bold) is 
nested within the A. iizukae clade (highlighted in gray). The photograph shows A. iizukae 
growing on PDA (Difco) media. 
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CHAPTER IX 
 
HIGH-RESOLUTION MS, MS/MS, AND UV DATABASE OF FUNGAL 
SECONDARY METABOLITES AS A DEREPLICATION PROTOCOL FOR 
BIOACTIVE NATURAL PRODUCTS 
 
Tamam El-Elimat, Mario Figueroa, Brandie M. Ehrmann, Nadja B. Cech, Cedric J. 
Pearce, and Nicholas H. Oberlies. Journal of Natural Products 2013, 76, 1709-1716. 
 
A major problem in the discovery of new biologically active compounds from 
natural products is the re-isolation of known compounds. Such re-isolations waste time 
and resources, distracting chemists from more promising leads. To address this problem, 
dereplication strategies are needed that enable crude extracts to be screened for the 
presence of known compounds before isolation efforts are initiated. In a project to 
identify anticancer drug leads from filamentous fungi, a significant dereplication 
challenge arises, as the taxonomy of the source materials are rarely known, and, thus, the 
literature cannot be probed to identify likely known compounds. An ultra-performance 
liquid chromatography-photodiode array-high-resolution tandem mass spectrometric 
(UPLC-PDA-HRMS-MS/MS) method was developed for dereplication of fungal 
secondary metabolites in crude culture extracts. A database was constructed by recording 
HRMS and MS/MS spectra of fungal metabolites, utilizing both positive- and negative-
ionization modes. Additional details, such as UV-absorption maxima and retention times, 
were also recorded. Small-scale cultures that showed cytotoxic activities were 
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dereplicated before engaging in the scale-up or purification processes. Using these 
methods, approximately 50% of the cytotoxic extracts could be eliminated from further 
study after the confident identification of known compounds. The specific attributes of 
this dereplication methodology include a focus on bioactive secondary metabolites from 
fungi, the use of a 10-min chromatographic method, and the inclusion of both HRMS and 
MS/MS data. 
Many natural product drug discovery programs utilize bioactivity-directed 
fractionation methodologies for the isolation of lead compounds from crude extracts, in 
which the bioassay results guide the purification processes.243,244 While countless studies 
demonstrate the utility of this approach in identifying new drug leads, with taxol and 
camptothecin possibly the most well-known examples,245-247 it is often criticized for 
resulting in the re-isolation and re-characterization of previously known compounds. This 
criticism of natural products research grows in significance annually, as over 246,000 
compounds have been described from Nature, with approximately 4,000 new ones added 
each year.151 Thus, to expedite the discovery of new leads, and to avoid the re-isolation of 
previously known compounds, it is crucial to discriminate between known vs. new 
compounds as early as possible. This process, which is termed “dereplication”,248 enables 
the efficient use of human and financial resources,249,250 so that efforts can be focused on 
the discovery of structurally novel compounds.249,251 
Early dereplication strategies focused largely on botanical extracts. The ability to 
characterize a plant’s taxonomy (at least to the genus level) based on morphology can 
simplify the dereplication process, as it enables botanical extracts to be screened for 
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known chemical compounds specific to the taxa under investigation. Some examples 
include colchicinoids in Colchicum spp.,252 acetogenins in plants of the Annonaceae,253 
phenolics in the genus Lippia,254 steroidal alkaloids in Buxus spp.,255 and triterpenoids in 
the genus Actaea.256  
In contrast, dereplication can be more complicated for organisms of unknown 
taxonomy.257,258 This is the case for our ongoing research aimed at identifying anticancer 
drug leads from non-sporulating filamentous fungi.11,17 Fungi are known to produce 
structurally diverse secondary metabolites that display a wide range of biological 
activities. Although fungi are relatively under-investigated,8,23 a major challenge with 
these organisms as a source of bioactive lead compounds is the production of 
mycotoxins, which can be observed across different fungal species. Examples of these 
include aflatoxins, ochratoxins, trichothecenes, citreoviridin, fumonisins, and various 
indole-derived tremorgenics.13 Indeed, a promising side application for the presently 
described dereplication procedure is the rapid identification of mycotoxins in foods, as 
mycotoxins continue to present safety challenges for the food supply.259,260 While 
molecular methods have accelerated the process,45 assignment of fungal taxonomy can be 
a tedious procedure, and regardless, only about 100,000 of the estimated 1.5 to 5.1 
million species of fungi have been ascribed a scientific name.8,23 Hence, the taxonomy of 
fungi being studied in natural products programs is often not known at all, or only 
determined after compounds have been isolated. Thus, there is a critical need for better 
strategies to dereplicate crude fungal extracts for the presence of known chemical 
entities, including mycotoxins and other biologically relevant compounds. In doing so, 
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resources for drug discovery can be devoted into those samples most likely to yield new 
chemical entities.17  
Several dereplication methods have been reported in the literature for fungal 
secondary metabolites; however, all of these are hampered by at least one, if not several, 
limitations, including long run times (30 min or more), low-resolution mass 
measurements, and/or lack of confirmatory MS-MS data.257,261-264 A recent LC-UV/vis-
MS-based dereplication strategy utilized UV spectra (acquired with a photodiode array 
detector) and ESI+/ESI- time-of-flight MS for assignment of 719 microbial natural 
product and mycotoxin reference standards.262 While effective, only 17% (29 
compounds) of our database of cytotoxic fungal compounds overlapped with the 
standards used, as this earlier procedure did not have a focus on compounds with 
biological activity.262 Moreover, a 30-min chromatographic method was utilized,262 
which may be too long for routine processing of scores of samples simultaneously, 
particularly for shared instruments. Finally, CID MS/MS data were not reported,262 which 
serve to fingerprint and confirm the identity of dereplicated compounds. Thus, the goal of 
the present study was to harness the powerful resolution and short analysis time afforded 
by ultra-performance liquid chromatography (UPLC) coupled to the outstanding mass 
accuracy of an Orbitrap mass spectrometer to develop a rapid and effective method to 
dereplicate biologically active fungal extracts. In addition, MS/MS and UV (photodiode 
array) spectra were employed as an integral part of the strategy, so as to differentiate 
isobaric compounds often present in natural product extracts. Finally, given the 
likelihood of the co-elution of compounds in complex mixtures separated over short (<10 
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min) chromatographic run times, a data analysis strategy was incorporated 
(ACD/IntelliXtract), aimed at rapidly deconvoluting complex LC/MS chromatograms. 
Results and Discussion 
The foundation of the present UPLC-PDA-HRMS-MS/MS dereplication procedure 
was the construction of a database for the identification of more than 170 fungal 
secondary metabolites via recording chromatographic retention times, UV data, and full-
scan (high-resolution) mass spectra and MS/MS spectra in both positive and negative 
electrospray ionization (ESI) modes. The chromatographic and tune methods were 
developed using a mixture of 36 compounds representing diverse structural classes that 
ranged from terpenenoids to polyketides to depsipeptides. To test the developed method, 
a mixture of ten structurally diverse compounds was prepared and analyzed (Figures 114 
and 115, Supporting Information). The resulting 10-min chromatographic method and 
associated high-resolution mass spectra could be used to discriminate between all the 
compounds in the database. Of these, only two resorcylic acid lactones, 7-epi-zeaenol and 
15-O-desmethyl-5Z-7-oxozeaenol,19 did not ionize in the ESI+ mode, whereas 17 
compounds, mostly trichothecenes,231 did not ionize in the ESI- mode (Table 38, 
Supporting Information). Also, the molecular ion peaks of aphidicolin and 
viridicatumtoxin were the only ones not detected in the positive-ion mode, due to the 
facile loss of H2O; however, the molecular ion peak for the latter was observed in the 
negative-ion mode. All MS/MS fragmentation data were collected using collisionally 
induced dissociation (CID) with 30% collision energy, and the ten most intense 
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fragments for each compound were utilized in the database (Table 38, Supporting 
Information).  
To initiate the dereplication process, small-scale cultures of fungi were grown on a 
solid medium and extracted using previously described protocols;19,22,62,63 the extracts 
were then evaluated for cytotoxicity against a panel of human cancer cell lines in culture, 
including MCF-7, H-460, and SF-268 cells.50,265 Samples deemed active were prepared 
for analysis by dissolving a sub-milligram aliquot of the bioactive crude extracts in equal 
volumes of MeOH and dioxane to obtain a final concentration of 2 mg/mL. The 
subsequent dereplication strategy utilized a three-step approach (Figure 112). First, 
UPLC-HRMS was used to acquire the TIC (total ion chromatogram) of the extract and 
hence measure the accurate masses of all ions detectable. This TIC was then uploaded 
into ACD MS Manager with add-in software Intellixtract, which cross-referenced the 
molecular ion peaks with the database that was constructed as a list of compound names, 
corresponding molecular weights, and retention times (Table 38, Supporting 
Information). These results were then confirmed manually using HRMS data, and the 
MS/MS and UV spectra were compared with the database to verify the identity of any 
hits. The use of the MS/MS data, retention times, and UV spectra confirmed the identity 
of the compounds in the extract; the only exception would be for the possible, albeit rare, 
case of isomers. Moreover, the ACD/IntelliXtract software, which has the capability to 
extract all chromatographic components in the LC/MS datasets, expedited the 
identification process, due to its capability of resolving overlapping and co-eluting 
components. Finally, using IntelliXtract, it was possible to reconstruct pure component 
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chromatograms for each chromatographic component and annotate spectral peaks with 
the mass of the protonated or deprotonated molecule.266  
 
 
Figure 112. Schematic of the workflow for the proposed dereplication protocol. Aliquots 
of active fungal extracts were evaluated using an UPLC-PDA-HRESIMS-MS/MS 
method, the data were analyzed using ACD Labs Intellixtract software and compared 
with an in-house database, and extracts producing known compounds were excluded. 
 
Using these procedures, 106 small-scale culture extracts were dereplicated. All of 
these displayed sufficiently potent cytotoxicity against a small cancer cell-line panel to 
warrant further investigation. However, based on the dereplication results, 55 samples 
were ruled out as containing known compounds. By doing so, resources were prioritized 
on samples most likely to yield new compounds. The three examples shown below 
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demonstrate the work flow of the dereplication methodology, illustrating its utility for a 
broad range of structural classes of bioactive natural products. 
 Dereplication of Verticillins (Epipolythiodioxopiperazine Alkaloids). An 
extract of the filamentous fungus MSX39480 displayed potent cytotoxic activity for the 
H460 cell line (94 and 88% inhibition of cell growth when tested at 20 and 2 µg/mL, 
respectively) and thus was subjected to the dereplication protocol. Seven 
epipolythiodioxopiperazine (ETP) alkaloids were dereplicated by matching retention 
times, HRMS, and MS/MS data, namely, 11'-deoxyverticillin (1), Sch 52900 (2), 
verticillin A (3), gliocladicillin A (4), gliocladicillin C (5), Sch 52901 (6), and verticillin 
H (7). To illustrate the value of the protocol, a compound eluting at 5.51 min with a m/z 
of 741.1285 was detected in the extract. The isotopic pattern of the molecular ion peak, in 
conjunction with intensity-ratio calculations, suggested the presence of four sulfur atoms. 
ACD/Intellixtract analysis of the UPLC-HRMS data identified this as compound 5, a 
dimeric ETP alkaloid, and the accurate mass and retention time data matched that of a 
standard of 5 (Figures 114 and 115). As a confirmation, excellent agreement between the 
MS/MS spectra of the standard and unknown was achieved (Figure 114). The same 
methodology was used to verify the identity of compounds 1-4, 6, and 7 (Figure 115). 
Dimeric ETP alkaloids are bioactive secondary metabolites reported to have potent 
cytotoxic267-276 and antibacterial activities,277-282 along with antiparasitic,283 
nematicidal,284 antiviral,285 and immunosuppressive properties.286 Hence, this class of 
compounds has been well-studied, including previously in our laboratory,62 and, thus, 
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their rapid dereplication allowed us to focus on other leads with a greater potential to 
yield new substances. 
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Figure 114. A. (+)-ESI SIC of crude MSX39480 extract (m/z: 681, 695, 697, 711, 725, 
727, 741), B. Overlay chromatographic peaks of gliocladicillin C, C. (+)-HRESIMS of 
gliocladicillin C, and D. MS/MS CID fragmentation spectra of gliocladicillin C. 
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Figure 115. ACD/Intellixtract analysis of the TIC of an extract of MSX39480. 
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Dereplication of Enniatins. On the small scale, an extract of the fungus MSX44407 
showed potent cytotoxicity (96 and 71% inhibition when tested against H460 cells at 20 
and 2 µg/mL, respectively). The TIC of the crude extract revealed the presence of three 
major compounds eluting at 6.74, 7.01, and 7.25 min (Figure 116). ACD/Intellixtract 
analysis of the UPLC-HRMS data matched the second and third compounds to the 
cyclodepsipepetides, enniatins D (9) and the unresolved isomers, enniatins E1 (10a) and 
E2 (10b), respectively; HRMS and MS/MS data confirmed these assignments (Figure 
116). While the mass spectrometric data of the first eluting compound did not match any 
substance in the database, the HRMS data yielded a molecular formula of C33H57N3O9 
(m/z 640.4138 [M+H]+, calcd for 640.4168). Searching the Dictionary of Natural 
Products151 using the molecular formula resulted in one lead, enniatin B (8). Although 8 
was not in the database, given its structurally similarity to compounds 9, 10a, and 10b, 
the extract was assigned as not of further interest. Twenty-nine enniatins, which are 
cyclohexadepsipeptides, have been characterized in the literature, either as a single 
compounds or mixtures of unresolved isomers, and a recent review discusses their range 
of biological activities.82 
Dereplication of Aflatoxins. Another culture, MSX40080, showed potent cytotoxic 
activity when tested against H460 cells (95 and 76% growth inhibition when evaluated at 
20 and 2 µg/mL, respectively). The TIC and PDA data of the crude extract suggested a 
series of structurally related compounds with distinctive UV absorption patterns. 
ACD/Intellixtract analysis of the UPLC-HRMS data lead to the identification of five 
compounds, 5-methoxysterigmatocystin (11), brevianamide P (12), sterigmatocystin (13), 
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aversin (14), and 6,8-di-O-methyl averufin (15). These assignments were confirmed by 
checking the HRMS and MS/MS spectra and UV absorption maxima with those in the 
database (Figures 117 and 118). Aflatoxins are regarded as nuisance mycotoxins with 
potent biological activity; hence their facile and rapid dereplication is important. These 
toxins have been investigated extensively due to their carcinogenic effects,287 particularly 
in contaminated grains.288 
In conclusion, UPLC-PDA-HRMS-MS/MS methodology has been developed and 
implemented for the dereplication of cytotoxic secondary metabolites in crude extracts of 
fungal cultures. This methodology has several attributes that distinguish it from previous 
systems. First, the database, which includes full-scan high-resolution mass spectra and 
MS/MS spectra from both the positive- and negative-ionization modes coupled with UV-
absorption maxima and retention times, is the first to be constructed based on cytotoxic 
fungal secondary metabolites. Furthermore, the use of UPLC enables a rapid (10 min) 
chromatographic method, the fastest utilized in a comprehensive natural product 
dereplication strategy. This in turn facilitates the rapid nature of the protocol, such that 
less than 25 min, including the time for sample preparation, is needed to acquire and 
interpret the data. Moreover, the use of HRMS and MS/MS data imparts a high degree of 
confidence in the structure of the dereplicated leads. Coupling these data with the use of 
the ACD/IntelliXtract, which extracts all chromatographic components in the LC-MS 
datasets and automatically assigns each as [M+H]+ or [M-H]-, expedites the identification 
process. In particular, the capability of the ACD/IntelliXtract to deconvolute overlapping 
and co-eluting components makes it possible to dereplicate trace compounds and enables 
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the application of a short (10-min) chromatographic run time. Finally, the method was 
designed as a qualitative tool, and as such, the sensitivity for individual compounds was 
not measured a priori, especially since sensitivity is compound specific. However, the 
coupling of the resolving power of the UPLC with the enhanced sensitivity of mass 
spectrometry enabled the detection of trace amounts of compounds in crude extracts. In 
using this protocol for over two years on hundreds of samples, compounds present in as 
low as 0.22 mg/g of extract were detected readily. 
A promising side application of the dereplication methodology developed could be 
the detection and identification of mycotoxins in food commodities and agricultural 
products. Mycotoxins have attracted world-wide attention due to their profound negative 
economic consequences. It has been estimated that one quarter of the world’s crops are 
contaminated with mycotoxins. Losses in the USA and Canada due to mycotoxins on the 
feed and livestock industries are of the order of $5 billion annually.289,290 The protocol 
described could be utilized in any laboratory having a mass spectrometer coupled with a 
UPLC, using the same analytical column, thereby enabling the identification of a suite of 
mycotoxins, even without reference standards. 
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Figure 116. (+)-ESI SIC of the crude extract of MSX44407 (m/z: 668, 654, 640). 
 
Figure 117. A. (+)-ESI TIC, B. SIC (m/z: 325, 355, 369, 378, and 397 for peaks 13, 11, 
14, 12, and 15, respectively), and C. UPLC-PDA of the crude extract of MSX40080. 
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Figure 118. (+)-HRESIMS and PDA spectra of compounds 11-15. 
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Experimental Section 
General Experimental Procedures. HRESIMS was performed on a Thermo LTQ 
Orbitrap XL mass spectrometer (ThermoFisher, San Jose, CA) equipped with an 
electrospray ionization source. Source conditions in the positive-ionization mode were set 
at 275 °C for the capillary temperature, 4.5 kV for the source voltage, 20 V for capillary 
voltage, and 95 V for the tube lens. For the negative-ionization mode, the source 
conditions for temperature were 3.5 kV for the source voltage, 42 V for capillary voltage, 
and 110 V for the tube lens. Nitrogen was utilized for the sheath gas and set to 25 and 20 
arb for the positive and negative modes, respectively. For the negative-ionization mode, 
nitrogen was also used as an auxiliary gas and set at 10 arb. In both modes, two scan 
events were carried out, full-scan (100-2000) and ion-trap MS/MS of the most intense ion 
from the parent mass list utilizing CID with a normalized collision energy of 30. External 
instrument calibration was performed using an LTQ ESI positive-ion calibration solution 
consisting of caffeine (20 µg/mL), MRFA (1 µg/mL) and Ultramark 1621 (0.001%) in an 
aqueous solution of CH3CN (50%), MeOH (25%) and acetic acid (1%). For the ESI 
negative-ion calibration, sodium dodecyl sulfate (2.9 µg/mL) and sodium taurocholate 
(5.4 µg/mL) were added to the LTQ ESI calibration solution instead of caffeine and 
MRFA. Thermo Scientific Xcalibur 2.1 software was used for instrument control and 
data analysis. UPLC was carried out on a Waters Acquity system [using a BEH C18 (2.1 
× 50 mm, 1.7 µm) column (Waters Corp., Milford, MA, USA) equilibrated at 40 °C]. A 
mobile phase consisting of CH3CN-H2O (acidified with 0.1% formic acid) was used, 
starting with 15:85 then increasing linearly to 100% CH3CN within 8 min, holding for 
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1.5 min and then returning to the starting conditions within 0.5 min. An Acquity UPLC 
photodiode array detector was used to acquire PDA spectra, which were collected from 
200-500 nm with 4 nm resolution. 
Reference Standards. Secondary metabolites were isolated and characterized from 
the Mycosynthetix Inc. library of filamentous fungi, as described previously.17,19-
22,62,63,82,105,291 
Extraction Procedure. Small-scale cultures of fungi were grown on a solid, grain-
based medium in 250 mL Erlermeyer flasks, as described in detail previously.19,62,63 To 
each flask were added 60 mL of 1:1 MeOH-CHCl3. The culture was chopped with a 
spatula and shaken overnight (~16 h; at ∼100 rpm) at rt. Each sample was filtered using 
vacuum, and the remaining residues were washed with small volumes of 1:1 MeOH-
CHCl3. To the filtrate, 90 mL CHCl3 and 150 mL H2O were added; the mixture was 
stirred for 2 h, and then transferred into a separatory funnel. The bottom layer was drawn 
off into a round-bottomed flask and evaporated to dryness. The dried organic extract was 
re-constituted in 100 mL of 1:1 MeOH-CH3CN and 100 mL of hexanes. The biphasic 
solution was stirred for 1 h and then transferred to a separatory funnel. The MeOH-
CH3CN layer was drawn off and evaporated to dryness under vacuum. This defatted 
material was then submitted for cytotoxic activity evaluation using a set of three cancer 
cell lines, as described previously.50,265 Extracts displaying potent cytotoxic activities 
(i.e., less than 20% survival when tested at 20 µg/mL) were dereplicated. A sub-
milligram aliquot of the bioactive extracts was used for dereplication analysis by 
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dissolving the extract in equal volumes of MeOH and dioxane to obtain a final 
concentration of 2 mg/mL in a total volume of 150 µL. 
Data Analysis. Data from 172 fungal secondary metabolites are in the Supporting 
Information (Table 38), which lists the metabolites, molecular formula, retention time, 
UV-absorption maxima, high-resolution full-scan mass spectra, and MS-MS data (top ten 
most intense peaks), utilizing both the positive- and negative-ionization modes. ACD MS 
Manager with add-in software IntelliXtract, Advanced Chemistry Development, Inc. 
(Toronto, Canada), was used for the primary analysis of the LC-MS data. 
Cytotoxicity Assay. The cytotoxicity measurements against the MCF-746 human 
breast carcinoma (Barbara A. Karmanos Cancer Center), NCI-H46047 human large cell 
lung carcinoma (HTB-177, American Type Culture Collection (ATCC), and SF-26848 
human astrocytoma (NCI Developmental Therapeutics Program) cell lines were 
performed as described previously.50,265 
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Supporting Information 
 
Figure 119. (+)-ESI TIC and SIC (m/z: 355, 508, 631, 325, 519, 1978, 654, 374, 357, and 
429) of a mixture of ten standard compounds. 
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Figure 120. Structures of the ten compounds analyzed in figure 119. 
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Table 38. Chemical Structures, Chemical Formulas, Retention Times, UV Absorption Maxima, (+)/(-)-ESI HRMS, and 
(+)/(-)-ESI CID MS/MS of 172 Fungal Secondary Metabolites 
 
# chemical structure and shemical formula Rt (min) 
UV 
(nm) 
Positive ionization mode Negative ionization mode 
[M+H]+ MS/MS [M-H]- MS/MS 
1.  
OH OH
O
O
OH
O
O
O
HO
H3CO2C
OH
O  
Acremoxanthone D (C33H26O13) 
4.91 
228, 
278, 
289 
363 
631.1429 
(-2.8) 
543.18, 571.13 
554.20, 525.21 
553.16, 497.21 
493.12, 509.20 
477.12, 387.19 
629.1292 
(-1.4) 
567.16, 507.17 
445.15, 569.13 
385.15, 492.13 
493.18, 357.10 
611.20, 463.10 
2.  
O
HH
O
O O
 
Trichodermin (C17H24O4) 
4.57 213 293.1747 (0.0) 
233.13, 215.12 
187.04, 168.96 
108.91, 275.05 
197.08, 124.98 
189.12, 205.09 
ND ND 
3.  
O
HH
O
O O
O
OH
 
Harzianum A (C23H28O6) 
4.25 306 401.1952 (-1.7) 
215.18, 233.16 
383.14, 187.06 
151.00, 159.11 
197.12, 132.97 
145.06, 171.10 
399.1813 
(-0.1) 
231.07, 248.76 
213.25, 149.07 
123.73, 337.35 
249.58, 265.41 
194.85, 369.14 
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4.  
OH O
O
O
OH
OH
O
HO
OH
O
O
OH
O  
Acremonidin C (C33H26O13) 
5.20 
226, 
280, 
345, 
434 
631.1426 
(-3.1) 
547.16, 459.14 
487.15, 571.19 
543.14, 447.17 
387.13, 359.16 
599.16, 553.21 
629.1286 
(-2.3) 
597.18, 461.16 
401.09, 383.09 
357.18, 435.23 
373.17, 553.26 
493.17, 331.16 
5.  
HO
O O H
H
 
Ergosterol peroxide (C28H44O3) 
8.73 226 429.3365 (+0.5) 
411.36, 393.33 
287.17, 269.26 
305.14, 191.09 
267.17, 177.10 
375.32, 341.39 
ND ND 
6.  
HO
O O H
 
5,8-Epidioxyergosta-6,9(11),22-trien-3-ol 
(C28H42O3) 
7.90 244 427.3110 (-1.6) 
409.31, 285.15 
303.19, 391.39 
339.23, 381.39 
267.18, 175.12 
363.32, 147.09 
ND ND 
7.  
O OH
HO
OO
OH  
Moniliphenone (C16H14O6) 
3.62 215, 283 
303.0865 
(+0.7) 
179.00, 271.08 
150.97, 146.89 
179.98, 284.16 
259.84, 285.15 
302.19, 183.24 
301.0720 
(+0.7) 
269.04, 283.19 
148.96, 225.03 
256.87, 150.76 
122.96, 104.82 
241.03, 211.02 
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8.  
N
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
OH2N
O
O
O
O
O
O O
O
O
O
O
O
HN
O
O
N
H O
H
N
O
N
H O
H
N
O OH
H2N O
O
N
H
OH
O
H
N
O
 
 
Alamethicin II (C93H152N22O25) 
6.58 210 1978.133 (-2.0) 
934.81 
764.93 
950.41 
948.92 
1203.09 
1959.34 
752.58 
1205.46 
1206.28 
949.75 
1976.117 
(-2.6) 
1849.16 
1440.77 
773.41 1568.03 
1412.95 
1327.86 
1958.19 
1667.01 
1848.52 
1425.92 
9.  
O
H
N
N
H
O H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
OH2N
O
O
O
O
O
O O
O
O
O
O
O
HN
O
O
N
H O
H
N
O
N
H O
H
N
O OH
H2N O
O
N
H
O
H
 
 
Longibranchin III (C91H150N22O25) 
6.16 209 1952.116 (-2.7) 
1932.67 
922.42 
1177.72 
919.79 
823.55 
1933.51 
836.82 
924.43 
738.34 
774.65 
1950.104 
(-1.6) 
1932.22 787.52 
1541.78 
1513.92 
1422.84 
1667.16 
1414.89 
1523.87 
1931.44 
1511.01 
10.  
OH OH
O
O
OH
O
O
OH
HO
O
O
O
 
Acremoxanthone C (C33H26O12) 
6.22 
222, 
272, 
365 
615.1481 
(-2.7) 
555.21, 495.18 
467.20, 523.15 
387.12, 195.05 
527.18, 583.19 
477.17, 505.21 
613.1343 
(-1.4) 
581.13, 477.28 
385.10, 551.17 
445.07, 553.20 
521.06, 491.09 
537.21, 359.17 
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11.  
O
O
O
O
OH
 
Obionin B (C21H24O5) 
7.47 
241, 
298, 
465 
357.1692 
(-1.2) 
339.25, 259.03 
357.28, 311.18 
329.20, 273.14 
245.04, 342.19 
258.09, 231.13 
355.1558 
(+2.0) 
341.15, 340.38 
355.17, 256.00 
270.21, 257.10 
327.22, 312.04 
313.17, 354.50 
12.  
HO
OH
O
O O
O O
O
O
O
 
Thielavin Q (C32H36O10) 
6.87 222, 274 
581.2368 
(-2.2) 
548.65, 165.05 
417.27, 357.02 
193.01, 547.61 
563.31, 562.36 
581.57, 549.61 
579.2232 
(-0.6) 
223.07, 414.86 
162.98, 414.21 
207.93, 176.05 
165.05, 491.30 
178.01, 535.83 
13.  
O
OOH
O
OH
OH
OH  
Zeaenol (C19H24O7) 
3.72 
237, 
270, 
311 
365.1595 
(0.0) 
285.09, 311.28 
329.25, 267.18 
219.09, 293.15 
237.06, 175.08 
347.16, 243.17 
363.1449 
(0.0) 
188.95, 207.04 
162.92, 173.94 
249.15, 191.02 
235.07, 161.04 
205.11, 187.08 
14.  
O
OOH
O
OH
OH
OH  
7-epi-Zeaenol (C19H24O7) 
3.97 
237, 
270, 
311 
ND ND 363.1442 (-1.9) 
206.98, 89.07 
163.04, 48.01 
249.09, 73.98 
191.15, 35.09 
230.96, 04.98 
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15.  O
OOH
O
O
HO
OH  
LL-Z1640-1 (C19H24O7) 
4.26 
232, 
270, 
311 
365.1590 
(-1.3) 
347.18, 29.27 
311.27, 37.00 
219.00, 28.99 
285.18, 75.00 
251.11, 01.19  
363.1450 
(+0.2) 
189.01, 45.07 
235.02, 06.93 
217.06, 74.00 
261.05, 05.09 
319.14, 01.29 
16.  O
OOH
O
O
HO
OHO  
Hypothemycin (C19H22O8) 
3.93 
230, 
265, 
306 
379.1380 
(-2.0) 
253.04, 235.08 
217.14, 329.13 
347.13, 207.08 
249.07, 303.07 
311.17, 191.10 
377.1247 
(+1.4) 
251.05, 359.05 
207.06, 178.99 
305.13, 341.19 
205.06, 232.90 
315.12, 193.00 
17.  
O
OOH
O OH
OH  
5,6-Dihydro-9-deoxyzeaenol (C19H26O6) 
4.71 
228, 
269, 
309 
351.1803 
(+0.3) 
333.16, 315.12 
297.11, 289.22 
271.16, 263.14 
279.13, 245.22 
231.19, 249.08 
349.1657 
(+0.1) 
303.21, 285.20 
302.24, 301.16 
259.13, 332.16 
329.15, 269.30 
347.27, 235.12 
18.  O
OOH
O
O
HO
OH  
5Z-7-Oxozeaenol (C19H22O7) 
4.20 
228, 
272, 
313 
363.1435 
(-0.9) 
345.05, 327.19 
237.01, 219.13 
309.22, 283.17 
319.12, 301.20 
299.25, 281.09 
361.1290 
(-0.7) 
235.01, 191.08 
343.15, 189.04 
217.06, 124.88 
299.16, 317.14 
273.13, 207.18 
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19.  O
OOH
HO
O
HO
OH  
15-O-Desmethyl-5Z-7-oxozeaenol 
(C18H20O7) 
3.42 
233, 
274, 
313 
ND ND 347.1129 (+1.1) 
220.93, 202.99 
176.98, 174.98 
329.07, 284.99 
303.18, 227.01 
311.17, 243.03 
20.  
OH OH
O
O
OH
OH
O
HO
OH
O
O
O  
Acremonidin A (C33H26O12) 
5.59 
217, 
278, 
287, 
359 
615.1473 
(-3.8) 
421.19, 195.00 
583.19, 333.16 
361.23, 523.23 
447.18, 555.24 
387.23, 495.24 
613.1337 
(-2.4) 
581.18, 445.17 
595.27, 521.19 
385.16, 477.24 
537.13, 419.15 
503.19, 563.37 
21.  
N
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
OH2N
O
O
O
O
O
O O
O
O
O
O
O
HN
O
O
N
H O
H
N
O
N
H O
H
N
O NH2
H2N O
O
N
H
OH
O
H
N
O
 
 
Atroviridin B (C93H153N23O24) 
6.31 211 1977.150 (-1.7) 
1008.80 
949.36 
1009.60 
1205.57 
1747.43 
1006.63 
1332.12 
771.44 
812.59 
1120.45 
1975.135 
(-1.8) 
1848.16 
1847.55 
786.59 1509.94 
1665.82 
1830.44 
1421.91 998.63 
1310.65 
1801.09 
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22.  
N
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
OH2N
O
O
O
O
O
O O
O
O
O
O
O
HN
O
O
N
H O
H
N
O
N
H O
H
N
O NH2
H2N O
O
N
H
OH
O
H
N
O
 
 
 
Polysporin B (C93H153N23O24) 
6.46 210 1977.151 (-0.9) 
949.10 
949.91 
750.45 
823.92 
765.90 
1204.52 
752.50 
935.66 
1848.75 
773.11 
1975.134 
(-2.2) 
1848.06 
772.50 
1848.80 
1666.00 
1830.22 
1046.68 
1212.17 
1649.47 
1956.35 
1424.98 
23.  
O
OOH
O
O
OH
OH  
5E-7-Oxozeaenol (C19H22O7) 
4.02 
228 
270 
311 
363.1433 
(-1.6) 
345.18, 327.18 
237.10, 219.09 
309.12, 301.16 
265.15, 283.19 
233.11, 275.12 
361.1293 
(+0.1) 
234.99, 191.09 
189.04, 343.19 
217.09, 125.03 
317.24, 299.12 
261.15, 273.08 
24.  
O
H
N
N
H
O H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
OH2N
O
O
O
O
O
O O
O
O
O
O
O
HN
O
O
N
H O
H
N
O
N
H O
H
N
O NH2
H2N O
O
N
H
O
H
 
Trichokonin VI (C90H149N23O24) 
5.87 210 1937.119 (-1.7) 
1657.07 
726.46 
922.29 
756.39 
1180.44 
1178.94 
1298.93 
923.33 
1586.79 
1564.66 
1935.102 
(-2.5) 
772.43 1917.19 
1651.98 
1495.80 
1296.80 
1808.14 
1737.05 
1407.86 
1581.23 
1161.67 
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25.  
O
H O
HO
OHO
H
HO
 
Epolone A (C32H40O6) 
6.42 
206 
220 
254 
363 
521.2882 
(-3.1) 
367.26, 503.39 
385.29, 201.19 
337.26, 164.93 
177.11, 245.16 
203.07, 189.00 
519.2751 
(-0.2) 
477.25, 383.31 
478.36, 459.46 
501.27, 164.01 
479.56, 419.06 
182.00, 351.47 
26.  O
HO
O
H O
HO
OHO
H
 
Pycnidione (C33H40O7) 
5.95 
220
, 
254
, 
363 
549.2829 
(-3.2) 
531.39, 485.31 
385.26, 513.41 
367.20, 365.31 
383.26, 201.02 
397.42, 503.40 
547.2694 
(-1.2) 
162.99, 505.35 
383.28, 487.39 
503.36, 529.28 
463.32, 461.41 
519.35, 469.32 
27.  
O
H
N
N
H
O H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
OH2N
O
O
O
O
O
O O
O
O
O
O
O
HN
O
O
N
H O
H
N
O
N
H O
H
N
O NH2
H2N O
O
N
H
OH
 
Trichokonin VII (C91H151N23O24) 
6.01 210 1951.134 (-1.8) 
724.56 
908.17 
1461.13 
 1092.90 
687.73 
823.14 
1844.45 
1933.36 
772.75 
1906.27 
1949.117 
(-3.1) 
786.56 1931.13 
1665.97 
1509.98 
1822.11 
1310.83 
1751.15 
1913.04 
1161.58 
1906.97 
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28.  
O
O
O
O
OH
OH
OH
HO
HO
OH  
Cephalochromin (C28H22O10) 
5.45 
230 
270 
293 
328 
417 
519.1267 
(-3.6) 
260.09, 501.21 
477.23, 459.17 
519.24, 473.13 
245.02, 476.34 
218.04, 219.01 
517.1138 
(-0.4) 
499.12, 517.14 
473.29, 258.04 
475.15, 457.23 
449.17, 500.23 
474.17, 431.27 
29.  
N
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
OH2N
O
O
O
O
O
O O
O
O
O
O
O
HN
O
O
N
H O
H
N
O
N
H O
H
N
O NH2
H2N O
O
N
H
OH
O
H
N
O
 
 
Alamethicin F50 (C92H151N23O24) 
6.15 217 1963.134 (-1.6) 
949.25 
1120.19 
752.50 
751.32 
950.26 
772.65 
950.87 
849.58 
1012.56 
1006.82 
1961.119 
(-1.9) 
1834.13 772.55 
1651.85 
1943.13 
1424.79 
1495.89 
1816.28 
1900.07 
1832.65 
1835.08 
30.  
N
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
OH2N
O
O
O
O
O
O O
O
O
O
O
O
HN
O
O
N
H O
H
N
O
N
H O
H
N
O NH2
H2N O
O
N
H
OH
O
H
N
O
 
 
Atroviridin D (C91H149N23O24) 
5.27 217 1949.118 (-1.8) 
720.23 
1016.80 
1090.70 
1192.25 
1551.42 
580.30 
739.55 
1947.104 
(-1.9) 
772.49 1834.02 
1929.20 
1496.03 
1652.13 
1296.88 
1173.65 
1407.82 
1581.10 651.41 
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31.  
N
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
OH2N
O
O
O
O
O
O O
O
O
O
O
O
HN
O
O
N
H O
H
N
O
N
H O
H
N
O NH2
H2N O
O
N
H
OH
O
H
N
O
OH
 
 
Atroviridin E (C92H151N23O25) 
 
5.35 215 1979.130 (-1.3) 
987.49 
988.14 
988.93 
1009.45 
1010.91 
1010.27 
1011.88 
623.04 
1001.74 
1000.73 
1977.113 
(-2.4) 
1032.40 
1849.36 
1685.33 
1496.26 
1903.04 
1061.79 
1800.68 
1820.18 
1795.63 
1737.30 
32.  
N
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
OH2N
O
O
O
O
O
O O
O
O
O
O
O
HN
O
O
N
H O
H
N
O
N
H O
H
N
O NH2
H2N O
O
N
H
OH
O
H
N
O
OH
  
 
Atroviridin F (C93H153N23O25) 
 
5.51 210 1993.148 (-0.2) 
1002.30 
1010.24 
665.31 
928.88 
1710.32 
1483.93 
933.94 
1174.82 
1104.70 
1276.67 
1991.138 
(+2.3) 
1535.84 
1919.80 
1187.93 
1115.79 
33.  
N
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
OH2N
O
O
O
O
O
O O
O
O
O
O
O
HN
O
O
N
H O
H
N
O
N
H O
H
N
O NH2
H2N O
O
N
H
OH
O
H
N
O
  
 
Atroviridin G (C91H149N23O24) 
 
5.55 217 1949.119 (-1.4) 
920.33 
1175.79 
1018.75 
1334.09 
1635.51 
1611.10 
921.22 
1573.14 
795.61 
972.47 
1947.102 
(-2.6) 
1820.12 
1819.52 
1802.04 772.46 
1482.02 
1911.05 
1322.50 
1567.10 
1296.50 
1480.89 
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34.  
N
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
OH2N
O
O
O
O
O
O O
O
O
O
O
O
HN
O
O
N
H O
H
N
O
N
H O
H
N
O NH2
H2N O
O
N
H
OH
O
H
N
O
OH
  
 
Atroviridin H (C91H149N23O25) 
6.25 217 1965.121 (+2.2) 
951.65 
767.41 
952.69 
766.55 
1207.64 
866.30 
867.39 
1206.61 
950.37 
865.36 
1963.105 
(+1.3) 
1835.18 773.56 
1427.01 
1944.18 
1836.29 
1399.03 
1313.84 
1408.86 
1553.87 
1834.49 
35.  
N
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
OH2N
O
O
O
O
O
O O
O
O
O
O
O
HN
O
O
N
H O
H
N
O
N
H O
H
N
O NH2
H2N O
O
N
H
OH
O
H
N
O
  
 
Atroviridin I (C91H149N23O24) 
5.98 217 1949.122 (-0.1) 
923.37 
921.46 
751.22 
754.46 
948.45 
1559.24 
1009.45 
936.56 
752.66 
1175.47 
1947.104 
(-1.9) 
1820.18 772.63 
1637.75 
1393.90 
637.41 
754.55 
1801.87 933.88 
1802.49 
1929.50 
36.  
N
H
H
N
N
H
H
N
N
H
OO
O
O
O O
OH
N
O
H
N
O
N
H O
H
N
O
N
O
NH
OH
  
 
Trichobrachin D-I (C55H97N11O13) 
6.04 220 1120.730 (-3.8) 
920.58 
512.31 
609.43 
921.58 
1120.73 
610.43 
 513.31 
1121.73 
922.58  
201.16 
1118.718 
(-1.7) 
1088.78 
1100.73 
1089.53 
1046.47 
1109.49 
1047.08 
1058.74 
1071.04 
1076.45 
1101.51 
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37.  
N
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
H
H
N
N
OH2N
O
O
O
O
O
O O
O
O
O
O
O
HN
O
O
N
H O
H
N
O
N
H O
H
N
O OH
H2N O
O
N
H
OH
O
H
N
O
  
 
Atroviridin J (C94H154N22O25) 
6.75 219 1992.150 (-1.4) 
948.23 
1203.45 
764.30 
863.19 
770.48 
1968.08 
1972.89 
877.11 
962.47 
756.66 
1990.134 
(-2.2) 
1863.14 
1454.96 
787.52 1426.88 
1582.04 
1327.88 
1862.52 
1972.16 
1681.03 
1422.89 
38.  
N
O
N
O
N
O
O
O
O
O
O
O
 
Enniatin D (C34H59N3O9) 
6.95 211 654.4293 (-4.7) 
196.06, 541.26 
210.09, 214.04 
441.23, 228.07 
626.34, 427.29 
328.30, 527.48 
652.4167 
(-1.8) 
229.99, 457.46 
439.15, 212.15 
425.28, 244.21 
226.20, 421.19 
339.28, 407.34 
39.  
O
N
O
O  
1,4-Perhydrooxazine-2,5-dione II 
(C12H21NO3) 
7.44 211 228.1605 (4.7) 
200.09, 99.99 
114.03, 156.23 
146.07, 210.27 
175.29, 228.27 
153.99, 159.93 
226.1451 
(+0.9) 
182.10, 183.00 
144.13, 184.05 
164.03, 208.13 
112.09, 154.11 
128.03, 197.32 
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40.  
N
O
N
O
N
O
O
O
O
O
O
O
 
 
Enniatin E1 (C35H61N3O9) 
 
N
O
N
O
N
O
O
O
O
O
O
O
 
 
Enniatin E2 (C35H61N3O9) 
7.17 206 668.4459 (-3.2) 
210.12, 228.10 
541.36, 196.09 
555.34, 214.04 
441.25, 640.35 
455.36, 328.22 
666.4336 
(+0.1) 
226.18, 439.34 
244.13, 230.13 
212.03, 453.22 
421.40, 435.44 
333.04, 236.16 
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41.  
 
N
O
N
O
N
O
O
O
O
O
O
O
 
Enniatin I (C35H61N3O9) 
7.22 211 668.4449 (-4.6) 
210.13, 541.35 
228.14, 196.12 
214.11, 441.28 
555.35, 640.41 
455.29, 328.21 
666.4335 
(0.0) 
226.18, 439.38 
244.19, 453.45 
212.18, 230.08 
421.37, 435.23 
339.44, 223.84 
42.  
 
N
O
N
O
N
O
O
O
O
O
O
O
 
Enniatin B1 (C34H59N3O9) 
7.01 211 654.4304 (-3.0) 
210.08, 196.09 
214.13, 541.45 
527.39, 228.09 
441.23, 626.45 
427.28, 314.16 
652.4178 
(-0.1) 
439.37, 212.01 
230.03, 425.27 
226.20, 244.12 
421.39, 438.61 
339.43, 407.27 
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43.  
O
NH
O
N
H
O
HN
OH
O
O
O
O
 
Roseotoxin S (C23H39N3O8) 
4.12 220 486.2796 (-2.8) 
468.34, 458.30 
440.35, 385.19 
287.18, 414.32 
273.18, 357.16 
333.26, 314.15 
484.2664 
(-0.2) 
440.12, 245.06 
289.21, 227.21 
440.77, 270.86 
466.34, 287.38 
301.38, 269.18 
44.  
O
O
HO
O
O
H H
 
Trichothecinol B (C19H26O5) 
4.03 206 335.1853 (+0.1) 
231.06, 195.09 
213.06, 249.08 
185.05, 125.05 
123.06, 201.17 
317.21, 171.08 
333.1710 
(+1.0) 
289.19, 286.96 
303.30, 318.13 
331.33, 226.95 
253.36, 248.81 
297.38, 265.09 
45.  
N
H
O
N
O
OO
O
O
H
N
OH
O
HN O
 
Trichodepsipeptide A (C36H56N4O9) 
6.41 224 689.4110 (-1.4) 
671.41, 661.44 
446.29, 576.35 
489.44, 428.35 
544.36, 421.38 
449.20, 371.29 
687.3984 
(+1.3) 
657.39, 518.22 
656.73, 291.21 
619.46, 611.42 
601.38, 643.31 
587.48, 307.35 
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46.  
O
O
O
O
O
H H
 
Crotocin (C19H24O5) 
4.24 215 333.1699 (1.0) 
247.10, 229.09 
201.09, 173.09 
211.06, 123.04 
187.04, 183.12 
159.01, 124.98 
ND ND 
47.  
HN
O
N
O
O
NH
O
O
O
N O
O
OH  
Guangomide A (C31H46N4O9) 
5.49 217 619.3325 (-2.1) 
362.18, 258.11 
445.20, 601.30 
344.19, 544.28 
276.18, 516.27 
473.38, 206.05 
617.3184 
(-1.4) 
461.21, 448.27 
274.17, 292.30 
185.93, 430.24 
204.10, 256.19 
217.04, 403.07 
48.  
O
HO
O
OHHH
O
O
HO  
Neosolaniol (C19H26O8) 
1.71 200 383.1703 (+0.6) 
365.33, 355.37 
382.51, 245.18 
340.74, 335.32 
305.14, 323.00 
215.34, 383.33 
ND ND 
49.  
OH
O
OH
O
O
O
 
Trichothosporon A (C22H30O7) 
3.24 226 407.2061 (-0.9) 
389.17, 371.24 
375.05, 353.20 
233.21, 303.18 
347.20, 247.22 
357.14, 379.22 
405.1924 
(+1.2) 
361.30, 373.03 
387.01, 390.26 
377.26, 262.47 
346.04, 241.19 
347.37, 316.90 
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50.  
O
O
OH
OHHH
O
O
O
O  
HT-2 Toxin (C22H32O8) 
3.90 222 425.2170 (+0.1) 
263.05, 245.08 
407.35, 408.29 
325.29, 227.10 
323.19, 199.17 
305.19, 215.06 
423.2022 
(-0.5) 
291.24, 355.16 
387.15, 393.04 
377.22, 278.55 
267.20, 404.90 
305.90, 395.79 
51.  
O O
O
H
OH  
Pestalotin (C11H18O4) 
3.20 237 215.1278 (0.0) 
197.05, 153.11 
183.13, 137.08 
141.06, 171.06 
165.13, 151.10 
169.02, 139.09 
213.1135 
(+1.2) 
169.08, 112.88 
151.10, 197.79 
181.05, 172.09 
139.04, 153.00 
185.97, 148.84 
52.  01008-35-5* 3.65 254, 359 
293.1391 
(2.5) 
275.14, 229.23 
257.18, 261.22 
191.13, 135.00 
215.02, 247.22 
233.27, 263.25 
291.1246 
(+2.7) 
249.00, 205.06 
163.00, 176.99 
175.06, 204.03 
231.97, 164.96 
243.18, 273.11 
53.   01008-34-4* 
3.26 254, 359 
293.1379 
(-1.4) 
275.22, 229.23 
191.12, 135.04 
257.16, 215.14 
107.07, 175.10 
177.15, 201.22 
291.1241 
(+1.1) 
249.14, 205.08 
162.97, 243.09 
263.20, 151.01 
135.03, 204.07 
175.01, 176.87 
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54.  
O
O
N
O
NH
O
NH
O
O
O
O
HN
OH  
Trichodepsipeptide B (C35H54N4O9) 
5.00 219 675.3963 (-0.1) 
657.39, 647.44 
432.29, 576.42 
421.35, 414.29 
449.29, 489.40 
530.29, 674.45 
673.3812 
(-0.9) 
643.36, 645.42 
504.37, 291.09 
655.23, 641.47 
485.66, 486.27 
559.42, 629.47 
55.  
O
HO
O
H
O
O
OH
H
 
Synthetic intermediate (C19H26O6) 
2.87 211 351.1710 (-0.6) 
247.10, 229.07 
217.11, 211.08 
201.16, 187.05 
333.15, 265.09 
173.08, 199.10 
ND ND 
56.  
O
OH
 
2-Hydroxyacoronene (C15H24O2)  
4.02 244 237.1846 (-1.5) 
219.09, 201.06 
147.04, 161.06 
151.02, 191.04 
163.05, 177.21 
165.05, 135.04 
235.1709 
(+2.5) 
217.18, 191.06 
235.04, 207.30 
192.00, 189.08 
149.00, 150.86 
175.01, 166.82 
 
 
286 
57.  
O OH
OH
 
Pughiinin A (C23H32O3) 
5.15 226, 282 
357.2422 
(-0.6) 
136.93, 215.13 
339.28, 203.14 
173.05, 159.12 
297.19, 145.03 
146.98, 191.10 
355.2286 
(+1.9) 
355.20, 313.08 
311.19, 134.90 
341.18, 244.98 
337.22, 327.19 
285.84, 269.04 
58.  
HN
N
N
O
H
HO
HN
O
N
O
N
O
HN
O
O
H
O
 
Ternatin (C37H67N7O8) 
5.72 215 738.5102 (-3.0) 
411.34, 720.51 
666.41, 326.20 
295.23, 395.30 
681.51, 635.46 
413.20, 710.54 
736.4969 
(-1.3) 
664.49, 511.46 
455.35, 665.23 
466.11, 493.43 
355.50, 357.34 
448.55, 466.71 
59.  
O
N
O
O  
1,4-Perhydrooxazine-2,5-dione I 
(C11H19NO3) 
6.75 217 214.1435 (-1.4) 
186.06, 85.96 
157.97, 140.94 
168.14, 172.04 
179.17 
212.1292 
(+0.1) 
167.98, 129.88 
169.18, 194.16 
111.79, 170.12 
170.96, 197.96 
150.12, 128.07 
60.  
O
O
O
O
O
H
 
Trichothecin (C19H24O5) 
4.60 226 
333.1698
9 
(+0.7) 
211.08, 229.09 
247.13, 201.08 
186.98, 203.09 
173.13, 175.10 
158.95, 125.03 
331.1553
3 
(+0.7) 
287.25, 263.06 
269.34, 313.13 
299.11, 271.15 
285.14, 277.34 
303.75, 258.90 
 
 
287 
61.  
N O
OH
O
H
 
CJ-15,696 (C19H19NO3) 
3.91 204, 233 
310.1433 
(-1.3) 
292.17, 268.18 
282.15, 200.07 
238.11, 214.07 
188.03, 254.11 
242.15, 240.17 
308.1288 
(-1.3) 
280.11, 308.18 
293.12, 236.21 
266.16, 262.17 
250.12, 198.06 
251.05, 281.17 
62.  
N
O
N
O
NH
O
O
O O
N
O
HN
 
T987A (C41H57N5O7) 
5.84 224 732.4310 (-2.7) 
619.36, 591.43 
704.43, 688.54 
520.33, 581.48 
458.29, 472.42 
633.46, 575.54 
730.4175 
(-1.3) 
631.41, 420.32 
501.38, 520.38 
402.20, 545.44 
273.08, 259.14 
547.39, 519.38 
63.  
 
01009-22-3P* 
 
3.22 237 215.1282 (+1.9) 
197.07, 153.09 
183.10, 137.07 
169.09, 151.06 
165.14, 141.06 
179.16, 119.11 
213.1136 
(+1.7) 
169.06, 198.08 
112.92, 150.93 
180.97, 141.40 
136.78, 82.97 
212.89, 170.04 
64.  
N
OH
O
OH
 
Pyridoxatin (C15H21NO3) 
4.55 213, 289 
264.1598 
(+1.4) 
139.93, 153.92 
167.97, 182.03 
180.03, 194.07 
208.03, 196.07 
166.04, 127.98 
262.1443 
(-2.2) 
234.09, 218.10 
243.98, 262.17 
242.20, 200.19 
124.98, 245.14 
216.18, 175.14 
 
 
288 
65.  01007-114-3* 6.01 219 338.2110 (-1.3) 
216.04, 230.09 
202.15, 189.95 
258.17, 256.13 
244.08, 282.14 
268.25, 242.14 
ND ND 
66.  
OH3C
H
CH3
O
H
O
O
HO
O
OO
H
 
Roridin E (C29H38O8) 
5.32 222, 263 
515.2634 
(-1.0) 
361.21, 231.11 
249.13, 497.35 
331.25, 213.08 
343.23, 185.02 
203.11, 159.11 
513.2496 
(+0.3) 
359.23, 402.67 
469.45, 385.42 
483.30, 451.41 
201.13, 265.11 
433.69, 429.01 
67.  
OHO
O
HO
HO
 
Ramiferin (C31H40O5) 
6.09 224, 282 
493.2941 
(-1.6) 
339.19, 475.31 
351.38, 369.33 
215.24, 189.03 
175.10, 203.20 
227.13, 357.35 
491.2798 
(-1.0) 
473.43, 445.27 
447.38, 474.30 
344.18, 491.15 
326.24, 455.41 
227.03, 421.59 
 
 
289 
68.  
N O
OH
OH
 
CJ-16,169 (C19H21NO3) 
4.19 206, 232 
312.1593 
(-0.5) 
294.19, 282.25 
200.07, 254.11 
214.11, 188.05 
240.15, 228.08 
270.19, 268.17 
310.1445 
(-1.2) 
280.15, 310.20 
308.13, 281.23 
252.11, 209.13 
236.18, 198.05 
262.07, 309.21 
69.  
OH3C
H
CH3
O
H
O
O
O
O
OO
HO
 
Verrucarin A (C27H34O9) 
4.49 226, 259 
503.2267 
(-1.7) 
457.12, 373.16 
249.10, 231.18 
333.29, 390.90 
213.09, 439.25 
185.12, 195.14 
501.2133 
(+0.6) 
253.17, 457.35 
473.30, 371.34 
225.08, 483.25 
209.16, 353.19 
335.13, 191.13 
70.  
O
O
O O
O
O
HO  
Purpactin A (C23H26O7) 
5.85 230, 282 
415.1754 
(+0.5) NF 
413.1606 
(+0.1) 
309.07, 353.15 
294.28, 323.17 
321.14, 134.88 
278.15, 191.12 
279.14, 293.21 
 
 
290 
71.  O
OH
HO
OH
OH
OH
O
 
Dihydroquercetin (C15H12O7) 
2.12 228, 289 
305.0660 
(+1.2) 
258.99, 287.01 
152.93, 194.94 
148.99, 231.02 
179.07, 122.88 
166.92, 161.07 
303.0508 
(-0.7) 
285.08, 176.90 
124.80, 275.06 
258.99, 179.00 
274.30, 241.09 
217.05, 214.83 
72.  
N
O
N
O
O O
O
O
N
OH
H
O
NO
H
CH3
H
OH
 
Hirsutatin A (C34H52N4O10) 
5.50 217 677.3739 (-2.5) 
659.37, 641.42 
434.27, 649.49 
514.28, 532.28 
489.22, 416.30 
421.33, 398.30 
675.3612 
(+0.2) 
645.31, 506.34 
505.25, 488.00 
444.11, 470.23 
291.25, 631.48 
613.37, 601.44 
73.  
OH OH
OH
HO
H
 
Aphidicolin (C20H34O4) 
3.62 ND 
321.2427 
(+0.8) 
(M+H-
H2O) 
222.08, 321.27 
295.29, 169.08 
339.37, 178.20 
322.40, 120.98 
269.28, 216.17 
ND ND 
 
 
291 
74.  HN
OH
OOHO
O
O
 
Cytochalasin D; Zygosporin A 
(C30H37NO6) 
4.33 220, 285 
508.2689 
(-1.0) 
430.24, 490.15 
448.25, 412.34 
388.44, 406.32 
370.27, 472.29 
384.42, 402.38 
506.2552 
(+0.8) 
348.33, 446.28 
366.27, 488.15 
428.23, 402.99 
385.26, 464.40 
462.34, 287.10 
75.  HN
OOHO
O
O
O
O
 
19,20-epoxycytochalasin Q (C30H37NO7) 
4.71 212 524.2629 (-2.7) 
404.26, 428.29 
446.28, 390.27 
386.22, 464.39 
368.17, 376.30 
418.26, 358.34 
522.2501 
(+0.8) 
462.37, 422.23 
480.36, 504.20 
444.28, 284.23 
401.30, 266.10 
404.21, 419.45 
76.  
O
OH
H
OH
O
H  
Brefeldin A (C16H24O4) 
3.71 228 281.1753 (+2.1) 
245.08, 263.11 
199.08, 217.16 
227.13, 163.04 
185.03, 132.98 
189.04, 235.12 
279.1605 
(+1.1) 
235.13, 261.12 
161.23, 251.17 
280.00, 252.07 
96.85, 190.99 
173.20, 138.84 
77.  
O
O
O
O
 
PC3 (C11H16O4) 
3.34 
3.67 230 
213.1126 
(+2.3) 
213.09, 110.88 
167.04, 195.10 
84.89, 138.93 
152.98, 124.99 
108.94, 106.94 
211.0976 
(+0.1) 
167.13, 183.93 
181.02, 211.08 
137.13, 178.84 
183.12, 96.85 
112.93, 192.84 
 
 
292 
78.  
N
O
O
HO
 
Leporin B (C22H25NO3) 
6.10 220, 241 
352.1900 
(-2.0) 
216.01, 230.09 
244.08, 296.17 
270.11, 335.20 
258.14, 282.13 
272.11, 278.11 
350.1762 
(+0.1) 
350.12, 115.88 
306.22, 197.97 
228.03, 332.30 
201.00, 214.01 
185.98, 322.16 
79.  
O
O
O
OH
HO
O
 
Viridiol (C20H18O6) 
2.95 244, 319 
355.1173 
(-1.0) 
281.05, 309.14 
337.12, 249.08 
277.13, 308.39 
279.21, 305.17 
253.15, 291.08 
353.1034 
(+1.0) 
278.96, 325.17 
335.16, 297.15 
338.10, 279.87 
294.41, 321.26 
277.25, 309.15 
80.  
O
OH
OH
OH
O
OH
OHOH
O
NH2
O  
Viridicatumtoxin (C30H31NO10) 
5.74 
235, 
383, 
432 
548.1908 
(-1.3) 
M+H-
H2O 
509.19, 548.23 
510.21, 549.23 
492.20, 380.23 
493.22, 523.23 
522.12, 530.21 
564.1869 
(-1.1) 
502.31, 547.22 
546.17, 520.27 
529.22, 485.19 
405.23, 459.32 
503.27, 379.25 
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81.  
N
OH
N
O
O
S
S OH  
Bisdethiobis(methylthio) gliotoxin 
(C15H20N2O4S2) 
3.33 215, 267 
357.0940 
(+0.7) 
309.04, 243.12 
291.01, 215.17 
192.11, 233.19 
261.20, 143.95 
281.22, 278.11 
355.0710 
(+2.2) 
277.11, 340.12 
325.09, 307.04 
327.11, 337.12 
309.09, 354.96 
278.08, 283.19 
82.  
O
O
O
OH
O
 
Heptelidic acid (C15H20O5) 
3.80 226 281.1390 (+2.2) 
263.02, 245.02 
217.05, 221.06 
235.06, 203.06 
189.04, 199.06 
227.05, 171.10 
279.1238 
(+0.2) 
205.23, 173.17 
235.10, 191.11 
217.03, 149.12 
207.11, 189.16 
176.94, 248.97 
83.  
O
O
O
OH
OHCl
 
Heptelidic acid chlorhydrin (C15H21ClO5) 
3.88 232 
317.1149 
(-2.1) 
neutral 
298.98, 253.10 
281.02, 245.06 
217.11, 263.07 
239.10, 203.13 
227.17, 235.20 
315.1006 
(+2.2) 
279.14, 271.02 
261.06, 234.92 
191.16, 204.95 
243.35, 217.04 
84.  O
OH
 
Phenylacetic acid (C8H8O2) 
1.41 211 137.0597 (-0.4) 
91.92, 136.93 
90.86, 119.97 
119.34, 115.92 
118.29, 124.57 
135.0453 
(+0.8) 
90.88, 134.93 
107.99, 119.71 
81.79, 92.88 
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85.  
O
OH
OH
O  
Decarboxy-citrinone 
C12H12O4 
4.37 
246, 
267, 
339 
221.0802 
(-3.0) 
174.99, 203.01 
192.99, 220.98 
164.99, 151.09 
146.99, 122.99 
137.01, 179.06 
219.0660 
(-1.2) 
219.04, 204.02 
174.97, 191.01 
177.02, 201.05 
148.94, 151.04 
217.13, 189.02 
86.  
COOH
O
O
4
 
(E)-8-(3-(oct-2-enoyl)oxiran-2-
yl)octanoic acid (C18H30O4) 
5.52 232 311.2217 (+0.2) 
293.25, 275.16 
257.17, 265.17 
110.93, 139.05 
247.20, 163.05 
177.02, 197.09 
309.2066 
(-1.6) 
291.16, 281.22 
273.12, 267.18 
265.30, 263.25 
247.29, 211.14 
209.08, 193.03 
87.  
COOH
OH
5
 
(10E,12E)-9-hydroxyoctadeca-10,12-
dienoic acid (C18H32O3) 
6.10 220 297.2422 (-0.9) 
282.04, 279.19 
283.06, 269.36 
297.29, 280.24 
251.18, 241.19 
237.14, 261.21 
295.2280 
(+0.5) 
182.98, 277.22 
155.06, 251.27 
138.92, 295.22 
267.21, 233.17 
137.05, 195.14 
88.  
H
H
HO N
O
O
OH
 
Equisetin (C22H31NO4) 
6.87 230, 295 
374.2322 
(-1.0) 
356.22, 346.27 
175.10, 170.04 
200.03, 177.15 
205.12, 184.02 
143.98, 231.14 
372.2169 
(-0.2) 
342.28, 298.18 
324.22, 343.37 
111.87, 123.85 
314.20, 281.97 
256.09, 371.94 
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89.  
H
H
HO N
O
O
OH
 
5′-epiequisetin (C22H31NO4) 
7.01 231, 296 
374.2323 
(-0.8) 
356.24, 346.27 
175.13, 170.01 
200.02, 177.11 
205.13, 184.02 
143.96, 231.13 
372.2173 
(+1.0) 
342.25, 298.29 
324.29, 343.26 
112.07, 124.01 
241.15, 135.95 
314.30, 230.14 
90.  
O
O
OH
OH
8
 
2,3-dihydroxypropyl stearate (C21H42O4) 
8.55 ND 359.3154 (-0.6) 
341.36, 267.16 
313.39, 359.35 
285.29, 342.06 
274.89, 331.37 
303.32, 255.14 
ND  
91.  
O
O
OH
OH
5
 
(E)-2,3-dihydroxypropyl octadec-6-
enoate (C21H40O4) 
7.98 226 357.2996 (-0.9) 
339.32, 265.26 
247.24, 283.17 
135.08, 149.09 
120.96, 163.08 
151.09, 177.07 
ND  
 
 
296 
92.  
H
N
N
HO
O
HN O
HN
O
H
NO
O
HN O
O
OH
OH
NH2O
4
 
Acuminatum C (C44H71N7O11) 
6.13 224, 276 
874.5264 
(-2.4) 
856.60, 551.29 
857.52, 775.52 
534.39, 839.51 
768.23, 434.17 
757.46, 838.57 
872.5120 
(-2.2) 
828.49, 854.69 
588.47, 549.41 
674.57, 606.53 
632.45, 437.49 
630.24, 829.34 
93.  
H
N
N
HO
O
HN O
HN
O
H
NO
O
HN O
O
OH
OH
NH2O
4
 
Acuminatum B (C45H73N7O11) 
6.42 224, 276 
888.5410 
(-3.5) 
870.54, 565.30 
871.56, 775.48 
548.33, 853.61 
434.17, 782.39 
852.78, 757.65 
886.5280 
(-1.7) 
842.49, 868.60 
563.48, 602.36 
646.45, 620.51 
688.46, 664.48 
437.28, 644.22 
 
 
297 
94.  
OO
OO
O
O OOH
OHO O
O  
Aurofusarin (C30H18O12) 
4.84 
243, 
269, 
380 
571.0860 
(-1.9) 
556.12, 511.15 
539.15, 557.18 
541.19, 512.17 
540.13, 497.18 
528.18, 524.11 
569.0726 
(0.0) 
523.16, 538.08 
537.29, 539.13 
524.01, 554.02 
509.19, 525.06 
540.12, 569.14 
95.  
OH
O
O
O
HO
 
AGI-7 (C11H8O5) 
3.04 
230, 
263, 
326 
221.0454 
(+4.1) 
178.98, 221.02 
160.96, 203.04 
136.92, 150.99 
175.11, 165.08 
193.06, 133.06 
219.0297 
(-1.1) 
218.85, 216.95 
177.01, 174.97 
191.05, 130.95 
146.90, 132.97 
148.87, 172.92 
96.  
H
N
O
O
N
O N
H
H
N
O
O
N
O N
H
H
N
O
O
N
O N
H
H
N
O
O
N
H O
O N
H
N
H
N
O
O
O
OH
OH
OH
OH
OH
OH
OH
HO
OH
 
Clonostachin (C78H134N14O25) 
5.38 220 1667.973 (+0.5) 
1612.73 763.39 
1650.04 
1583.62 
1616.32 
1671.57 
1665.954 
(-2.2) 
1501.97 
1538.92 
1374.79 
1483.88 
1501.33 
1049.60 
1288.72 
1356.65 
1161.68 
1502.62 
 
  
 
 
298 
97.  01009-91-5* 5.41 219 1681.983 (-2.7) 
847.22 
846.48 
854.06 
848.06 
845.84 
1403.76 
1077.69 
1516.99 
855.21 
1419.15 
1679.969 
(-2.1) 
1516.01 
1515.00 
1552.42 
1370.88 
1063.34 
1553.23 
1372.96 
850.95 
1388.48 
1374.97 
98.  
H
NN
N
H
N
HO
OH
N
N
O
O
O
O
H
H
S S
SS
 
Sch 52901 (C31H30N6O6S4) 
5.75 209, 300 
711.1161 
(-3.0) 
629.17, 647.13 
646.52, 383.22 
397.25, 465.13 
233.16, 479.12 
565.21, 232.11 
709.1040 
(+0.4) 
645.00, 610.97 
579.24, 613.26 
643.15, 554.17 
508.90, 577.26 
461.20, 463.31 
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99.  
H
NN
N
H
N
HO
OH
N
N
O
O
O
O
H
H
S S
SS
 
Verticillin H (C32H32N6O6S4) 
6.02 211, 302 
725.1321 
(-2.5) 
643.09, 661.02 
397.26, 415.10 
479.22, 579.36 
233.05, 232.12 
298.20, 478.50 
723.1199 
(+0.8) 
659.17, 658.53 
657.04, 625.13 
477.09, 411.16 
593.07, 595.43 
526.08, 568.45 
100.  
H
NN
N
H
N
HO
OH
N
N
O
O
O
O
H
H
S S
SS
 
Verticillin A (C30H28N6O6S4) 
5.45 217, 298 
697.1016 
(-1.5) 
615.16, 633.01 
383.18, 465.23 
233.09, 401.22 
632.28, 551.25 
284.13, 232.11 
695.0877 
(-0.5) 
631.12, 597.10 
565.19, 599.19 
660.91, 495.01 
463.07, 598.58 
629.20, 446.96 
 
 
300 
101.  
H
NN
N
H
N
HO
OH
N
N
O
O
O
O
H
H
S S
SS
OH
 
Sch 52900 (C31H30N6O7S4) 
5.19 213, 300 
727.1112 
(-2.3) 
645.10, 663.10 
413.23, 266.14 
383.22, 495.16 
662.42, 465.08 
296.16, 233.14 
725.0981 
(-0.6) 
661.01, 583.16 
597.09, 647.07 
661.98, 627.14 
643.08, 595.24 
617.16, 659.21 
102.  
H
NN
N
H
N
H
H
N
N
O
O
O
O
H
H
S S
SS
OH  
Gliocladicillin A (C31H30N6O5S4) 
5.41 206, 298 
695.1216 
(-2.5) 
629.09, 631.15 
479.00, 630.31 
397.18, 280.08 
268.17, 233.13 
613.17, 384.25 
693.1082 
(-0.8) 
629.06, 595.23 
627.06, 563.30 
461.24, 446.95 
561.35, 381.23 
597.05, 395.14 
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103.  
H
NN
N
H
N
HO
OH
N
N
O
O
O
O
H
H
S S
SS
OH  
Gliocladicillin C (C32H32N6O7S4) 
5.54 207 298 
741.1268 
(-2.7) 
659.16, 677.04 
413.26, 280.16 
495.12, 676.40 
397.31, 296.16 
479.00, 233.06 
739.1128 
(-2.0) 
675.09, 597.19 
611.07, 643.21 
657.26, 660.95 
567.21, 631.23 
675.94, 565.26 
104.  
H
NN
N
H
N
OH
N
N
H3C O
O
O
O CH3
H
H
S S
SS
 
11-Deoxyverticillin A (C30H28N6O5S4) 
5.12 215, 298 
681.1060 
(-2.5) 
615.11, 465.02 
617.22, 383.22 
616.30, 233.12 
268.15, 266.10 
384.23, 385.23 
679.0933 
(+0.2) 
615.00, 581.10 
613.06, 547.10 
446.93, 381.31 
549.33, 583.11 
644.81, 587.84 
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105.  
O O
O
OH O OH
HH
 
De-O-methyldihydrosterigmatocystin 
(C17H12O6) 
5.92 
230, 
248, 
333 
313.0610 
(-2.2) 
285.11, 313.09 
257.04, 286.19 
295.12, 243.11 
284.25, 202.99 
269.09, 258.10 
311.0563 
(+0.7) 
311.04, 282.99 
312.16, 283.99 
255.04, 242.89 
281.13, 182.99 
293.00, 255.99 
106.  
O O
O
OH O OH H
H
 
Sterigmatin (C17H10O6) 
6.22 
224, 
250, 
322 
311.0551 
(+0.3) 
283.10, 255.19 
269.07, 284.12 
293.25, 265.07 
311.18, 241.14 
267.13, 292.57 
309.0396 
(-2.8) 
309.19, 264.94 
281.12, 282.02 
240.83, 96.92 
248.11, 280.47 
266.22, 262.77 
107.  O
O
O
O
HO
OHOH  
Averufin (C20H16O7) 
6.35 
222, 
267, 
293, 
321, 
450 
369.0960 
(-2.3) 
351.11, 311.09 
299.12, 327.09 
285.09, 309.11 
333.12, 273.03 
323.12, 369.12 
367.0820 
(-1.0) 
367.05, 284.08 
295.14, 285.15 
368.25, 297.13 
282.98, 310.08 
296.05, 308.97 
108.  
O
H
O
H
O
OO
O
O
HO
H
HO
 
Roridin A (C29H40O9)  
4.46 224, 263 
533.2731
9 
(-2.5) 
249.09, 231.12 
333.22, 403.01 
385.10, 213.17 
185.06, 195.03 
203.15, 247.10 
531.2609
3 
(+1.8) 
401.39, 513.39 
487.27, 371.34 
469.34, 365.20 
357.21, 501.45 
237.16, 265.19 
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109.  
O
H
O
H
O
OO
O
O
HO
HO
 
Roridin D (C29H38O9) 
4.81 224, 259 
531.2576 
(-2.3) 
249.10, 231.21 
485.27, 403.03 
185.11, 213.12 
347.20, 203.13 
195.18, 331.22 
529.2455 
(+2.2) 
263.12, 485.19 
511.27, 501.29 
235.14, 441.26 
374.94 163.04 
237.13, 219.17 
110.  N
H
HO
O
HO
O
O OH
O
OH
OH
OH
OH
O
3 4
Virgineone (C40H63NO12) 
5.41 222, 280 
750.4418 
(-0.6) 
588.47, 570.44 
732.39, 552.64 
678.38, 612.61 
714.36, 552.04 
540.43, 696.54 
748.4251 
(-3.5) 
642.41, 686.41 
643.53, 480.41 
586.45, 687.58 
524.39, 436.45 
654.46, 506.58 
111.  N
H
HO
O
HO
O
O OH
OH
4 4
 
Virgineone aglycone (C34H53NO7) 
6.10 224, 280 
588.3879 
(-2.6) 
570.49, 552.40 
206.11, 534.43 
540.50, 337.39 
464.45, 400.34 
440.50, 365.43 
586.3731 
(-3.2) 
480.44, 481.53 
524.51, 436.42 
492.60, 542.61 
204.02, 406.33 
418.22, 525.65 
112.  01009-74-3* 5.91 
226, 
293, 
374 
 
586.43, 568.38 
730.27, 550.52 
676.40, 694.46 
587.13, 365.34 
538.43, 712.76 
 
584.35, 585.45 
746.57, 540.39 
566.52, 626.47 
522.53, 702.54 
703.57, 541.48 
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113.  
OH
OH
H
HO  
5,6-dihydroxybisabolol (C15H28O3) 
3.73 220, 281 
257.2118 
(+2.7) 
221.12, 239.09 
203.11, 127.02 
118.97, 133.05 
108.98, 147.03 
149.07, 240.04 
255.1968 
(+1.1) 
211.18, 237.25 
159.01, 136.96 
227.97, 81.03 
212.60, 201.22 
219.13, 208.92 
114.   01007-150-1* 5.24 
232, 
257, 
293, 
372 
287.0918 
(+1.4) 
269.12, 272.07 
254.07, 259.15 
287.16, 257.09 
258.13, 226.08 
267.11, 270.00 
285.0774 
(+1.8) 
255.15, 284.98 
270.11, 240.97 
257.04, 225.02 
239.92, 270.98 
196.83, 242.03 
115.  01007-150-3 (01008-93-2)* 6.39 
228, 
259, 
287, 
380 
257.0811 
(+1.1) 
257.09, 242.02 
214.11, 243.05 
258.11, 225.04 
226.14, 227.13 
213.25, 215.06 
ND ND 
116.   01007-150-4* 6.77 
232, 
254, 
289, 
369 
271.0963 
(-0.8) 
256.08, 271.10 
239.04, 228.10 
257.10, 241.11 
240.07, 272.22 
227.25, 212.95 
ND ND 
117.  
O
O
O
O
 
Betulinan A (C20H16O4) 
5.52 
224, 
265, 
324 
321.1121 
(0.0) 
289.26, 306.11 
293.15, 274.21 
258.08, 271.11 
290.17, 261.22 
259.18, 233.11 
319.0985 
(+2.7) 
304.00, 291.10 
276.01, 319.20 
287.20, 289.18 
247.08, 292.07 
277.13, 231.27 
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118.  
OH
OH
O
 
BTH-II0204-207:A (C19H16O3) 
4.87 
224, 
259, 
311 
293.1172 
(-0.2) 
261.16, 278.08 
277.13, 275.16 
292.20, 233.18 
262.12, 243.12 
259.20, 232.11 
291.1033 
(+2.1) 
276.05, 263.00 
291.00, 173.00 
275.09, 219.09 
247.18, 273.11 
264.07, 249.12 
119.  
O
O
O
  
Betulinan C (C19H14O3) 
5.64 
226, 
259, 
337 
291.1018 
(+0.6) 
276.06, 259.08 
260.10, 231.11 
273.09, 213.08 
263.08, 258.09 
245.16, 291.16 
289.0881 
(+3.8) 
289.07, 261.03 
275.06, 260.11 
288.20, 245.03 
271.15, 287.09 
262.00, 259.09 
120.  01008-147-2* 3.56 220 239.1278 (+0.1) 
221.04, 195.16 
154.93, 183.07 
203.06, 132.98 
137.01, 193.14 
164.96, 177.12 
237.1134 
(+0.5) 
181.06, 237.22 
219.15, 123.06 
174.97, 152.93 
146.84, 146.04 
137.01, 192.98 
121.  
OH
O
5
 
6,9-Octadecadienoic acid (C18H32O2) 
7.25  281.2476 (+0.2) 
263.21, 264.23 
246.28, 245.18 
148.84, 151.06 
120.97, 135.15 
221.24, 163.15 
ND ND 
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122.  
HN
O OHO
OAc
HH
OH
 
Cytochalasin C (C30H37NO6) 
4.83 219, 283 
508.2684 
(-1.9) 
430.32, 490.16 
448.38, 412.30 
388.37, 406.40 
472.20, 402.26 
466.27, 370.55 
506.2543 
(-1.1) 
446.26, 488.23 
241.16, 428.18 
460.29, 464.51 
418.24, 436.11 
403.32, 291.21 
123.  HN
O OHO
OAc
HH
O
 
Cytochalasin QHYP (C30H37NO6)  
5.00 213, 285 
508.2683 
(-2.1) 
490.20, 430.31 
448.26, 412.26 
402.36, 388.40 
406.31, 394.32 
384.27, 374.42 
506.2544 
(-0.8) 
446.28, 464.46 
488.25, 428.27 
463.70, 385.33 
388.33, 436.35 
354.36, 418.37 
124.  
O
H
CH3
O
H
O
O
O O
O
O
 
8-Acetoxyneosolaniol (C21H28O9) 
3.28 226 425.1804 (-0.5) 
305.18, 215.13 
245.03, 263.05 
173.12, 365.33 
199.07, 191.08 
227.17, 169.12 
ND ND 
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125.  
O
H
O
H
OH
O
OH
O
O
O  
Isoneosolaniol (C19H26O8) 
2.42 219 383.1696 (-1.3) 
263.11, 323.10 
245.14, 305.09 
365.11, 227.08 
199.07, 287.15 
215.07, 217.11 
ND ND 
126.  
O
COOHOH
 
Abscisic acid (C15H20O4) 
3.16 222, 263 
265.1437 
(+1.1) 
247.07, 229.09 
219.14, 209.10 
201.16, 205.09 
187.18, 163.07 
203.11, 185.15 
263.1287 
(-0.6) 
152.92, 219.08 
204.05, 201.09 
110.91, 161.04 
245.06, 186.10 
138.14, 137.38 
127.  O
OMe
OH O OMe
O
O
HH
 
5-Methoxysterigmatocystin (C19H14O7) 
4.84 
230, 
244, 
274, 
330 
355.0812 
(0.0) 
340.09, 327.16 
325.07, 341.19 
355.17, 312.12 
311.19, 326.09 
328.18, 297.10 
353.0663 
(-1.2) 
338.04, 325.12 
257.01, 307.33 
308.88, 353.36 
285.03, 339.18 
262.81, 269.23 
128.  O
OH O OMe
O
O
HH
 
Sterigmatocystin (C18H12O6) 
5.03 
232, 
244, 
326 
325.0707 
(+0.1) 
310.11, 297.13 
325.10, 311.13 
282.12, 281.08 
293.10, 296.09 
298.15, 283.12 
323.0559 
(-0.5) 
323.18, 308.18 
294.99, 323.96 
276.69, 305.33 
280.00, 252.45 
309.09, 278.90 
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129.  
O
O
MeO
OMe O
O
OH
H
H
 
Aversin (C20H16O7) 
5.21 
222, 
285, 
315, 
441 
369.0966 
(-0.7) 
351.16, 341.13 
339.15, 340.17 
313.13, 352.18 
323.19, 369.13 
327.14, 354.13 
367.0823 
(-0.1) 
337.10, 339.15 
338.08, 352.05 
353.22, 349.14 
292.85, 323.30 
367.09, 329.15 
130.  
O
N
H
N
N
OO
H
 
Brevianamide P (C22H23N3O3) 
4.92 
224, 
287, 
443 
378.1806 
(-1.7) 
231.11, 361.21 
322.18, 321.15 
360.22, 287.19 
350.28, 243.16 
248.11, 230.11 
376.1663 
(-1.1) 
285.07, 284.07 
319.09, 229.11 
256.19, 188.01 
160.86, 227.98 
244.21, 333.16 
131.  O
O
O
O
MeO
OHOMe  
6,8-Di-O-Methyl averufin (C22H20O7) 
6.55 
224, 
287, 
443 
397.1277 
(-1.2) 
339.17, 379.18 
313.13, 327.14 
355.17, 337.07 
361.25, 301.22 
351.22, 380.22 
395.1139 
(+0.6) 
311.92, 297.02 
395.27, 377.22 
313.05, 327.12 
323.12, 309.09 
337.02, 291.47 
 
 
309 
132.  
O
H
O
H
O
O
OO
OH
O
HO  
Roridin L (C29H38O9) 
4.37 222, 259 
531.2578 
(-2.0) 
377.25, 513.22 
359.34, 401.21 
247.10, 229.15 
265.19, 383.30 
395.21, 495.36 
529.2442 
(-0.2) 
375.26, 485.37 
401.04, 247.14 
417.35, 511.32 
451.09, 265.12 
499.05, 233.32 
133.  
O
H
O
H
O
O
O
O
O
O
 
Verrucarin J, Muconomycin B 
(C27H32O8) 
5.53 222, 261 
485.2161 
(-1.8) 
343.25, 231.12 
373.25, 213.20 
249.17, 185.05 
201.07, 187.11 
203.13, 159.01 
483.2027 
(+0.5) 
389.21, 439.15 
173.09, 465.21 
235.05, 395.32 
160.81, 373.07 
211.28, 254.99 
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134.  
O
H
O
H
O
O
OO
O
O
 
Roridin H; Verrucarin H (C29H36O8) 
6.07 224, 259 
513.2472 
(-2.2) 
231.12, 359.22 
249.15, 213.20 
201.12, 495.19 
182.76, 203.18 
185.10, 331.23 
ND ND 
135.  O O
O
OH O OH
HH
 
De-O-methylsterigmatocystin (C17H10O6) 
6.03 
228, 
248, 
333 
311.0551 
(+0.1) 
283.07, 311.11 
282.10, 284.20 
269.01, 255.03 
241.04, 200.97 
264.02, 312.15 
309.0407 
(+0.7) 
309.14, 265.07 
281.18, 240.94 
266.10, 263.12 
96.88, 290.17 
156.71, 172.94 
136.  
HN
O OHO
OAc
HH
 
Zygosporin G (C30H37NO5) 
5.93 217, 276 
492.2736 
(-1.8) 
474.18, 414.34 
396.30, 432.33 
267.19, 249.30 
372.32, 386.41 
322.32, 390.41 
490.2610 
(+2.3) 
444.37, 472.40 
462.36, 446.30 
315.53, 307.06 
428.46, 460.32 
399.45, 193.24 
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137.  
N
O
O
O
O  
Versimide (C9H11NO4) 
1.65 214 198.0760 (-0.3) 
165.95, 198.10 
96.98, 82.96 
80.90, 95.01 
68.91, 92.98 
106.95, 121.02 
ND ND 
138.  
O
O
OH O
O
OH
OH
O
 
Aigialomycin A (C19H22O8) 
3.77 
232, 
263, 
304 
379.1379 
(-2.2) 
253.00, 235.00 
343.25, 361.09 
325.15, 231.00 
265.00, 206.98 
249.05, 126.98 
377.1235 
(-1.7) 
251.01, 359.09 
207.03, 305.07 
341.21, 178.98 
233.12, 315.16 
205.06, 263.06 
139.  
HO
O
O O
OH
HO
 
Nidulalin B (C16H14O6) 
3.60 222, 276 
303.0859 
(-1.3) 
192.95, 271.13 
178.99, 136.86 
167.09, 179.59 
193.75, 286.30 
88.99, 109.03 
301.0709 
(-3.0) 
268.99, 283.08 
134.84, 225.04 
257.20, 241.05 
91.00, 108.87 
165.03, 269.74 
140.  
O
O
OH O
O
OH
O HO
 
Dihydrohypothemycin (C19H24O8) 
4.01 
219, 
265, 
304 
381.1534 
(-2.7) 
363.12, 345.18 
327.12, 303.13 
253.00, 265.09 
309.24, 249.15 
285.11, 235.02 
379.1393 
(-1.6) 
178.94, 307.11 
233.05, 361.05 
277.12, 163.98 
180.96, 343.13 
205.03, 335.13 
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141.  01020-76-1* 4.16 
222, 
272, 
350 
321.0961 
(-2.3) 
261.04, 303.11 
289.09, 219.00 
247.06, 271.11 
192.95, 149.02 
275.17, 136.98 
319.0819 
(-1.3) 
275.18, 243.22 
287.23, 257.09 
205.13, 300.92 
162.74, 219.88 
215.03, 220.99 
142.  
O O
O
HO
 
Pyrenochaetic acid C (C13H16O4) 
4.40 
217, 
250, 
304 
237.1185 
(-1.2) 
219.08, 175.09 
194.05, 195.10 
236.06, 200.99 
192.95, 161.95 
160.01, 177.05 
235.0974
0 
(-0.8) 
191.00, 176.06 
235.09, 163.18 
120.96, 191.60 
177.23, 207.15 
179.11, 68.98 
143.  
O
O OHOH
OO
O
OOH OH
O O
OH
OH
 
Secalonic acid A (C32H30O14) 
5.26 
222, 
263, 
337 
639.1688 
(-2.8) 
561.27, 589.16 
579.27, 621.25 
501.27, 571.27 
455.21, 543.17 
603.28, 511.28 
637.1545 
(-2.8) 
577.30, 619.24 
543.19, 417.23 
605.23, 559.11 
587.15, 541.34 
593.29, 499.24 
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144.  
O
O OHOH
OH
OO
O
OOH OH
OH
O O
 
Secalonic acid E (C32H30O14) 
5.50 
220, 
265, 
337 
639.1691 
(-2.7) 
561.24, 589.26 
579.26, 621.20 
455.31, 571.26 
501.19, 603.25 
543.35, 607.30 
637.1538 
(-3.1) 
593.25, 543.30 
605.30, 619.19 
549.29, 577.20 
561.22, 499.29 
575.37, 587.15 
145.  
O
O OHOH
OH
OO
O
OOH OH
OH
O O
 
Secalonic acid G  (C32H30O14) 
5.39 
220, 
259, 
337 
639.1693 
(-2.5) 
561.28, 589.23 
579.24, 621.23 
571.22, 455.32 
501.28, 543.20 
603.35, 511.28 
637.1542 
(-3.3) 
577.20, 593.13 
543.19, 619.21 
605.25, 561.31 
499.29, 587.18 
533.24, 525.23 
146.  O
O OHOH
OH
OO
O
O
HO
HO
OHO
O
 
Penicillixanthone A (C32H30O14) 
5.90 
220, 
262, 
335 
639.1694 
(-2.2) 
621.23, 589.24 
579.26, 561.24 
571.32, 603.37 
501.40, 543.14 
589.94, 455.33 
637.1542 
(-3.2) 
605.18, 577.26 
619.12, 593.22 
543.15, 561.36 
587.20, 557.20 
551.21, 525.24 
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147.  01020-138-1* 5.29 
220, 
259, 
335 
639.1691 
(-2.8) 
561.23, 589.24 
579.27, 571.24 
501.21, 455.22 
621.23, 565.29 
547.35, 193.01 
637.1541 
(-3.4) 
593.19, 561.21 
543.33, 549.29 
517.20, 365.25 
577.19, 605.35 
533.21, 575.22 
148.  
N H
N
NH
N
H
O
N
OO
O O
O
O
 
New Natural Product, reported by 
synthesis (C33H47N5O7) 
5.29 222, 289 
626.3533 
(-2.4) 
466.26, 594.46 
595.36, 513.32 
598.38, 422.31 
483.37, 296.13 
596.38, 297.22 
624.3387 
(-2.6) 
464.24, 594.42 
465.41, 592.44 
477.23, 254.21 
562.46, 225.21 
595.04, 340.21 
149.  
N H
N
NH
N
H
O
N
OO
O
O
O
 
Apicidin (C34H49N5O6) 
5.44 222, 287 
624.3737 
(-2.9) 
464.24, 592.44 
593.37, 511.36 
294.20, 596.46 
420.28, 481.33 
467.17, 594.47 
622.3593 
(-2.8) 
462.32, 592.46 
463.44, 475.22 
590.57, 223.01 
252.07, 336.32 
310.22, 183.04 
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150.  
OH
O
OH
OH OH
 
(8R*,9R*,10S*,6Z)-
trihydroxyoctadec-6-enoic acid 
(Oxylipin) (C18H34O5) 
4.32 220 331.2476 (-0.8) 
313.39, 285.40 
289.27, 331.25 
316.26, 302.98 
295.33, 281.01 
275.39, 206.99 
329.2322 
(-3.5) 
311.34, 211.15 
199.04, 293.17 
168.92, 181.11 
275.24, 192.98 
227.16, 197.11 
151.  HN
O OO
HH
OH
O
O
OH
 
19,20-Epoxycytochalasin D (C30H37NO7) 
4.03 217 524.2637 (-1.2) 
428.30, 446.23 
464.30, 404.28 
386.33, 390.29 
410.32, 400.32 
368.28, 239.12 
522.2488 
(-1.7) 
480.38, 504.22 
462.32, 444.23 
268.27, 422.25 
324.37, 404.32 
348.24, 266.16 
152.  HN
O OO
HH
OH
O
O
OH
 
19,20-Epoxycytochalasin C (C30H37NO7) 
4.54 215 524.2634 (-1.6) 
428.30, 446.30 
386.29, 464.25 
404.26, 390.32 
400.34, 418.30 
410.25, 281.14 
522.2490 
(-1.4) 
404.24, 462.32 
480.42, 362.32 
504.24, 402.28 
401.22, 444.17 
464.29, 360.29 
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153.  
HN
O OO
HH
O
O
O
 
18-Deoxy-19,20-epoxycytochalasin Q 
(C30H37NO6) 
5.18 211 508.2683 (-2.1) 
430.29, 412.35 
402.31, 448.33 
265.17, 267.14 
384.31, 346.18 
374.38, 372.29 
506.2542 
(-1.1) 
460.19, 446.19 
428.34, 464.37 
478.00, 308.28 
307.25, 318.08 
423.13, 436.18 
154.  
O
OH
O
H H
 
Trichodermol (C15H22O3) 
3.22 230 251.1642 (+0.1) 
233.12, 215.07 
187.20, 205.14 
197.13, 108.95 
136.92, 158.98 
95.03, 173.13 
ND ND 
155.  OO
O OH
OH
 
Decaspirone C (C20H18O5) 
4.45 
230, 
298, 
326 
339.1223 
(-1.3) 
321.14, 285.07 
303.15, 159.00 
143.95, 159.98 
144.97, 253.07 
130.91, 321.77 
337.1076 
(-1.7) 
319.04, 293.17 
159.10, 275.04 
291.20, 234.95 
251.17, 337.01 
263.02, 158.02 
 
 
317 
156.  O O
O O
O
 
Palmarumycin CP3 (C20H14O5) 
5.07 
226, 
298, 
326 
335.0913 
(-0.4) 
307.14, 289.14 
174.98, 161.01 
279.15, 158.95 
175.99, 317.08 
147.05, 160.01 
333.0760 
(-2.6) 
158.94, 289.03 
305.06, 315.18 
271.08, 303.16 
157.92, 261.16 
287.08, 146.96 
157.  OH
OH
O
O
O
 
Palmarumycin CP4 (C20H16O5) 
5.36 
224, 
298, 
326 
337.1068 
(-0.6) 
319.17, 158.98 
301.14, 160.00 
130.97, 253.11 
161.09, 291.12 
174.96, 277.25 
335.0920 
(-1.5) 
158.91, 251.16 
291.13, 157.87 
307.14, 317.08 
273.05, 250.06 
233.04, 289.05 
158.  O O
O OH
OH
 
Palmarumycin CP17 (C20H14O5) 
5.80 
228, 
298, 
365 
335.0910 
(-1.1) 
303.15, 158.94 
285.10, 174.94 
161.03, 176.00 
317.07, 143.97 
160.05, 275.12 
333.0764 
(-1.4) 
159.06, 265.15 
315.24, 289.01 
158.42, 333.13 
189.95, 312.96 
178.00, 286.94 
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159.  OO
O OH
 
Palmarumycin CP2 (C20H14O4) 
5.03 222, 331 
319.0960 
(-1.6) 
159.93, 301.14 
158.96, 160.96 
174.92, 302.12 
130.99, 273.08 
145.01, 132.92 
317.0814 
(-1.6) 
158.89, 174.96 
299.12, 316.98 
298.30, 172.97 
159.95, 173.99 
273.18, 316.09 
160.  AcO
O
AcO
OH
OH
O
OH
O
O
OH
OAc OAc
 
Phomoxanthone A (C38H38O16) 
6.56 
220, 
254, 
333 
751.2224 
(-1.2) 
673.16, 691.17 
631.35, 733.04 
613.31, 571.20 
511.24, 553.30 
732.32, 678.34 
749.2068 
(-2.6) 
689.19, 629.24 
569.26, 671.24 
509.38, 611.31 
647.28, 731.25 
629.85, 587.18 
161.  
O
O
HO
O
H
 
Chermesinone A (C17H22O4) 
4.15 222, 354 
291.1585 
(-2.2) 
189.22, 245.17 
273.20, 231.24 
201.20, 145.13 
255.17, 161.19 
174.20, 175.21 
ND ND 
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162.  
O
O
O
O O
H
H
 
Chermesinone B (C18H20O5) 
4.50 222, 354 
317.1379 
(-1.3) 
233.08, 215.08 
187.07, 159.08 
245.13, 273.12 
205.14, 189.11 
281.14, 188.12 
315.1230 
(-2.5) 
273.15, 229.01 
271.13, 253.06 
189.00, 210.98 
231.11, 187.08 
243.15, 225.08 
163.  
OH
O
O
O H
 
 
5’-formyl-2’-hydroxyl-4’-methoxy-(E,E)-
sorbophenone (C14H14O4) 
5.33 
225, 
266, 
311, 
343 
247.0960 
(-2.0) 
178.95, 197.03 
190.97, 218.97 
229.03, 201.06 
150.93, 190.00 
164.98, 177.07 
245.0815 
(-1.6) 
227.09, 230.05 
211.96, 183.95 
150.02, 245.06 
163.93, 213.00 
202.07, 200.90 
164.  
OH
O
O
O H
 
5′-Formyl-2′-hydroxy-4′-methoxy-(E)-4-
hexenophenone (C14H16O4) 
5.48 
253, 
282, 
322 
249.1119 
(-0.9) 
178.88, 231.02 
221.11, 152.94 
206.95, 164.93 
203.07, 193.08 
176.97, 175.05 
247.0971 
(-2.2) 
163.81, 247.07 
177.88, 217.12 
188.97, 231.00 
149.94, 177.14 
202.98, 232.04 
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165.  OH
O
O  
1-(2’-hydroxy-4’-methoxy-5’-
methylphenyl)-2,4-E,E-hexadien-1-
one 
(C14H16O3) 
6.16 
234, 
310, 
357 
233.1171 
(-0.5) 
214.99, 164.97 
205.05, 191.09 
151.01, 187.01 
176.99, 204.12 
201.12, 233.09 
231.1025 
(-0.7) 
215.97, 197.94 
213.00, 203.15 
231.08, 175.01 
150.00, 137.03 
201.02, 184.94 
166.  01021-11-2* 5.48 
243, 
277, 
314 
279.1230 
(+1.1) 
247.02, 208.94 
235.08, 183.06 
229.12, 150.91 
261.17, 217.01 
204.96, 193.11 
277.1077 
(-1.5) 
277.14, 193.92 
192.84, 247.06 
219.06, 179.85 
261.02, 262.21 
206.98, 163.95 
167.  
O
OHO
HO
 
1-(2’-hydroxy-4’-methoxy-5’-
hydroxymethylphenyl)-E-4-hexen-1-
one (C14H18O4) 
4.64 
233, 
275, 
319 
251.1277 
(-0.5) 
180.97, 233.16 
215.09, 221.09 
158.96, 186.99 
136.99, 205.08 
177.06, 203.02 
249.1131 
(-0.6) 
231.05, 216.06 
248.95, 135.05 
213.04, 176.99 
188.11, 217.09 
233.03, 201.01 
168.  01021-2-7* 4.44 
230, 
311, 
350 
249.1126 
(+0.1) 
231.05, 180.93 
219.15, 207.08 
203.00, 200.95 
204.08, 213.07 
191.07, 174.97 
247.0974 
(-0.8) 
163.96, 232.01 
247.19, 199.03 
229.11, 178.03 
214.03, 217.06 
200.94, 230.92 
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169.  01021-12-1* 4.43 
223, 
250, 
314, 
335 
263.0913 
(-0.3) 
245.05, 195.04 
204.07, 177.02 
187.00, 191.12 
188.95, 219.11 
217.00, 175.99 
261.0765 
(-1.3) 
188.99, 217.02 
187.98, 199.06 
171.06, 187.31 
173.02, 202.11 
246.08, 168.89 
170.  
O
O
O
O
 
5,7-dimethoxy-1(3H)-isobenzofuranone 
5,7-Dimethoxyphthalide (C10H10O4) 
 
2.50 
217, 
258, 
291 
195.0647 
(-2.6) 
194.99, 134.90 
149.03, 139.02 
165.01, 162.99 
145.00, 119.01 
120.91, 90.90 
193.0501 
(-2.6) 
177.88, 192.84 
148.96, 149.89 
162.91, 146.91 
165.01, 133.78 
175.02, 134.88 
171.  
O
O
O
O  
4,6-Dimethoxy-1(3H)-isobenzofuranone 
4,6-Dimethoxyphthalide (C10H10O4) 
 
3.53 
197, 
222, 
250, 
308 
195.0647 
(-2.6) 
194.99, 134.89 
148.92, 162.92 
144.87, 118.93 
177.01, 166.97 
150.99, 138.96 
193.0501 
(-2.9) 
148.93, 193.01 
146.85, 177.95 
167.00, 121.07 
133.91, 134.93 
165.19, 174.90 
172.  01021-127-2* 6.40 
193, 
219, 
232, 
276, 
326 
235.1322 
(-2.8) 
165.06, 235.04 
217.04, 151.01 
193.06, 189.03 
191.11, 179.09 
174.96, 177.03 
233.1176 
(-3.0) 
233.01, 189.14 
149.96, 218.20 
136.96, 178.03 
174.85, 217.47 
203.20, 164.07 
ND: Not Detected 
*New compound, not published yet 
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CHAPTER X 
 
CHEMICAL DIVERSITY OF METABOLITES FROM FUNGI, CYANOBACTERIA, 
AND PLANTS RELATIVE TO FDA-APPROVED ANTICANCER AGENTS 
 
Tamam El-Elimat, Xiaoli Zhang, David Jarjoura, Franklin J. Moy, Jimmy Orjala, A. 
Douglas Kinghorn, Cedric J. Pearce, and Nicholas H. Oberlies. ACS Medicinal 
Chemistry Letters 2012, 3, 645-649. 
 
A collaborative project has been undertaken to explore filamentous fungi, 
cyanobacteria, and tropical plants for anticancer drug leads. Through principal 
component analysis, the chemical space covered by compounds isolated from these three 
sources over the last four years was compared to each other and to the chemical space of 
selected FDA-approved anticancer drugs. Using  literature precedence, nine molecular 
descriptors were examined: molecular weight, number of chiral centers, number of 
rotatable  bonds, number of acceptor atoms for H-bonds (N,O,F), number of donor atoms 
for H-bonds (N and O), topological polar surface area using N,O polar contributions, 
Moriguchi octanol-water partition coefficient, number of nitrogen atoms, and number of 
oxygen atoms. Four principal components explained 87% of the variation found among 
343 bioactive natural products and 96 FDA-approved anticancer drugs. Across the four 
dimensions, fungal, cyanobacterial and plant isolates occupied both similar and distinct 
areas of chemical space that collectively aligned well with FDA-approved anticancer 
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agents. Thus, examining three separate resources for anticancer drug leads yields 
compounds that probe chemical space in a complementary fashion. 
 
In a multidisciplinary project to identify anticancer leads from diverse natural 
product sources, 343 distinct compounds have been characterized from aquatic 
cyanobacteria, filamentous fungi, and tropical plants; over 33% of these represent new 
chemical entities, and many of the known compounds have not been evaluated as 
anticancer leads previously.11,292 The compounds were isolated based on bioactivity in 
one or more anticancer-related in vitro assays, and the structural variety of the resulting 
leads was broad, ranging from peptides to polyketides to terpenoids and myriad 
combinations thereof.19-22,105,293-296 One of our goals was to measure how this chemical 
diversity compared to that of FDA-approved anticancer agents. 
In assessing the chemical diversity of a set of compounds, most approaches rely 
upon computational analyses of structural and physicochemical parameters, also known 
as molecular descriptors.297-300 Typically, these molecular descriptors include topological 
descriptors, physical property descriptors, atom and bond counts, surface area descriptors, 
and charge descriptors.301 Each compound can therefore be defined in a chemical 
reference space of the n-dimensions of interrelated molecular descriptor variables.301 A 
standard approach for reducing the dimensionality of the descriptors, while maintaining 
almost all of the variation among the compounds, is principal components analysis 
(PCA).301-303 Although the multivariate statistical methods behind PCA and rotations to 
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simple structure involve complex algorithms, bivariate plots of the components often 
impart meaning that tend to be missed by bivariate plots of the original variables. 
PCA has been used to compare molecular properties of different classes of 
compounds, particularly in relation to libraries of natural products (Table 40, 
Supplementary Information). Feher and Schmidt297 utilized ten molecular descriptors and 
PCA to examine three different compound libraries: natural products, molecules from 
combinatorial synthesis, and drug molecules. For this, the Chapman and Hall Dictionary 
of Drugs was used as a source of drug molecules (n = 10,968); the combinatorial database 
was assembled from the following databases: Maybridge HTS database, the ChemBridge 
EXPRESS-Pick database, the ComGenex collection, the ChemDiv International Diversity 
Collection, the ChemDiv CombiLab Probe Libraries, and the SPECS screening 
compounds database [out of the 670,536 combinatorial compounds, a random selection 
of 2% was used (n = 13,506)]; the natural compounds (n = 3,287) were assembled from 
the following sources: the BioSPECS natural products database, the ChemDiv natural 
products database, and the Interbioscreen IBS2001N and HTS-NC databases.297 Singh et 
al.300 presented a multiple criteria approach for the comparative analysis of combinatorial 
libraries, drugs, natural products, and molecular libraries small molecule repository using 
six molecular descriptors.300 A set of 20 natural products and 20 synthetic drugs (half of 
them being the top selling drugs of 2004) were compared for structural diversity by 
Tan304 using PCA with nine molecular descriptors. A similar study of the top 200 selling 
drugs of 2006 relative to Merck’s sample collection, 595 natural products, using nine 
molecular descriptors was carried out by Singh and Culberson.299 As catalogued in Table 
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40, even though the sample sets varied, there was some overlap between the molecular 
descriptors utilized in all four studies. 
To examine the chemical space covered by secondary metabolites we isolated in 
pursuit of anticancer leads (105 from filamentous fungi, 75 from cyanobacteria, and 163 
from tropical plants) and FDA-approved anticancer agents (96), nine molecular 
descriptors were selected (Table 40): molecular weight (MW), number of chiral centers 
(nCC), number of rotatable bonds (nRBN), number of acceptor atoms for H-bonds 
[N,O,F; nHAcc], number of donor atoms for H-bonds [N and O; nHDon], topological polar 
surface area using N,O polar contributions [TPSA(NO)], Moriguchi octanol-water 
partition coefficient (MLOGP), number of nitrogen atoms (nN), and number of oxygen 
atoms (nO). Four of these descriptors (MW, nHDon, nHAcc, and MLOGP) were used in 
formulating the “rule of five”.305 The topological polar surface area is an important 
parameter when assessing the solubility, permeability, and transport of a compound.306 
Chirality is a key characteristic of natural products, often reflected in their 
stereospecificity and affinity toward chiral biological targets.299 For better binding with 
receptors, rigid structures are preferable over flexible ligands, as binding is 
thermodynamically preferred and accompanied by lower entropy and hence stronger 
binding;299,307 calculating the number of rotatable bonds is an indicator of the rigidity of 
structures. Finally, oxygen and nitrogen atoms are important for the specific binding of 
ligands to receptors.297 In total, we used nine molecular descriptors and the same set 
utilized by Tan304 (Table 40). 
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Very high correlations were observed between the eight molecular descriptors and 
MW. This is most apparent from the correlation coefficients in row 1 of Table 41 (all 
except two were close to r = 0.9, see Supporting Information). This was not surprising, as 
the high correlations were a consequence of the eight other descriptors being highly 
dependent on the size of the compounds, and thus, their variation can be most simply 
explained by their MW. Therefore, to understand how the compounds differ from each 
other by more than the simple measure of MW, the eight other descriptors for each 
compound were transformed to relative measures by dividing each by a compound’s 
MW. For example, dividing nN by MW provides a size independent measure of nitrogen 
abundance in a compound. After standardization, the correlations in Table 42 (Supporting 
Information) revealed that all the measures remain somewhat correlated with each other; 
however, these correlations were no longer as dependent on MW. As MW was included 
as one of the variables in the PCA, it remains represented in the decomposition of 
variation of the compounds. 
Results of the PCA (Table 39) revealed that the first, second, third, and fourth 
principal components explained 44%, 17%, 13%, and 13% of the total compound 
variance across all nine measures, respectively, and accounted for 87% of the variance in 
total. The loadings in Table 39 were obtained by varimax rotation308 in an attempt to 
achieve simpler structure, but the results differed little from the un-rotated solution, 
which was the simple PCA solution. Factor one explained almost half of the variance and 
was dominated by loadings of TPSA(NO), nHAcc, MLOGP (negative), nO, and nHDon, 
which reflects the relatively higher correlations among these variables (with MLOGP 
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negatively correlated). Since TPSA(NO), nHAcc, nO, and nHDon are reflective of the 
polarity of a compound and they dominate this factor, it appears that these compounds 
vary most with regard to polarity (after standardization by MW). As MLOGP is a 
measure of molecular hydrophobocity, it was reseaonable for it to be negatively 
correlated with the polarity descriptors. Factor two was dominated by the abundance of 
nitrogen atoms, and to some degree, was relative to the abundance of oxygen atoms, as 
seen by the negative loading there. Essentially, the FDA-approved anticancer drugs have 
a higher abundance of nitrogen than the natural product isolates. Factor three was 
dominated by nRBN and was negatively correlated with nCC. Finally, factor four was 
dominated by MW, but it was somewhat associated with nCC, even after normalization. 
This suggested an intriguing postulate, in that chiral centers may impart a greater degree 
of drug-like properties, especially when considering the nCC in compounds like taxol245 
and the recently approved eribulin [Halaven],309 which are 11 and 19, respectively. 
Plots of the principal components impart a visual representation of the data. Since 
component 1 explained 44% of the variance, it was held constant, and Figures 121-123 
(Supporting Information) compare component 1 to components 2, 3, and 4, respectively. 
In Figure 121D there is much overlap, but some drugs seem to have higher values on 
both components 1 and 2. Also plant sources tend to have lower values on component 2 
(Figure 121C), which was dominated by the abundance of nitrogen as noted above. 
Figure 122 again shows much overlap, with plant sources (and some fungi), showing 
higher values for component 3 (Figure 122A and 122C). Component 3 was dominated by 
nRBN, and was somewhat inversely relative to nCC. Figure 123 shows much overlap in 
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MW, but some of the fungal secondary metabolites had relatively high MWs, and the 
means for both cyanobacteria and fungi were higher than for drugs and tropical plants. 
 
Table 39. Loadings for the First Four Principal Components for PCA 
Analysis of Fungal Secondary Metabolites (n = 105), Cyanobacteria (n 
= 75), Tropical Plants (n = 163) and Anticancer Drugs (n = 96) 
principal 
component 
PCLOA 01 PCLOA 02 PCLOA 03 PCLOA 04 
Eigenvalue 3.69 1.62 1.27 1.25 
cumulative 
Eigenvalue (%) 44 61 74 87 
MW 0.20 0.13 0.19 0.88 
nRBN -0.02 -0.08 0.89 0.25 
nN 0.28 0.91 0.01 0.05 
nO 0.80 -0.59 0.02 -0.02 
nHDon 0.65 0.49 0.08 0.10 
nHAcc 0.94 0.14 0.06 0.04 
TPSA(NO) 0.95 0.24 0.05 0.01 
MLOGP -0.85 -0.14 0.11 -0.33 
nCC -0.10 -0.29 -0.64 0.54 
 
By inspecting the PCA plots, there were anticancer drugs residing outside the 
overlapping area with the isolated compounds; perhaps these drugs possess key structural 
features that should be considered in the natural product isolation studies. Accordingly, 
these non-overlapping drugs were identified from each plot, and it was found that they 
were mainly the same across all plots. The drugs were allopurinol, leucovorin calcium, 
aminolevulinic acid, fluorouracil, hydroxyurea, dacarbazine, cytarabine, azacitidine, 
decitabine, amifostine, fludarabine phosphate, temozolomide, nelarabine, and zoledronic 
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acid (Figure 124). Structurally, all these drugs are abundant in nitrogen and most are 
nucleoside-based drugs. Mechanistically, although they are listed among the FDA-
approved anticancer drugs, not all are used specifically as cancer chemotherapeutic 
agents, with some being employed adjunctively with other anticancer drugs.310 Hence, the 
above reasons could at least, in part, explain why the compounds from the three 
investigated natural resources failed to cover the chemical space occupied by those drugs. 
Moreover, as noted by a reviewer of this manuscript, there are likely some technical 
biases embedded in the data, as many synthetic compounds favor the inclusion of N 
atoms while natural product isolates tend to favor inclusion of O atoms; such biases may 
evolve to be irrelevant in the future. 
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Figure 121. Plots of the first two principal components of the isolated secondary 
metabolites from A) filamentous fungi (n = 105), B) cyanobacteria (n = 75), and C) 
tropical plants (n = 163) relative to anticancer agents (n = 96). Plot D combines the data 
from all three natural product sources (n = 343) vs. anticancer agents (n = 96). 
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Figure 122. Plot of the first and third principal components of the isolated secondary 
metabolites from filamentous fungi (n = 105), cyanobacteria (n = 75), tropical plants (n 
= 163) and anticancer drugs (n = 96). 
 
Analyzing the different plots clearly shows that anticancer drugs tended to cover a 
larger chemical space than the three analyzed sets of compounds, although with high 
overlap among them. This could be explained, at least in part, by the fact that the 
anticancer drugs included both natural and synthetic compounds. Of the 96 FDA-
approved drugs studied, 59% were either natural products or compounds derived and/or 
inspired from natural products, in agreement with Newman and Cragg.5 However, the 
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sum conclusion was that the isolates from fungi, cyanobacteria and tropical plants 
represented somewhat different areas of chemical space, and thus, the collective strategy 
of probing these three natural resources for anticancer drug leads individually should be 
complementary.  
 
Supporting Information 
 
Experimental Procedures. The natural products utilized in this study were isolated 
in pursuit of anticancer leads. The recent literature may be examined for examples of 
descriptions of the isolation and structure elucidation of compounds from filamentous 
fungi, cyanobacteria, and tropical plants by our collaborative team. The FDA-approved 
anticancer agents were selected from two complementary sources: those posted on the 
website of the Developmental Therapeutic Program NCI/NIH and the recently approved 
anticancer drugs from the orange book on the FDA website. All molecular descriptors, 
except number of chiral centers, were calculated using Dragon software for molecular 
descriptor calculation (version 6.0 – 2010; Talete srl, Milano, Italy). The number of chiral 
centers was tabulated by inspection. SAS was used for principal component analysis 
varimax rotation of the 9 variable correlation matrix (Proc Princomp and Factor). 
Components score were obtained after variance standardization. 
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Table 40. Molecular Descriptors Utilized in the Current Study Compared to 
Related PCA Studies in the Literature 297,299,300,304 
molecular descriptors 
Feher and 
Schmidt29
7 
Singh 
et al.300 
Tan30
4 
Singh and 
Culberson29
9 
Current 
study 
molecular weight (MW) ---     
number of chiral centers (nCC)  ---    
number of rotatable bonds 
(NRBN)      
number of solvated acceptor 
atoms for H-bonds (N,O,F) 
[NAcc,solv] 
     
number of solvated donor atoms 
for H-bonds (N and O) 
[NDon,solv] 
   ---  
topological polar surface area 
[TPSA(NO)] ---     
octanol/water partition 
coefficient ---     
number of nitrogen atoms (nN) --- ---    
number of oxygen atoms (nO) --- ---    
number of C-N bonds (nCN)  --- --- --- --- 
number of C-O bonds (nCO)  --- --- --- --- 
number of C-halogen bonds 
(nCX)  --- --- --- --- 
number of C-S bonds (nCS)  --- --- --- --- 
ratio of aromatic atoms to ring 
atoms  --- --- --- --- 
ring fusion degree  --- --- --- --- 
normalized bond flexibility --- --- ---  --- 
 
  
 
334 
Table 41. Pearson Correlation Coefficients for Raw Data 
correlation 
coefficient 
MW nRBN nN nO nHDon nHAcc TPSA MLOGP nCC 
MW 1.0000 0.8713 0.8185 0.8878 0.9001 0.9466 0.9459 -0.6667 0.6500 
nRBN 0.8713 1.0000 0.8174 0.7533 0.8493 0.8681 0.8702 -0.6292 0.4024 
nN 0.8185 0.8174 1.0000 0.6271 0.8768 0.8777 0.8795 -0.7712 0.3450 
nO 0.8878 0.7533 0.6271 1.0000 0.8061 0.9202 0.9097 -0.7564 0.6632 
nHDon 0.9001 0.8493 0.8768 0.8061 1.0000 0.9258 0.9607 -0.7850 0.4993 
nHAcc 0.9466 0.8681 0.8777 0.9202 0.9258 1.0000 0.9906 -0.8427 0.5682 
TPSA 0.9459 0.8702 0.8795 0.9097 0.9607 0.9906 1.0000 -0.8373 0.5591 
MLOGP -0.6667 -0.6292 -0.7712 -0.7564 -0.7850 -0.8427 -0.8373 1.0000 -0.3916 
nCC 0.6500 0.4024 0.3450 0.6632 0.4993 0.5682 0.5591 -0.3916 1.0000 
 
Table 42. Pearson Correlation Coefficients for Molecular Weight Standardized Data 
correlation 
coefficient MW nRBN nN nO nHDon nHAcc TPSA MLOGP nCC 
MW 1.0000 0.2423 0.1755 0.0879 0.2571 0.2449 0.2201 -0.4706 0.1445 
nRBN 0.2423 1.0000 -0.0071 0.0249 0.0669 0.0604 0.0296 0.0694 -0.2509 
nN 0.1755 -0.0071 1.0000 -0.3057 0.4915 0.4680 0.4842 -0.3778 -0.2184 
nO 0.0879 0.0249 -0.3057 1.0000 0.2136 0.6711 0.6170 -0.5665 0.0529 
nHDon 0.2571 0.0669 0.4915 0.2136 1.0000 0.5692 0.7763 -0.5713 -0.1417 
nHAcc 0.2449 0.0604 0.4680 0.6711 0.5692 1.0000 0.9172 -0.8048 -0.1255 
TPSA 0.2201 0.0296 0.4842 0.6170 0.7763 0.9172 1.0000 -0.7766 -0.1471 
MLOGP -0.4706 0.0694 -0.3778 -0.5665 -0.5713 -0.8048 -0.7766 1.0000 -0.0515 
nCC 0.1445 -0.2509 -0.2184 0.0529 -0.1417 -0.1255 -0.1471 -0.0515 1.0000 
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Table 43. Summary Statistics of Different Properties Among Secondary 
Metabolites from Filamentous Fungi (n = 105), Cyanobacteria (n = 75), 
Tropical plants (n = 163) and Anticancer Drugs (n = 96) 
source Variables 
Raw data 
After MW 
standardization 
Mean Std. Dev. Mean Std. Dev. 
Anticancer Drugs 
(n = 96) 
MW 
RBN 
nN 
nO 
nHDon 
nHAcc 
TPSA 
MLOGP 
CC 
412.76 
5.31 
3.02 
4.92 
3.09 
8.00 
113.88 
1.12 
3.30 
248.04 
5.12 
2.79 
4.73 
3.46 
5.69 
89.62 
2.24 
4.87 
1.000 
0.012 
0.009 
0.011 
0.008 
0.020 
0.295 
0.003 
0.006 
0.000 
0.008 
0.008 
0.007 
0.008 
0.009 
0.164 
0.007 
0.007 
Cyanobacteria 
(n = 75) 
MW 
RBN 
nN 
nO 
nHDon 
nHAcc 
TPSA 
MLOGP 
CC 
628.78 
7.77 
3.79 
6.01 
5.12 
9.12 
150.41 
2.30 
6.28 
338.39 
7.35 
4.44 
6.10 
5.27 
10.49 
152.65 
3.55 
4.31 
1.000 
0.011 
0.005 
0.007 
0.007 
0.011 
0.193 
0.006 
0.010 
0.000 
0.007 
0.004 
0.005 
0.004 
0.008 
0.106 
0.006 
0.004 
Filamentous Fungi 
(n = 105) 
MW 
RBN 
nN 
nO 
nHDon 
nHAcc 
TPSA 
MLOGP 
CC 
660.36 
12.14 
4.19 
8.98 
5.74 
13.17 
196.95 
0.53 
5.69 
555.30 
17.60 
7.72 
6.87 
8.11 
14.29 
218.11 
3.65 
3.92 
1.000 
0.014 
0.003 
0.014 
0.007 
0.018 
0.263 
0.004 
0.010 
0.000 
0.012 
0.004 
0.004 
0.004 
0.004 
0.073 
0.005 
0.006 
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Table 43 (Continued). Summary Statistics of Different Properties Among 
Secondary Metabolites from Filamentous Fungi (n = 105), 
Cyanobacteria (n = 75), Tropical plants (n = 163) and Anticancer Drugs 
(n = 96) 
source Variables 
Raw data 
After MW 
standardization 
Mean Std. Dev. Mean Std. Dev. 
Tropical Plants 
(n = 163) 
MW 
RBN 
nN 
nO 
nHDon 
nHAcc 
TPSA 
MLOGP 
CC 
450.42 
5.90 
0.06 
6.57 
2.37 
6.60 
100.87 
2.70 
4.58 
152.31 
4.25 
0.27 
3.68 
2.10 
3.65 
52.82 
1.84 
5.46 
1.000 
0.014 
0.000 
0.014 
0.005 
0.014 
0.220 
0.007 
0.009 
0.000 
0.011 
0.001 
0.005 
0.003 
0.005 
0.064 
0.004 
0.008 
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Figure 123. Plot of the first and fourth principal components of the isolated secondary 
metabolites from filamentous fungi (n = 105), cyanobacteria (n = 75), tropical plants (n 
= 163) and anticancer drugs (n = 96). 
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